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× g    gravitational acceleration  
°C    degrees Celsius  
μl    microliter  
µm   micrometer 
µM   micromolar 
aa    amino acid  
AlkB   alkane-1-monooxygenase from Pseudomonas putida Gpo1 
AlkG   rubredoxin from Pseudomonas putida Gpo1 
AlkT   rubredoxin reductase from Pseudomonas putida Gpo1 
bp    base pair  
CamA   putidaredoxin reductase from Pseudomonas putida  
CamB   putidaredoxin from Pseudomonas putida 
cdw   cell dry weight 
CPR   cytochrome P450 reductase 
cww   cell wet weight  
CYP   cytochrome P450 monooxygenase     
CYP153A16  CYP153A monooxygenase from Mycobacterium marinum M. 
CYP153A M. aq. CYP153A monooxygenase from Marinobacter aquaeolei VT8 
CYP153A P. sp. CYP153A monooxygenase from Polaromonas sp. JS666 
DAD   diode array detector 
DCA   dicarboxylic acid 
DMSO   dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
DSMZ   German Collection of Microorganisms and Cell Cultures 
E. coli   Escherichia coli  
FAD   flavin adenine dinucleotide 
FdR   NAD(P)H-dependent ferredoxin oxidoreductase 
Fdx   ferredoxin 
FMN   flavin mononucleotide 
g    gram  
GC    gas chromatography  
GC/FID   gas chromatography coupled to flame ionization detector  
GC/MS   gas chromatography coupled to mass spectrometry  
G6P   glucose-6-phosphate 
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G6PDH   glucose-6-phosphate dehydrogenase 
h    hour  
HPLC   high-performance liquid chromatography 
IPTG   isopropyl-β-ᴅ-thiogalactopyranoside  
kbp   kilobase pair  
kDa    kilo Dalton  
l   liter 
LB    lysogeny (Luria-Bertani) broth  
MaqFdR  ferredoxin reductase from Marinobacter aquaeolei VT8 
MaqFdx  ferredoxin from Marinobacter aquaeolei VT8 
MmFdR  ferredoxin reductase from Mycobacterium marinum M. 
MmFdx  ferredoxin from Mycobacterium marinum M. 
mg    milligram  
min    minute  
ml    milliliter  
mM    millimolar 
OCT   octane-degrading plasmid in Pseudomonas putida Gpo1 
OD600   optical density measured at 600 nm  
OHFA   hydroxylated fatty acid 
P. putida  Pseudomonas putida 
PCR   polymerase chain reaction 
PMSF    phenylmethanesulfonyl fluoride  
PspFdR  ferredoxin reductase from Polaromonas sp. JS666 
PspFdx   ferredoxin from Polaromonas sp. JS666 
RID   refractive index detector 
ROS   reactive oxygen species 
rpm   revolutions per minute 
SDS-PAGE   sodium dodecyl sulfate polyacrylamide gel electrophoresis  
TB    terrific broth  
WT    wild type  
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Abstract 
 
The selective oxyfunctionalization of alkanes and fatty acids is a challenging task in basic and 
applied chemistry. Biocatalysts belonging to the superfamily of cytochrome P450 
monooxygenases (CYPs) can introduce oxygen into a wide variety of molecules in a very regio- 
and stereospecific manner, which can be used for the synthesis of fine and bulk chemicals. CYPs 
from the bacterial CYP153A subfamily have been described as alkane hydroxylases with high 
terminal regioselectivity. In the present work, CYP153A monooxygenases were screened for the 
synthesis of industrially relevant ω-hydroxylated aliphatic compounds, such as primary 
alcohols, α,ω-diols, ω-hydroxyfatty acids (ω-OHFAs) and α,ω-dicarboxylic acids (α,ω-DCAs). One 
enzyme candidate was tailored by rational design and applied in whole cell biotransformations 
with recombinant E. coli or Pseudomonas strains. The biocatalytic systems were further 
improved by utilizing a fusion enzyme construct for increased coupling efficiency. 
  
CYP153A enzymes from Polaromonas sp. (CYP153A P. sp.), Mycobacterium marinum 
(CYP153A16) and Marinobacter aquaeloei (CYP153A M. aq.) were screened in vitro towards 
medium- to long-sized linear alkanes, alcohols and fatty acids using the redox partners of 
P450cam from Pseudomonas putida. CYP153A P. sp. was found to possess a predominant alkane 
ω-hydroxylase activity, while CYP153A16 and CYP153A M. aq. were identified as predominantly 
fatty acid ω-hydroxylases. CYP153A M. aq. offered higher flexibility for the synthesis of primary 
alcohols, α,ω-diols and ω-OHFAs of different size and saturation level. CYP153A M. aq. was thus 
selected as a model enzyme to create a small focused library of 19 variants aiming the terminal 
hydroxylation of C6-C7 primary alcohols and C6-C8 fatty acids via a shift in substrate range or a 
higher enzyme activity. Active site hotspots G307 and L354 were found to greatly influence 
enzyme activity or substrate specificity. Conversions of n-octane, 1-heptanol and nonanoic acid 
with variant G307A compared to the wild type enzyme were higher by 3- to 10-fold and equally 
ω-regioselective (>97 %). Further kinetic analyses demonstrated that variant G307A was 2- to 
20-fold more catalytically efficient towards octanoic, nonanoic and tetradecanoic acids owing to 
a higher turnover number rather than an increased substrate affinity. Residue L354 was found 
to be determinant for the enzyme selectivity, with mutations L354I and L354F causing a 73 % 
and 17 % decrease in ω-regioselectivity in oxidation reactions towards nonanoic acid, 
respectively. 
 
In order to increase the efficiency of redox biocatalysis, mutation G307A was incorporated into a 
fusion protein comprised by CYP153A M. aq. and the reductase domain (CPR) of P450 BM3 from 
Bacillus megaterium. The G307A variant within the fusion protein yielded 25 – 41 % higher 
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conversion levels towards octanoic, dodecanoic and oleic acids compared to the wild type fusion 
construct in whole cell biotransformations. The performance of non-engineered and non-
solvent-adapted E. coli and P. putida strains was compared in shake flask biotransformations 
towards n-octane and dodecanoic acid. E. coli has been shown to be a suitable host for 1-octanol 
or 12-hydroxydodecanoic production. In the absence of an additional carbon and energy source, 
bioconversions by resting E. coli and P. putida cells, containing the engineered fusion construct, 
yielded 0.26 and 0.015 g l-1 1-octanol from 10 % (v/v) n-octane in 8 and 2 h, respectively. In a 
similar setup, resting E. coli and P. putida cells respectively produced 0.49 and 0.1 g l-1 12-
hydroxydodecanoic acid from 1 g l-1 dodecanoic acid in 8 h. Additional feeding with glucose and 
glycerol decreased fatty acid consumption as carbon or energy source, but did not contribute to 
increase the product yields. In contrast to E. coli, P. putida cells tended to aggregate, consumed 
the substrate or targeted products rapidly and produced larger amounts of overoxidized 
products. Final product yields in both E. coli and P. putida were affected by the decrease in 
product formation rates after 8 h. High hydrogen peroxide accumulation was identified as a 
limitation in the pseudomonads. E. coli cells produced high acetate levels which could contribute 
to the reduction of CYP activity and stability. 
  
In summary, this work constitutes the first example of rational engineering of a CYP153A 
enzyme, which allowed the identification of key residues for activity and substrate specificity 
within the enzyme subfamily. CYP153A enzymes have also been applied for the first time in the 
ω-hydroxylation of fatty acids. Comparative in vivo studies with recombinant E. coli and P. putida 
cells provided information on the effects of host strains on product yields, eventually leading to 
the generation of an efficient bacterial whole cell biocatalyst for the synthesis of selected ω-
hydroxylated aliphatic compounds. 
Zusammenfassung 15 
 
Zusammenfassung 
 
Die selektive Oxyfunktionalisierung von Alkanen und Fettsäuren ist eine herausfordernde 
Aufgabe sowohl in der chemischen Grundlagenforschung als auch in der angewandten Chemie. 
Biokatalysatoren aus der Superfamilie der Cytochrom-P450-Monooxygenase Enzyme (CYPs) 
können Sauerstoff regio- und stereospezifisch in eine Vielzahl von Molekülen einbauen, welche 
zur Synthese von Fein- und Bulk-Chemikalien verwendet werden können. CYPs aus der 
bakteriellen Unterfamilie CYP153A sind als Alkan-Hydroxylasen mit hoher terminaler 
Regioselektivität beschrieben worden. In der vorliegenden Arbeit wurden CYP153A 
Monooxygenasen durch Substrat-Screening für die Darstellung industriell relevanter ω-
hydroxylierter, aliphatischer Verbindungen, wie primäre Alkoholen, α,ω-Diole, ω-
Hydroxyfettsäuren (ω-OHFAs) und α,ω-Dicarbonsäuren (α,ω-DCAs), getestet. Ein Enzym-
kandidat wurde durch rationales Design angepasst und für Ganzzellbiotransformationen mit 
rekombinanten E. coli oder Pseudomonas Stämmen verwendet. Die biokatalytischen Systeme 
wurden durch Verwendung eines Fusionskonstrukts für erhöhte Kopplungseffizienz verbessert. 
 
CYP153A-Enzyme aus Polaromonas sp. (CYP153A P. sp.), Mycobacterium marinum (CYP153A16) 
und Marinobacter aquaeloei (CYP153A M. aq.) wurden gegenüber mittel- und langkettigen 
linearen Alkanen, Alkoholen und Fettsäuren mit den Redoxpartnern von P450cam aus 
Pseudomonas putida in in-vitro Experimenten untersucht. CYP153A P. sp. wies überwiegend 
Alkan ω-Hydroxylase-Aktivität auf, wenn auch CYP153A16 und CYP153A M. aq. überwiegend als 
Fettsäure ω-Hydroxylasen identifiziert wurden. CYP153A M. aq. zeigte eine höhere Flexibilität 
für die Synthese von primären Alkoholen, α,ω-Diolen und ω-OHFAs mit variablen Kettenlängen 
und unterschiedlichen Sättigungsgraden. Aus diesem Grund wurde CYP153A M. aq. als Modell-
Enzym für die Erstellung einer kleinen fokussierten Bibliothek von 19 Varianten ausgewählt. 
Ziel dieser Bibliothek war die terminale Hydroxylierung von C6- und C7-primären Alkoholen und 
C6- bis C8-Fettsäuren durch eine Verschiebung des Substratspektrums oder eine Erhöhung der 
Enzymaktivität. Die Aminosäuren G307 und L354 im aktiven Zentrum wurden als Hotspots mit 
einem starken Einfluß auf die Enzymaktivität bzw. die Substratspezifität ermittelt. Die 
Substratumsätze von n-Oktan, 1-Heptanol und Nonansäure waren 3- bis 10-fach höher mit der 
Variante G307A im Vergleich zu denen des Wildtyp-Enzyms bei gleichbleibender ω-
Regioselektivät (>97 %). Weitere kinetische Analysen zeigten, dass die Variante G307A eine um 
den Faktor zwei bis 20 erhöhte katalytische Effizienz gegenüber Oktansäure, Nonansäure und 
Tetradekansäure besaß, was auf den höheren Umsatz (höhere Turnover Number) 
zurückzuführen ist. Die Aminosäure L354 wurde als essentiell für die Selektivität des Enzyms 
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nachgewiesen, da die Mutationen L354I und L354F einen Rückgang der ω-Regioselektivität um 
73 % bzw. 17 % in Oxidationsreaktionen gegenüber Nonansäure verursachten. 
 
Um die Effizienz der Redoxbiokatalyse zu erhöhen, wurde die Mutation G307A in ein 
Fusionsprotein, welches aus der Monooxygenasedomäne aus CYP153A M. aq. und der 
Reduktase-Domäne (CPR) von P450 BM3 aus Bacillus megaterium aufgebaut ist, eingeführt. Die 
Variante G307A im Fusionsprotein ergab 25 – 41 % höhere Substratumsätze von Oktansäure, 
Dodekansäure und Ölsäure im Vergleich zum Wildtyp-Fusionskonstrukt bei 
Ganzzellbiotransformationen. Die Leistungsfähigkeit von nicht-stammentwickelten und nicht-
Lösungsmittel-adaptierten E. coli und P. putida-Zellen wurde in Biotransformationen von n-
Oktan und Dodekansäure in Schüttelkolben verglichen. E. coli wurde als besser geignet für die 
Darstellung von 1-Oktanol oder 12-Hydroxydodekansäure im Vergleich zu P. putida befunden. In 
Abwesenheit einer zusätzlichen Kohlenstoff- und Energiequelle produzierten ruhende E. coli 
und P. putida-Zellen, welche das erzeugte Fusionskonstrukt beherbergten, 0.26 bzw. 0.015 g l-1 
1-Oktanol aus einer 10 % (v/v) n-Oktanstammlösung in 8 und 2 h Reaktionsdauer. In einem 
ähnlichen experimentellen Aufbau erzeugten ruhende E. coli und P. putida-Zellen in 8 h 0.49 
bzw. 0.1 g l-1 12-Hydroxydodekansäure aus 1 g l-1 Dodekansäure. Zusätzliche Fütterung mit 
Glukose und Glycerin erzielte einen geringeren Verbrauch der Fettsäuren, aber keine Erhöhung 
der Produktausbeuten. Im Gegensatz zu E. coli neigten P. putida-Zellen zu aggregieren. Des 
Weiteren konnte beobachtet werden, dass das Substrat  und das Zielprodukt von den Zellen 
abgebaut wurden und größere Mengen an weiter oxidierten Produkten detektiert wurden. Die 
Ausbeute des Endprodukts in beiden E. coli und P. putida Ansätzen wurde nach 8 h 
Reaktionsdauer durch den Rückgang der Produktbildungsraten beeinträchtigt. Eine hohe 
Akkumulation vom Wasserstoffperoxid wurde als Limitierung in den Pseudomonaden 
identifiziert. In E. coli wurde eine hohe Acetatkonzentration detektiert, die zur Verringerung der 
Aktivität und Stabilität der CYPs beitragen könnte. 
  
Zusammenfassend stellt diese Arbeit das erste Beispiel für das Engineering eines CYP153A-
Enzyms durch rationales Design dar, welches die Identifizierung wichtiger Aminosäurereste für 
die Aktivität und die Substratspezifität der Enzym-Unterfamilie ermöglichte. CYP153A-Enzyme 
wurden ebenfalls zum ersten Mal in der ω-Hydroxylierung von Fettsäuren angewandt. 
Vergleichende in-vivo-Untersuchungen mit rekombinanten E. coli und P. putida-Zellen stellen 
Informationen über die Einwirkung von Wirtsstämmen auf Produktausbeuten bereit, was 
schließlich zu der Erzeugung eines effizienten bakteriellen Ganzzellbiokatalysators zur Synthese 
ausgewählter ω-hydroxylierter, aliphatischer Verbindungen führen kann. 
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1 Introduction 
 
1.1 Applications of ω-oxyfunctionalized aliphatic compounds 
 
ω-Hydroxylated hydrocarbons such as primary alcohols and α,ω-diols are of great industrial 
interest due to their use as fuels, versatile solvents, plasticizers, surfactants, cosmetic 
ingredients and precursors for polymer intermediates (table 1.1).1 Terminally oxyfunctionalized 
fatty acids such as ω-hydroxyfatty acids (ω-OHFAs) and α,ω-dicarboxylic acids (α,ω-DCAs) are 
valuable chemicals for adhesives, lubricants, antiseptics, macrolide antibiotics and potential 
anticancer agents.2-5 They are also attractive for the fragrance industry and for several 
commodity and advanced plastic applications (figure 1.1; supplementary material table 6.3). ω-
OHFAs serve as building blocks for the synthesis of poly(ω-hydroxyfatty acids), which are 
polyethylene-like polyhydroxyalkanoates exhibiting high durability, hydrolytic resistance and 
compatibility with other composite materials like polyamides and polyesters.6 In addition, 
unsaturated ω-OHFAs and α,ω-DCAs can be used to synthesize network copolyesters as the 
double bond sites enable their linkage to different types of monomers. These sites can also be 
decorated with flame-retardant moieties for industrial coatings or with bioactive functionalities 
for their application as components of bioresorbable materials, tissue engineering scaffolds and 
drug delivery vehicles.3, 7-11  
 
Table 1.1. Industrial applications of medium-chain primary alcohols and α,ω-diols1, a 
Product Industrial use 
1-alcohols 
C6 Hexylglycol, UV-absorber, solvent in the production of trimethylquinone 
C8 Octylamine, plasticizer, catalyst 
C6 -C10 Plasticizers, surfactants, solvents, coalescent aids 
C12-C17 Lubricant oils, alcohol ethoxylates and alcohol ethoxysulfates 
α,ω-diols 
C4 –C12 Coatings, adhesives, plasticizers, polyesters, polyamides, polyurethanes, 
poly(diol co-citrates) 
aProduct information sheets from Shell Chemicals and BASF SE. 
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 Reaction type Method Reagent/Catalyst Ref. 
1 ω-Hydroxylation  Biocatalytic CYP, AlkB 12-15 
2 ω-Oxidation Biocatalytic CYP, FAO 16, 17 
3 Condensation Catalytic Ti[OiPr]4 6 
4 Lactonization (Bio)catalytic Thioates, lipases 18-20 
5 Condensation (Bio)catalytic Acid, CalB 9, 21 
6 Ketonization Catalytic Base, MnO2/CeO2/ZrO2 22 
7 Baeyer-Villiger oxidation (Bio)catalytic Peroxy acids, BVMO 23-26 
8 Chemical derivatization (Non)-catalytic Several 27 
Figure 1.1. Fatty acid 
derivatives for the 
preparation of polymers 
and fragrances. 
Abbreviations: CYP: 
cytochrome P450 
monooxygenase, FAO: 
fatty alcohol oxidase, 
CalB: Candida antarctica 
lipase B, BVMO: Baeyer-
Villiger monooxygenase. 
 
1 
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8 
5 
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Fatty acid 
chain length: n  
ω-Hydroxy fatty acid  
(ω-OHFA)   
chain length: n 
α,ω-Dicarboxylic acid 
(α,ω-DCA) 
chain length: n 
Poly-ω-hydroxy fatty acid 
P(ω-OHFA) 
chain length: n; Mw: 53-140K 
 
Lactone  
ring size: n+1 
Heteropolymer (R = -O, -NH) 
chain length: n; x,y: variable 
 
O
R
O
xy R
Cyclic ketone 
ring size: n-1  
Lactone 
ring size: n 
Derivatized cyclic 
ketone 
ring size: n-1 
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1.2 Synthesis of ω-oxyfunctionalized aliphatic compounds 
 
Saturated hydrocarbons are a large constituent of petroleum and natural gas, but there are 
currently few processes to directly convert these into more valuable functionalized products. In 
fact, most alcohols, aldehydes and fatty acids are produced from unsaturated hydrocarbons, 
commonly referred to as olefins, rather than alkanes because of the low reactivity of these 
compounds. Primary alcohols ranging from C11 – C15 are obtained from olefins by means of the 
Shell Hydroformylation (SHF) technology since the late 1970s. This platform exploits the  
homogeneously catalyzed hydroformylation or “oxo” reaction.28 The SHF technology can be 
basically described as the phosphine-modified cobalt-catalyzed addition of carbon monoxide 
and hydrogen to olefins to form aldehydes and alcohols under low pressure conditions. The 
concept of ligand modification has been further developed to allow the hydrogenation of 
aldehyde intermediates to alcohols in one step and to control reaction selectivity via steric 
impacts.29-32  
 
Non-edible vegetable oils are also an important source of fatty acids and derivatives. Compared 
to petrochemical feedstocks, they possess important advantages such as renewability and 
relatively stable prices. Medium- to long-chain ω-OHFAs can be synthesized by cross-metathesis 
of unsaturated fatty acid esters, followed by hydroformylation and hydrogenation of the 
carbonyl group.33-35 They can also be obtained by partial reduction of α,ω-DCAs.36 The diacids 
can be prepared by the catalytic ring-opening of lactones and cyclic ketones.37-39  
 
The selective terminal functionalization of alkanes is a reaction that poses a greater challenge 
than olefin-based processes. Although the thermodynamically unfavorable C1 atom can be 
induced to react by exposure to radicals or metal centers, weaker C-H bonds will be oxidized 
preferentially without an adequate selectivity control.40 Another issue is that, even if site-specific 
activation is achieved by the use of a tailored catalyst, its activity on partial oxidation products is 
difficult to regulate. This is problematic when the ω-alcohol is the desired final product, because 
the oxygenated molecule is more reactive than the starting material and thus, more prone to 
undergo overoxidation to the aldehyde or carboxylic acid. Several methods for the C-H 
oxygenation of saturated hydrocarbons have been developed, some of them with moderate 
success in the control of activity and product selectivity. In this section, the properties, 
advantages and drawbacks of the most relevant chemical and biological catalysts described in 
the literature are presented. 
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1.2.1 Chemical catalysts 
 
Chemical synthetic approaches for selective alkane functionalization are based on 
heterogeneous, biomimetic and organometallic catalysis.41, 42 It has been proposed that C-H 
activations begin with the formation of an intermediate alkane sigma-complex, in which a metal 
center interacts with the electron pair forming the C-H σ-bond.43 Following the formation of this 
intermediate, the coordinated C-H bond is cleaved to yield the product. The C-H cleavage step 
causes the main difference among the approaches.40  
 
Heterogeneous and biomimetic catalysis rely on the same mechanism, the homolytic cleavage of 
the C-H bond by an H-atom abstracting species. However, there is a problem with homolytic 
cleavage: homolysis rates of C-H bonds are inversely proportional with the strength of the 
bonds, which implies a constraint for selectivity and activity. One of the major difficulties is to 
make the reaction stop at the desired product because the product has at least one C-H bond 
weaker than the starting material.41 In heterogeneous catalysis by metal oxides, the effect of 
bond strength on the reaction rate is reduced by applying elevated temperatures. It is also 
important to make the metal-oxygen (M-O) bond of the catalyst be of intermediate strength. A 
too strong M-O bond leads to low reactivity; a weak one, to overoxidation.44 In biomimetic 
catalysis, reactions can be run at milder conditions. Selectivity is addressed by using shape-
selective scaffolds that resemble those of metalloenzymes.40, 41  
 
In organometallic activation C-H cleavage occurs by different mechanisms, e.g., nucleophilic 
attack by water on the metal-alkane complex (Shilov chemistry). As C-H homolysis is not 
involved, thermodynamic factors are minimized allowing a better control of the reaction 
selectivity. Primary positions become easier sites to attack and oxygenated products might not 
be further oxidized because they are not necessarily more thermodynamically favoured than 
their precursors. Nevertheless, the vast majority of organometallic complexes are highly 
sensitive to oxygen and other oxidants and therefore not stable under catalytic oxidation 
conditions.40  
 
Information on various metal catalysts (e.g., mononuclear metal cores, metalloporphyrins and 
platinum-chloride complexes) which enter the above-mentioned classification can be found in 
the literature.45-54 Herein we illustrate three examples for the oxidation of n-alkanes by shape-
selective biomimetic catalysts because they are considered to be milder than other catalysts 
(figure 1.2). They contain non-toxic high-oxidation state transition metal ions (e.g., MnIII, FeIII 
and CoIII) and operate between 25 and 60°C. However, as explained before, controlled activity 
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and selectivity have not been completely solved and they generally result in the mixture of at 
least two regioisomeric alcohols and/or their overoxidized derivatives.  
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Shape-selective chemical catalysts for the oxyfunctionalization of n-alkanes. (A) 
Biomimetic non-heme iron complex: Oxidation of n-hexane by an immobilized mononuclear iron 
carboxylate complex.50 (B) Biomimetic metalloporphyrin complex: Oxidation of n-heptane by the 
MnIII acetate complex of bis-pocket porphyrin [Mn(TTPPP)(OAc)].47, 48 (C) Heterogeneous 
microporous catalyst: Oxidation of n-hexane by the molecular sieve MnAlPO-18.52  
OH
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+
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1.2.2 Biocatalysts  
 
Chemically-based approaches for the selective oxidation of hydrocarbons are not economical as 
they rely on expensive transition metals and complex ligand designs for the control of 
selectivity.40 They are not sustainable either because they often require harsh reaction 
conditions and high energy-demanding processes. Similarly to chemical biomimetic catalysts, 
biological catalysts carry out homolytic C-H cleavage under physiological temperatures and 
pressures. Biocatalysts, however, offer higher C1 selectivity and lower byproduct formation than 
biomimetic catalysts.41   
 
For their biotechnological potential, several ω-oxidizing microorganisms and their enzymes 
have been studied intensively during the last two decades. Such enzymes are oxygenases whose 
substrate ranges depend on the chain length of the hydrocarbon.46, 55-57 Short-chain alkanes (C1-
C4) are hydroxylated by binuclear metallic monooxygenases of different bacterial origin. 
Medium-chain alkanes (C5-C16) are oxidized by non-heme diiron monooxygenases or 
alternatively by cytochrome P450 monooxygenases (CYP or P450s). Longer alkanes (≥C16) can 
be oxidized by yeast CYP enzymes, flavin-containing alkane monooxygenases, dioxygenases and 
other oxygenases. Several of these biocatalysts are presented in table 1.2.  
 
Table 1.2. Examples of native and engineered microbial alkane and fatty acid ω-hydroxylases 
Enzyme Strain(s) 
Enzyme characteristics 
Ref. 
Components  
Substrate 
spectrum 
Remarks 
Binuclear metallic (di)iron or di(copper) alkane monooxygenases 
Methane monooxygenases  
sMMO 
(soluble) 
Methylococcus 
capsulatus (Bath) 
(1)  Diiron hydroxylase  
(2)  NADH-dependent, 
[2Fe-2S]- and FAD-
containing reductase  
(3) Regulatory protein  
C1-C7 
(halogenated)-
alkanes, 
alkenes, 
cycloalkanes, 
aromatic 
compounds 
Regioselectivity 
depends on the chain 
length of the 
substrate (27 % ω-
OH from C5 alkane; 
63 % ω-OH from 
C6 alkane) 
58-60 
pMMO 
(particulate) 
Methylococcus 
capsulatus 
(Bath), 
Methylosinus 
trichosporium 
OB3b, 
Methylocystis sp. 
(1) Dicopper-or 
copper/iron 
hydroxylase  
(2) Reductase 
(3) Regulatory  protein 
61-63 
Propane monooxygenases  
PMO Arthrobacter 
strain B3aP 
Putative components: 
(1) Diiron hydroxylase 
(2) Reductase 
(3) Coupling protein 
C1-C3 alkanes  Products include 1-
alcohols, 2-alcohols, 
aldehydes and acids  
64 
Gordonia sp. TY-
5, Mycobacterium 
sp. TY-6, 
Pseudonocardia 
sp. TY-7 
C3-C6 alkanes  
 
 
65, 66 
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Table 1.2. (continued) 
Enzyme Strain(s) 
Enzyme characteristics 
Ref. 
Components  
Substrate 
spectrum 
Remarks 
Binuclear metallic (di)iron or di(copper) alkane monooxygenases 
Butane monooxygenases  
sBMO 
(soluble) 
Thauera 
butanivorans sp. 
("Pseudomonas 
butanovora")  
(1) Iron-containing 
hydroxylase  
(2) NADH-dependent 
flavo-FeS reductase  
(3) Small regulatory 
protein  
C2-C9 alkanes 
(especially C3-
C5), C2-C4 1-
alcohols, 
aromatic, 
halogenated 
compounds  
85 % ω-regio-
selectivity towards 
C4 alkane. Ketone 
formation is 
prevented by 
addition of 1-
propanol or 1-
pentanol 
67-72 
Nocardioides CF8 Putative copper-
containing BMO (similar 
to pMMO) 
C3-C4 alkanes  73 
Integral-membrane non heme-iron alkane monooxygenases 
AlkB Pseudomonas 
putida GPo1 
(“Pseudomonas 
oleovorans“) 
(1)  Integral-membrane 
alkane hydroxylase 
(AlkB) 
(2) Rubredoxin 
reductase (AlkT) 
(3) Rubredoxin (AlkG) 
C5-C16 alkanes 
(especially C3-
C12),  cyclo-
alkanes, N-
benzyl-
pyrrolidine, 
C5-C12 fatty 
acid methyl 
esters 
≥ 95 % ω-regio-
selectivity 
15, 74-76 
(1)  AlkB-BMO2  
(V129M/L132V/ 
I233V) mutant  
(2)  AlkT; (3) AlkG 
C3-C8 alkanes 150 % higher 
productivity than 
wild type AlkB 
77 
AlkB-like 
 
 
Mycobacterium 
vaccae JOB5 
Putative diiron cluster  C2-C16 alkanes, 
alcohols,  
chlorobutanol 
and fatty acids 
Similar to sMMO 
and AlkB 
78, 79 
Dietzia sp. Native fusion protein:  
(1) AlkB domain  
(2) Rubredoxin domain 
C8-C40 alkanes 
(especially 
C18-C32) 
Not fully 
characterized yet 
80 
Heme-iron monooxygenases 
Cytochrome P450 monooxygenases (P450s or CYPs) 
CYP52 Candida tropicalis, 
Candida maltosa, 
Candida apicola, 
Yarrowia lipolytica  
(1)  Membrane-bound 
CYP52 
(2)  Membrane-bound 
NADPH-dependent 
reductase 
>C12 alkanes 
and fatty acids 
1-alcohols, ω-
OHFAs and α,ω-
DCAs as products 
12, 14, 17, 
81 
CYP153 Acinetobacter sp. 
EB104, OC4, 
Alcanivorax 
borkumensis SK2, 
Mycobacterium sp. 
HXN-1500 and 
several others 
(1) CYP153  
(2) NAD(P)H-
dependent 
ferredoxin 
reductase 
(3) [2Fe-2S] ferredoxin  
C4-C16 alkanes, 
alkenes, 
cycloalkenes, 
1-alcohols, L-
limonene, N-
benzyl-
pyrrolidine 
≥ 95 % ω-
regioselectivity 
82-88 
 Mycobacterium sp. 
HXN-1500 
(1) CYP153A6-BMO1 
(A97V) mutant 
(2) Ferredoxin 
reductase 
(3) Ferredoxin 
C3-C8 alkanes 75 % higher activity 
than wild type 
CYP153A6; 89 % ω-
selectivity towards 
C4 alkane  
77 
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Table 1.2. (continued) 
Enzyme Strain(s) 
Enzyme characteristics 
Ref. 
Components  
Substrate 
spectrum 
Remarks 
Heme-iron monooxygenases 
Cytochrome P450 monooxygenase (P450s or CYPs) 
CYP153 Acinetobacter sp. 
OC4, Alcanivorax 
borkumensis SK2 
Chimeric fusion protein: 
(1) CYP153  
(2) FMN/[2Fe-2S]- 
reductase domain 
of P450RhF  
C6-C14 alkanes, 
alkenes 1-
alcohols, 
cycloalkanols  
Production of 1-
alcohols and α,ω-
diols from C5-C12 
alkanes 
89-92
 
CYP124 Mycobacterium 
tuberculosis 
(1) CYP124 
(2) Ferredoxin 
reductase 
(3) Ferredoxin 
C12-C16 methyl-
branched fatty 
acids 
Low activity and 
low ω-regioselec-
tivity towards 
linear fatty acids 
93 
CYP101 
mutant 
Pseudomonas putida (1) CYP101 (9 point 
mutations) 
(2) Ferredoxin 
reductase 
(3) Ferredoxin 
C2-C3 alkanes Low ω-regio-
selectivity towards 
C3 alkane 
94 
CYP102A 
mutants/ 
reaction 
tuning 
Bacillus megaterium, 
Bacillus subtilis 
Natural fusion protein: 
(1) Mutated heme 
domain: 
CYP102A1 (77-9H) 
CYP102A3 (S189Q/ 
A330V)  
(2)  FAD/FMN-
reductase domain 
C8- C12 alkanes 50% ω-regio-
selectivity towards 
C8 alkane 
95-97 
Bacillus megaterium (1) Native CYP102A1 
heme domain  
(2) FAD/FMN-
reductase domain 
C1 alkane Tuning of activity 
by addition of 
perfluorocarboxylic 
acids  
98, 99 
Putative 
CYPs 
Corynebacterium sp. 
strain 7E1C, 
Anabaena 7120 
(1) Putative CYP 
(2) NAD(P)H-dependent 
flavoprotein 
alkanes, fatty 
acids 
C8 alkane yielded 
76 % 1-octanol and 
24 % octanoate in 
Corynebacterium. 
CYP110 is a 
hypothetical fatty 
acid ω-hydroxylase 
in Anabaena 
100-103 
Long-chain alkane oxygenases 
CHA0 Pseudomonas 
fluorescens CHA0 
Inferred alkane 
oxygenase 
C18-C28 alkanes Discovered in 
complementation 
studies 
104 
AlkM Acinetobacter sp. M-1 (1) Integral-
membrane copper 
dioxygenase 
(2) Rubredoxin 
(3) Rubredoxin 
reductase 
C10-C44 alkanes 
and alkenes 
Strongly inhibited 
by Fe2+ and Zn2+ 
105, 106 
LadA Geobacillus 
thermodenitrificans 
NG80-2 
Soluble FMNH2 or 
NADPH-dependent 
metal-free flavoprotein 
monooxygenase 
C15-C36 alkanes Thermostable  107, 108 
LadA (F146N/N376I) 
mutant 
C16 alkane 3.4-fold  higher 
activity than wild 
type LadA 
109 
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As indicated in table 1.2, all biocatalysts are multicomponent proteins. This makes their 
functional expression difficult. Some of them (e.g. binuclear metallic enzymes) are even quite 
unstable and subject to strong product inhibition.110 Given their substrate range and stability, 
AlkB and CYP monooxygenases are more relevant to the scope of this work. AlkB enzymes have 
relatively high turnover rates, but their membrane-integrated nature limits their application in 
in vitro studies.111 In the following section we describe the CYP superfamily, focusing on the 
membrane-bound CYP52 and soluble CYP153 enzymes. Other microbial CYPs are much less 
documented, have poor performance or ω-regiosepecificity towards aliphatic compounds. 
 
1.2.2.1 Cytochrome P450 monooxygenases  
 
CYP enzymes (EC 1.14.x.x) catalyze the cleavage of molecular oxygen by the incorporation of one 
atom of molecular oxygen into a substrate molecule while reducing the second one to water.112 
The proposed reaction mechanism catalyzed by CYPs is shown in figure 1.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Proposed catalytic cycle of cytochrome P450 monooxygenases in hydroxylation 
reactions. The catalytically active iron-oxo ferryl species (Compound I) is highlighted in yellow. 
Graphic adapted from Denisov et al.113  
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The substrate first displaces a water molecule (1) and binds FeIII (2), which is then reduced to 
FeII (3) by a one-electron transfer. FeII binds dioxygen to form an oxy-ferrous intermediate (4). A 
second one-electron reduction generates a negatively charged iron-peroxo complex (5a), which 
is protonated to yield an iron-hydroperoxo intermediate (5b). The O-O bond of this intermediate 
is cleaved, resulting in the release of one water molecule and the formation of the iron-oxo ferryl 
species, known as compound I (6). The activated oxygen atom of compound I oxidizes the 
substrate (7). The product is finally displaced by a water molecule. In addition to these steps, 
there are three side reactions: (i) the autoxidation shunt, in which the oxy-ferrous intermediate 
(4) is oxidized with production of a superoxide anion, (ii) the peroxide shunt, where the 
coordinated peroxide or hydroperoxide anion (5a,b) dissociates from the iron, resulting in 
hydrogen peroxide formation, and (iii) the oxidase shunt, wherein the activated oxygen from 
compound I (6) is reduced to water instead of resulting in oxidation of the substrate. These 
three processes are often referred to as uncoupling.113  
 
The vast majority of CYPs are active only after interacting with one or more redox proteins from 
which they obtain their reducing equivalents. The electron transfer chain usually begins with the 
delivery of two electrons from NAD(P)H to the redox protein(s) and then to the heme iron 
catalytic site. Depending on the topologies of the heme and the reductase components, CYPs 
have been grouped in up to 10 classes.114 However, the most widespread topology classification 
includes only 4 classes (figure 1.4).115, 116  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Topologies of CYP enzymes. FAD, flavin adenine dinucleotide; FeS, iron-sulfur ferredoxin, 
FMN, flavin mononucleotide. Examples of each class are: (I) P450cam (CYP101) from Pseudomonas 
putida, (II) Human CYP3A4, (III) P450 BM3 (CYP102A1) from Bacillus megaterium, (IV) P450 RhF 
from Rhodococcus sp. Graphic adapted from O’Reilly et al.115 
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CYP enzymes have been widely studied for synthetic applications due to their high chemo-, 
regio- or stereoselectivity and broad substrate spectrum. However, their cofactor dependence, 
low turnover number and low stability have limited their use in industrial processes.117-119 
Current applications of CYPs are restricted to microbial fermentation processes to produce high 
value-added pharmaceuticals and fine chemicals that are difficult to obtain by chemical 
syntheses. The conversion of progesterone to cortisone by Rhizopus sp., established in the 1950s 
by Pharmacia and Upjohn (now Pfizer), is the first industrial application of a CYP.120, 121 The 11β-
hydroxylation of Reichstein S to hydrocortisone by Curvularia sp.122 is a process run at 100 
tons/year at Schering.123 Pravastatin, a drug that reduces cholesterol levels in blood, is produced 
by the microbial hydroxylation of compactin at Sankyo Pharma and Bristol-Myers Squibb, with 
an annual market value of US$ 3.6 billion.123 The fungal strain Beauveria bassiana Lu 700, which 
hydroxylates 2-phenoxypropionic acid to 2-(4′-hydroxyphenoxy)propionic acid is used for the 
synthesis of a number of agrochemicals at BASF.124 This strain is also able to selectively 
hydroxylate other aromatic carboxylic acids.125 Several other examples of the industrial 
applications of CYPs have been reviewed in the literature.119, 123, 126 
 
1.2.2.1.1 Fungal CYP52 monooxygenases 
 
Selective terminal oxidation reactions occur naturally in mammals, plants and in certain fungi 
and bacteria.127 Fungal CYP52 enzymes are membrane-bound microsomal monooxygenases that 
belong to class II CYPs, comprised by the CYP protein and an accompanying NADPH-dependent 
FAD/FMN-containing cytochrome P450 reductase (NCP). CYP52 monooxygenases ‒ as well as 
NCPs ‒ are encoded in one organism by different gene isoforms. The isoenzymes have 
diversified in their inducibility and substrate specificity. CYP52 genes have been found in 
filamentous fungi, including Aspergillus, and in yeasts of the genera Candida, Yarrowia and 
Pichia, to name a few.128 The most studied CYP52 enzymes belong to Candida maltosa, Candida 
tropicalis and Yarrowia lipolytica, where they have been found to be responsible for the ω-
hydroxylation of alkanes, fatty acids and alkylbenzenes.129, 130  
 
C. maltosa contains at least 8 CYP52 gene isoforms.131, 132 From them, CYP52A3 and CYP52A4, 
have been fully characterized.14 CYP52A3 converts its preferred substrate hexadecane to 1-
hexadecanol as major product, but it also produces the corresponding aldehyde, acid, ω-OHFA 
and α,ω-DCA.17 CYP52A4 prefers dodecanoic acid as substrate, yielding the corresponding ω-
OHFA. C. tropicalis possesses at least 18 CYP52 gene isoforms.12 Two of them, CYP52A13 and 
CYP52A17, are known to act preferentially on oleic and tetradecanoic acid, respectively. Both 
enzymes yield the corresponding ω-OHFAs and α,ω-DCAs, with CYP52A17 displaying higher 
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diacid formation.81 Y. lipolytica has also been explored for its potential in alkane ω-oxidation.13 
This microorganism counts with 12 gene isoforms. CYP52F1, for instance, acts on decane and 
dodecane. CYP52F2 oxidizes molecules larger than dodecane. Other three isoenzymes have ω-
hydroxylation activities towards dodecanoic acid.133-135  
 
Yeast CYP52 enzymes currently constitute the basis of the bio-based production of terminally 
oxidized fatty acids from alkanes or fatty acids. In all cases, metabolic engineering is required to 
prevent substrate and product depletion. One example is the accumulation of 20 g l-1 α,ω-DCA 
from 23 g l-1 dodecane after 50 h in a Y. lipolytica strain wherein four peroxisomal acyl-CoA 
oxidases (POX genes) were deleted.136 The latest achievement consists of the production of 174 g 
l-1 ω-OHFA and 6 g l-1 α,ω-DCA from 200 g l-1 methyl tetradecanoate after 6 days using an 
improved C. tropicalis strain. The host was engineered to overexpress a genome-integrated 
codon-optimized version of CYP52A17 under the control of the fatty acid-inducible isocitrate 
lyase (ICL) promoter. Since the target product was the ω-OHFA compound, a total of 16 genes 
(the native CYP52A17, 4 other CYP52 isoenzymes, 4 fatty acid alcohol oxidases and 7 alcohol 
dehydrogenases) ought to be deleted in order to prevent unspecific substrate oxidation and 
minimize ω-OHFA overoxidation.4 A recently constructed Y. lipolytica mutant lacking all its 
constitutive CYP52 gene isoforms is also a promising host for specific CYP52 characterization 
studies and biotechnological applications.137  
 
1.2.2.1.2 Bacterial CYP153 monooxygenases  
 
CYP153 enzymes are class I CYPs that operate as three-component systems, comprised by the 
CYP itself, an iron-sulfur ferredoxin and a FAD-containing ferredoxin reductase, which are 
necessary for the transfer of electrons from NADH to the CYP active site (figure 1.5).86, 138 
Enzymes of the CYP153A subfamily are regarded as promising biocatalysts due to their 
functional expression in soluble form as well as their high regioselectivity for the ω-position of 
alkanes and other compounds.87 Previous to this work, CYP153 enzymes are not mentioned in 
the literature as fatty acid ω-hydroxylases.  
 
 
 
 
 
 
Figure 1.5. Schematic representation of a soluble CYP153A enzyme system catalyzing a typical n-
alkane oxidation reaction. FdR, FAD-containing ferredoxin reductase; Fdx, ferredoxin.  
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CYP153 enzymes are found in α-, β- and γ-Proteobacteria (Gram-negatives) and Actinomycetales 
(high G+C Gram-positives) from oil-contaminated soil and marine environments.104, 139 
CYP153A1 from Acinetobacter sp. EB104 was the first cloned and molecularly characterized 
CYP153.86 In the early 2000s, Witholt and van Beilen collected a total of 137 alkane-degrading 
strains from natural and artificial environments, which were used as sources of CYP153A 
enzymes.140 Fifteen of them, including Mycobacterium sp. HXN-1500, were isolated from a 
trickling-bed bioreactor by Engesser’s group at the University of Stuttgart.141 Due to its higher 
turnover rates towards n-alkanes compared to other CYP153A enzymes, CYP153A6 from 
Mycobacterium sp. HXN-1500 has been further characterized, engineered and applied in whole 
cell biotransformations.77, 83, 84, 88, 142 CYP153A6 converts C6 to C11 to primary alcohols with a 
maximal turnover of 70 min-1 and ≥95 % ω-regiospecificity.83 Not only does this enzyme possess 
higher hydroxylation activity towards n-octane, but it is also able to catalyze the terminal 
oxidation of 1-octene and cyclohexene to the corresponding alcohols and epoxides, of styrene to 
styrene epoxide, p-cymene to p-isopropylbenzyl alcohol and of L-limonene to the anticancer 
agent perillyl alcohol (figure 1.6).83, 84 Two-phase bioconversions of L-limonene to perillyl 
alcohol by CYP153A6 and natural redox partners in Pseudomonas putida have resulted in a 
production yield of 6.8 g l-1 in the organic phase after 75 h.88 Lately, bioconversions of n-octane 
by CYP153A6 expressed with its natural redox partners in E. coli resulted in the production of 
8.7 g l-1 1-octanol after 48 h using 20 % (v/v) substrate and 11 gcdw l-1 resting cells.142 
 
Misawa and collaborators have also made great contributions in the field by analyzing 
CYP153A13a (P450balk) from Alcanivorax borkumensis SK2 and 16 other new CYP153A genes 
isolated from polluted soil and groundwater.85 The same group later found that CYP153 from 
Acinetobacter sp. OC4 (P450aci) had the ability to oxidize C6-C12 primary alcohols to α,ω-diols. 
Biotransformations of n-octane with 200 gcww l-1 E. coli cells containing P450aci and its natural 
redox partners yielded 2.3 g l-1 1-octanol and 0.7 g l-1 1,8-octanediol after 24 h.90 P450aci and 
CYP153A13a were later co-expressed with the redox partners of P450cam ‒ namely 
putidaredoxin reductase (CamA) and putidaredoxin (CamB) ‒ or expressed as a fusion protein 
with the reductase domain of P450RhF (RhFred). Besides converting n-octane to the 
corresponding 1-alcohol and α,ω-diol, they hydroxylated cyclohexane to cyclohexanol and ω-
oxidized the aliphatic chain of n-butyl-substituted aromatic and heterocyclic compounds (figure 
1.6).91 More strikingly, CYP153A13a-RhFred has been found to hydroxylate the p-position of 
halogenated or acetyl-substituted phenolic compounds.143 Other studies on CYP153A13a-
RhFred include substrate binding, coupling efficiency and bioconversion towards n-alkanes.89 
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Figure 1.6. Substrate spectra of well-characterized CYP153A enzymes. CYP153A6 from 
Mycobacterium sp. HXN-1500, CYP153A13a from Alcanivorax borkumenesis SK2 and CYP153A7 from 
Sphingopyxis macrogoltabida. 
 
Prior to this work, rational design studies on CYP153A enzymes have not been reported in the 
literature. Structural insights have been provided by a substrate-docked homology model of 
CYP153A6, which allows the visualization of 11 active site residues.83 This model suggested that 
the active site of CYP153A6 is predominantly hydrophobic in nature. Recently, the crystal 
structure of a CYP153A enzyme was published for the first time. It belongs to CYP153A7 
(P450pyr) from Sphingopyxis macrogoltabida (PDB ID 3RWL),144 a catalyst useful for the 
selective hydroxylation of N-substituted azetidines and piperidines (figure 1.6).145 However, the 
CYP153A6 CYP153A13a 
CYP153A7 
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final structure lacks 9 residues located in a loop on the top of the cavity leading to the active site. 
This region was not visible in the electron density maps, a phenomenon that has also been 
described for the substrate-free state (“open state”) of P450cam.146 
 
Directed evolution on CYP153A enzymes has been carried out in Arnold’s laboratory. CYP153A6 
was randomly mutated in vivo to shift its substrate range towards shorter gaseous alkanes. 
Mutator strains were used to generate a library of 108 plasmid variants encoding CYP153A6. The 
plasmids were incorporated in adapted P. putida Gpo12(pGEc47∆B) cells, which lack the alkane-
degrading OCT plasmid and are thus unable to grow on alkanes without gene complementation. 
Evolved variants were selected by enhanced cell growth on the target alkanes as the sole carbon 
source. The effects of plasmid mutations and host adaptation were excluded by recloning the 
promising variants into a wild type vector and transferring them into a wild type strain. A single 
point mutation (A97V) was observed to be responsible for the 75 % increase in activity towards 
n-butane compared to the wild type enzyme in whole cell bioconversions using E. coli. However, 
the effect of the mutation – located in a loop region outside the active site – was not clearly 
understood.77  
 
1.3 Bacterial whole cell bioconversions with oxygenases 
 
In biocatalytic reactions with oxygenases whole cells are preferred over isolated enzymes 
primarily because cells are capable of regenerating NAD(P)H. Cells may also confer higher 
oxygenase stability by providing a protected compartment (soluble enzymes) or a better 
organization of its components (membrane-bound enzymes). Additionally, cells contain the 
necessary machinery to scavenge reactive oxygen species originating from uncoupling, which 
could inactivate the enzyme. Despite these advantages, important issues such as 
substrate/product toxicity, low substrate uptake, byproduct formation, limited oxygen transfer 
and reduced cofactor availability should be overcome.147-149  
 
1.3.1 Pseudomonas and E. coli as cell factories 
 
The selection of the ideal host strain relies on high cell growth rates in simple media and access 
to knowledge and tools for its genetic manipulation. Other strain-related factors directly 
influencing the efficiency of a biocatalytic process include tolerance towards the 
substrate/product(s), stable recombinant protein expression, high NAD(P)H regeneration rate, 
low byproduct formation and the possibility of reuse for multiple reaction cycles.150 In this 
32 Introduction 
 
sense, Pseudomonas strains possess desirable features such as: 1) simple nutrient demand, 2) 
robustness to tolerate and modify several toxic aliphatic, aromatic and heterocyclic compounds, 
3) efficient cofactor supply, and 4) inherent self-immobilization ability which facilitates the 
formation of stable and catalytically active biofilms.151-154  
 
Pseudomonas putida and related strains are nowadays used in diverse industrial applications, 
including the synthesis of bio-based materials, de novo synthesis and biotransformation of fine 
chemicals and pharmaceuticals.153 Most of these processes exploit the unique xenobiotic-
degrading enzymatic machinery of pseudomonads and are thus based on metabolically-
engineered overproducing strains. The application of Pseudomonas strains in recombinant 
oxygenase-based biotransformations is still on the research level. In general, Pseudomonas 
strains seem more advantageous than E. coli because they have a network of glucose metabolism 
with multiple reduction and oxidation steps leading to a more efficient generation of redox 
power.155 In terms of solvent tolerance, Pseudomonas putida strains are able to grow in the 
presence of high organic solvent concentrations (e.g. 6 % (v/v) 1-butanol).156 However, solvent-
tolerant strains also need more energy and cofactor to sustain defense mechanisms when 
exposed to toxic compounds.157-159 Considering that the carbon source is one of the highest 
operation costs in a bioprocess, the use of a Pseudomonas biocatalyst is economically justified if 
it exhibits not only a significantly higher solvent tolerance compared to other industrial 
production organisms (e.g., E. coli), but a similar product yield on carbon source as well.160 
Oxygen transfer is also a critical factor during reactions with the strictly aerobic pseudomonads; 
therefore, the process design should allow sufficient aeration to support both cell 
growth/maintenance and redox catalysis. Additional issues that should be addressed for 
industrial applications have been discussed elsewhere.161  
 
In a recent study on the synthesis of (S)-styrene oxide from styrene in a biphasic system, 
recombinant E. coli (containing styrene monooxygenase/reductase) and Pseudomonas sp. strain 
VLB120∆C were compared.160 This pseudomonad is a solvent-tolerant strain expressing styrene 
monooxygenase and reductase constitutively but lacking styrene oxide isomerase, which 
mediates the conversion of the target product styrene oxide to phenylacetaldehyde. 
Biotransformations in E. coli resulted in higher specific activities, product yields on glucose and 
volumetric productivities than the investigated Pseudomonas strain. Nevertheless, the 
pseudomonad provided the advantages of tolerance towards higher product titers and higher 
process durability. In contrast to E. coli, the pseudomonad did not accumulate the byproduct 2-
phenylethanol because it was able to degrade it.160 Moreover, Pseudomonas sp. produced ten 
times less acetate than E. coli (0.3 vs. 3.6 g l-1). Acetate formation is known to reduce the cofactor 
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regeneration yield per glucose consumed and to negatively influence the proton gradient across 
the cytoplasmic membrane.162, 163 
   
A step forward in the application of pseudomonads in redox biocatalysis consists of the 
establishment of biofilm-forming and engineered Pseudomonas strains for efficient styrene oxide 
production in novel continuous reactors. The bioprocess resulted in high volumetric 
productivities as well as improved tolerance and robustness comparable to those of planktonic 
cultures.164-166 
 
1.3.2 Growing and resting cells as whole cell biocatalysts 
 
One key question in whole cell biocatalysis is whether to use growing or resting cells. Growing 
cells are capable of constant oxygenase synthesis and they should have a more active 
metabolism for cofactor regeneration. However, most of the available energy and cofactor are 
used for biomass formation rather than for redox biocatalysis. These cells also have low 
durability and low tolerance to substrate/product toxicity. Metabolically active resting cells have 
lower carbon and energy demands than growing cells, thus the cofactor formed during central 
carbon catabolism can be exploited more efficiently for biocatalysis rather than for cell growth. 
This results in higher specific activities and product yields on energy source. In addition, resting 
cells display a higher biomass durability which might enable their reuse, provided high 
oxygenase activities are retained over time. 167-170  
 
Most limitations observed in whole biotransformations with resting cells depend on factors 
intrinsically associated to the biocatalyst (e.g., enzyme stability, enzyme kinetics, uncoupling) 
rather than on the metabolic capacity of the host strain.167 For example, in the oxygenase-
mediated epoxidation of styrene in biphasic medium, maximal specific activities with resting E. 
coli cells doubled those of growing cells in a similar setup.171 Toxicity was not a problem and the 
enzyme was not deactivated, but product formation rates decreased steadily mainly due to 
product inhibition.167 In another study with E. coli containing a recombinant Baeyer-Villiger 
monooxygenase, space-time yields of non-growing cells were 20 times higher than those of 
growing cells. Here the duration and rate of the oxidation reaction were limited by the 
intracellular stability of the oxygenase and the rate of substrate transport across the cell 
membrane.169 Therefore, strategies to minimize product inhibitory effects on the biocatalyst 
include the application of two-liquid phase systems and in situ product removal techniques. The 
use of solvent tolerant strains can also contribute to avoid inhibition by efficient transport of the 
product out of the cell.172 
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1.4 Aim of the work 
 
Within the frame of the “Systems Biology of Pseudomonas for Industrial Biocatalysis”i and 
“Developing the Next Generation of Biocatalysts for Industrial Chemical Synthesis”ii projects, the 
aim of this work was to develop a stable recombinant bacterial system harboring a 
regioselective alkane hydroxylase to catalyze the omega-oxyfunctionalization of industrially-
relevant aliphatic compounds, including alkanes, primary alcohols and fatty acids (scheme 1). 
For this purpose, the following tasks were established:  
• Identification of appropriate bacterial cytochrome P450 monooxygenases or non-heme 
monooxygenases via substrate screening or database-driven search. 
• Tailoring of the biocatalyst by rational design or directed evolution to suit the target 
substrates and functional expression of the best candidates in solvent-tolerant Pseudomonas 
and E. coli strains.  
• Improvement of the designed biocatalytic system by optimization of electron coupling 
efficiency in solvent-tolerant Pseudomonas or E. coli strains using a protein engineering or 
systems biology approach. 
 
 
 
 
 
 
 
 
 
 
Scheme 1 
                                                          
i German Federal Ministry of Education and Research (BMBF)  
ii European Union’s 7th Framework Programme FP7/2007-2013, Grant Agreement No. 266025 
 
Microorganism 
Alkane / fatty acid  
 ω-hydroxylase 
Enzyme 
R-H R-OH 
 
Solvent tolerant 
Recombinant                
whole cell biocatalyst 
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2 Experimental section 
 
2.1 Genes, vectors and strains 
 
Genes, vector constructs and strains are detailed in supplementary material section 6.1. 
 
2.2 Procedures 
 
2.2.1 Substrate screening of CYP153A biocatalysts 
 
Materials and methods for the screening of CYP153A enzymes towards linear alkanes,173 
primary alcohols173 and fatty acids174 are described in the corresponding references. 
 
2.2.2 Creation of a focused mutant library of CYP153A from Marinobacter 
aquaeolei 
 
2.2.2.1 Site-directed mutagenesis  
 
Plasmid pET28a(+) harboring His6-tagged CYP153A M. aq. was mutated using the QuikChange 
standard protocol. Nineteen variants were created by PCR amplification with the 
oligonucleotides indicated in table 2.1. Competent E. coli DH5α cells were transformed with the 
DpnI-treated PCR mixtures. Isolated plasmids with the desired mutations were verified by 
sequencing (GATC-Biotech, Köln, Germany) and used to transform E. coli BL21(DE3) cells.  
 
Table 2.1.  Primers for site-directed mutagenesis 
Variant Primer Sequence (5’ → 3’) 
M143R F CTG TCG GTG GAA CGT TTC ATA GCG ATG GAT CC 
  R GGA TCC ATC GCT ATG AAA CGT TCC ACC GAC AG 
I145M F CG GTG GAA ATG TTC ATG GCG ATG GAT CCG CC 
  R GG CGG ATC CAT CGC CAT GAA CAT TTC CAC CG 
I145F F CG GTG GAA ATG TTC TTT GCG ATG GAT CCG CC 
  R GG CGG ATC CAT CGC AAA GAA CAT TTC CAC CG 
F = Forward primer; R = Reverse primer (complementary sequence); mutated codons (bold) 
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Table 2.1.  (continued) 
Variant Primer Sequence (5’ → 3’) 
I145S/T F CG GTG GAA ATG TTC ASC GCG ATG GAT CCG CC 
  R GG CGG ATC CAT CGC GST GAA CAT TTC CAC CG 
T302M      F T ATC GGT AAT TTG RTG CTG CTC ATA GTC GGC G    
  R C GCC GAC TAT GAG CAG CAY CAA ATT ACC GAT A 
T302V F G GAG TTT ATC GGT AAT TTG GTG CTG CTC ATA GTC GGC GGC AAC GAT ACG AC 
 R GTC GTA TCG TTG CCG CCG ACT ATG AGC AGC ACC AAA TTA CCG ATA AAC TCC 
L303T F T ATC GGT AAT TTG ACG ACC CTC ATA GTC GGC G 
  R C GCC GAC TAT GAG GGT CGT CAA ATT ACC GAT A 
V306T F TG ACG CTG CTC ATA ACC GGC GGC AAC GAT ACG 
  R CGT ATC GTT GCC GCC GGT TAT GAG CAG CGT CA 
G307A/V F C GGT AAT TTG ACG CTG CTC ATA GTC GYG GGC AAC GAT ACG ACG CGC 
  R GCG CGT CGT ATC GTT GCC CRC GAC TAT GAG CAG CGT CAA ATT ACC G 
L354I/F      F G GTG TCG GAA ATC ATC CGC TGG CAA ACG CCG WTT  GCC TAT ATG CGC CGA ATC GCC 
GCC AAG CAG GAT GTC GAA CTG 
  R CAG TTC GAC ATC CTG CTT GGC GGC GAT TCG GCG CAT ATA GGC AAW CGG CGT TTG 
CCA GCG GAT GAT TTC CGA CAC C 
M357F F CAA ACG CCG CTG GCC TAT TTT CGC CGA ATC GCC AAG CAG G 
 R CCT GCT T GG CGA TTC GGC GAA AAT AGG CCA GCG GCG TTT G 
M357Y               F G CCG CTG GCC TAT TWT CGC CGA ATC GCC AAG 
  R CTT GGC GAT TCG GCG AWA ATA GGC CAG CGG C 
M357N F G CCG CTG GCC TAT AAC CGC CGA ATC GCC AAG 
  R CTT GGC GAT TCG GCG GTT ATA GGC CAG CGG C 
F465L     F GTG CAG TCC AAC CTG GTG CGG GGC TAT TC 
  R GA ATA GCC CCG CAC CAG GTT GGA CTG CAC 
F465I F GTG CAG TCC AAC ATT GTG CGG GGC TAT TC 
  R GA ATA GCC CCG CAC AAT GTT GGA CTG C AC 
F465Y 
  
F GTC GAA GAG CCC GAG CGG GTG CAG TCC AAC TAT GTG CGG GGC TAT TCC AGG TTG 
ATG GTC 
R GAC CAT CAA CCT GGA ATA GCC CCG CAC ATA GTT GGA CTG CAC CCG CTC GGG CTC TTC 
GAC 
F = Forward primer; R = Reverse primer (complementary sequence); mutated codons (bold) 
 
2.2.2.2 Protein expression, purification and quantitation 
Expression and purification of the His6-tagged CYP153A M. aq. variants were carried out as 
described elsewhere.173 Concentrations of the P450 enzymes were determined by the carbon 
monoxide (CO) differential spectral assay described by Omura and Sato.175, 176 
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2.2.2.3 In vitro oxidation assays and kinetic analysis  
 
All variants including wild type enzyme were screened in a preliminary assay using cell-free 
extracts resulting from disrupted cells resuspended in 50 mM potassium phosphate buffer pH 
7.5 and protease inhibitor (0.1 mM PMSF). Reaction mixtures were run for 4 h at 30°C in a final 
volume of 0.5 ml containing 50 mM potassium phosphate buffer pH 7.5, 2 µM P450 (as lysate), 
10 µM CamA, 20 µM CamB, 1 mM substrate in ethanol (n-alkane and primary alcohols) or in 
DMSO (fatty acids), 1 mM NADH and the glucose-6-phosphate/glucose-6-phosphate 
dehydrogenase (G6P/G6PDH) system (1 mM MgCl2, 5 mM G6P and 12 U ml-1 G6PDH) for 
cofactor regeneration.174 Reactions with poorly expressible variants were run with 0.2 µM CYP. 
The results were contrasted with those obtained with 0.2 µM wild type enzyme. Procedures 
concerning reaction setups with purified proteins for substrate conversions (wild type enzyme 
and variants G307A, L354I and L354F) and the determination of kinetic parameters (wild type 
enzyme and variant G307A) are detailed in the corresponding reference.174 Sample treatment 
and GC/MS analysis of substrates and products are therein described as well.  
 
2.2.3 Bacterial whole cells for the synthesis of ω-oxyfunctionalized aliphatic 
compounds 
 
2.2.3.1 Biotransformations of n-octane by growing P. putida cells containing 
CYP153A gene clusters  
 
2.2.3.1.1 Cloning of CYP153A gene clusters 
 
Alkane hydroxylase gene clusters from Mycobacterium marinum M. (ATCC BAA-535), 
Marinobacter aquaeolei VT8 (DSM 11845) and Polaromonas sp. JS666 (ATCC BAA-500) were 
isolated from genomic DNA. Each cluster was comprised by the CYP153A monooxygenase and 
two neighbouring redox proteins annotated as putative electron partners of the corresponding 
CYP enzyme (table 2.2; suplemmentary material section 6.1.1). For their expression in 
Pseudomonas, plasmids derived from the L-rhamnose-inducible pJOE177, 178 and the n-alkane-
inducible pCom179 series were utilized.   
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Table 2.2. Alkane hydroxylase gene clusters and plasmid constructs 
Strain  Gene cluster 
abbreviation  
Gene cluster composition (5’→ 3’) 
and size 
Plasmids 
Mycobacterium 
marinum M. 
MmAlk 
MmFdx→CYP153A16→MmFdR 
(2932 bp) 
pJOE-MmAlk 
pCom10-MmAlk 
Marinobacter 
aquaeolei VT8 
MaqAlk 
MaqFdx→CYP153A M.aq.→ MaqFdR 
(3063 bp) 
pJOE-MaqAlk 
pCom10-MaqAlk 
Polaromonas sp. 
JS666 
PspAlk 
CYP153A P. sp→ PspFdR→PspFdx 
(2898 bp) 
pJOE-PspAlk 
pCom10-PspAlk 
Fdx, ferredoxin; FdR, ferredoxin reductase  
 
Vectors were provided as pJOE4782.1180 and pCom10-alkB-BMO277 constructs by J. 
Altenbuchner (University of Stuttgart) and F. H. Arnold (California Institute of Technology), 
respectively (supplementary material figure 6.1). Plasmid pJOE4782.1 originally contains genes 
encoding malE (maltose-binding protein) and eGFP (enhanced green fluorescent protein) 
between sites NdeI and HindIII. In a previous work at our institute, the NdeI site was mutated to 
introduce an XbaI site. The malE-eGFP region was excised with endonucleases XbaI and BsrGI 
(BsrGI cuts eGFP 3 bp before its stop codon) to insert the gene coding for P450 BM3.181 Here we 
removed the P450 BM3 gene insert to introduce the MmAlk gene cluster, while the original 
pJOE4782.1 was used to insert the MaqAlk and PspAlk operons. Plasmid pCom10-alkB-BMO2 
did not contain an NdeI site; therefore, primer 5’-TAA AAA TTG GAG AAT TCA TAT GCT TGA GAA 
ACA CAG AGT TC-3’ and its complementary sequence 5’-GAA CTC TGT GTT TCT CAA GCA TAT 
GAA TTC TCC AAT TTT A-3’ were designed to insert the restriction site into the construct 
following the QuikChange site-directed mutagenesis protocol. The gene clusters were amplified 
using a standard PCR protocol with the primers indicated in table 2.3. The PCR-amplified gene 
clusters were digested and ligated with the corresponding linearized vectors.  
 
Table 2.3. Primers for cloning the alkane ω-hydroxylase gene clusters  
Primer name Sequence (5’ → 3’) Use 
MmAlk_Xba_F C TAG tct aga GGA GAT ATT GAA ATG GCA GTT GTC A Cloning of MmarAlk into 
pJOE MmAlk_BsrG_R G TAC tgt aca TCA GTC CGA GCC GGC 
MmAlk_Eco_F AA TTg aat tcA ATT CCA ATG GCA GTT GTC ACA TTT GTC Cloning of MmarAlk into 
pCom10 MmAlk_Hind_R A GCT aag ctt TCA GTC CGA GCC GG 
MaqAlk_Nde_F TA cat atg GGC GGT CAC GAT GGG CC Cloning of MaqAlk into 
pJOE and pCom10 MaqAlk_Hind_R A GCT aag ctt TCA ACT CTG GAG CCT TCC GT 
PspAlk_Nde_F GGT cat atg AGA TCA TTA ATG AGT GAA GCG ATT GTG GTA 
AAC AAC C 
Cloning of PspAlk into 
pJOE and pCom10 
PspAlk_Hind_R A GCT aag ctt TCA GTG CTG GCC GAG CGG 
Restriction site (lower-case letters); ribosome binding site (underlined); start/stop codon (bold) 
Experimental section 39 
 
The resulting constructs were verified by sequencing (GATC-Biotech, Köln, Germany). The pJOE 
vector constructs were sequenced with the forward primer 5'-GGC GCT TTT TAG ACT GGT CG-3', 
which hybridized with the L-rhamnose promoter, and with the reverse primer 5'-GAG CAA ACT 
GGC CTC AGG CA-3', which encodes a region of the pJOE vector. The pCom10 vector constructs 
were sequenced with the forward primer 5'-TGG GCG GCT TAA CTT TCT CAG TTA-3', which 
hybridized with the PalkB promoter region, and with the reverse primer 5'-TTA TCA GAC CGC 
TTC TGC GTT CT-3´, which is complementary to a section of the pCom10 vector. The complete 
sequences were verified by additional sequencing with two primers matching specific regions of 
each cluster: 5'-CGA AGA ACC TGC GTG AGA TG-3' (811-830) and 5'-GAT CCT GTG GGA GGA GCT 
G-3' (1601-1620) for MmAlk; 5'-TAG TGG CAC CGA AAA ACC TGA AG-3' (811-833) and 5'-CAT 
CCG AAC GTG TGG AGA GTC-3' (1760-1790) for MaqAlk and; 5'-CGG ACG AAT ACC GCA AGC TG-
3' (821-840) and 5'- ACG TCG GAC TCG AGA TCG C -3' (1731-1749) for PspAlk. Vector constructs 
were used to transform Pseudomonas putida KT2440 by electroporation.182  
 
2.2.3.1.2 Verification of functional expression of MmAlk in a pseudomonad 
 
P. putida S12 cells were transformed with the pJOE-MmAlk construct and with religated empty 
pJOE (negative control) by electroporation. One colony of each recombinant strain was grown 
overnight in 5 ml LBKan medium at 30°C, 180 rpm. Two milliliters of the pre-culture were used to 
inoculate 400 ml TBKan medium. When an OD600 of 0.6 was reached, cells were induced with 0.2 
% L-rhamnose plus 0.5 mM 5-aminolevulinic acid and incubated at 25°C, 180 rpm for 20 h. Cells 
were harvested, suspended in 50 mM potassium phosphate buffer pH 7.5 with 100 µM PMSF and 
disrupted by sonication (3 x 2 min, 1.5 min intervals). P450 concentrations were determined in 
the cell-free extracts as described elsewhere.175, 176 Cell lysates (4 mg total protein ml-1), 0.1 mM 
cytochrome c and 0.5 mM NADH were used for the cytochrome c reductase assay.183 n-Octane 
oxidation reactions were performed in 50 mM potassium phosphate buffer pH 7.5 with 1 mM 
substrate, 1 mM NADH, the G6P/G6PDH cofactor regeneration system and cell lysate to a final 
concentration of 3 µM P450. Sample treatment and GC/MS analysis proceeded as previously 
described.173   
 
2.2.3.1.3 n-Octane oxidation by growing P. putida KT2440 cells   
 
P. putida KT2440 transformants containing the pJOE constructs were grown in 200 ml TBKan 
medium, while those harboring pCom10 vectors were grown in 200 ml modified M12 mineral 
medium (MM-BVTKan). The medium consisted of 10X mineral salts solution (22 g l-1 (NH4)2SO4, 4 
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g l-1  MgSO4·7H2O; 0.4 g l-1 CaCl2; 0.2 g l-1 NaCl), 50X phosphate solution (100 g l-1 KH2PO4) and 
100X trace elements solution (0.2 g l-1 ZnSO4·7H2O, 0.1 g l-1 MnCl2·4H2O; 1.5 g l-1 Na3-
citrate·2H2O; 0.1 g l-1 CuSO4·5H2O; 0.002 g l-1 NiCl2·6H2O; 0.003 g l-1 NaMoO4 ·2H2O; 0.03 g l-1 
H3BO3 and 1 g l-1 FeSO4·7H2O). MM-BVTKan was supplemented with additional citrate (5 g l-1) as 
carbon source to prevent repression of the PalkB promoter by glucose.184 Cultures were left to 
grow at 30°C, 180 rpm, induced for recombinant protein expression at exponential growth 
phase (OD600 = 0.6) and fed with 15 % (v/v) n-octane upon induction. In the case of pCom10-
containing strains, the substrate acted as inducer as well. To prevent carbon and energy source 
depletion, 5 g l-1 glucose and 5 g l-1 citrate were added to TBKan and MM-BVTKan, respectively, 6 
and 12 h after starting the cultures. Fifty mililiter culture samples were collected at different 
time points after induction/substrate addition for the measurement of optical cell densities 
(OD600) and quantitative analysis of products by GC/FID. For the determination of 1-octanol 
concentrations, 0.5 ml culture samples were treated with 20 µl 37 % HCl and extracted twice 
with 0.5 ml ethyl acetate containing 0.2 mM 1-hexanol as internal standard. Samples were 
analyzed on a GC/FID (Shimadzu, Japan) equipped with an Agilent DB-5 column (30 m x 0.25 
mm x 0.25 µm) with hydrogen as carrier gas (flow rate, 1.1 ml/min; linear velocity, 32 cm/s). 
The injector and detector temperatures were set at 250°C and 310°C, respectively. The column 
oven was set at 40°C for 2 min, raised to 160°C at a rate of 10°C/min, then raised to 300°C at 
80°C/min. 1-Octanol was measured from calibration curves estimated from a series of standard 
solutions treated in the same manner as the samples. 
 
2.2.3.2 Biotransformations of n-octane and fatty acids by resting P. putida and E. 
coli cells containing engineered CYP153A in a fusion construct  
 
2.2.3.2.1 Subcloning of fusion genes  
 
The wild type (CYP153A M. aq.–CPRBM3) and mutant (CYP153A M. aq. (G307A)–CPRBM3) fusion 
chimeras were created as pET28a(+) vector constructs (Daniel Scheps, unpublished data). For 
comparison studies in P. putida and E. coli strains, the fusion proteins were subcloned into 
pJOE4782.1 (XbaI/BsrGI). The fragments were amplified with the forward primer 5’- C TAG tct 
aga ATG CCA ACA CTG CCC AGA ACA TTT-3’ and the reverse primer 5’-G TAC tgt aca TTA CCC 
AGC CCA CAC GTC TTT-3’ (restriction sites in lower-case letters; start/stop codons in bold) 
following a standard PCR protocol. Each digested PCR-amplified fusion gene was ligated with the 
linearized pJOE vector. Correct constructs were verified by sequencing (GATC-Biotech). 
Religated pJOE without insert was later used as negative control. 
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2.2.3.2.2 n-Octane and fatty acid oxidations by resting P. putida and E. coli cells  
 
Strains P. putida KT2440, P. putida S12, E. coli JM109 and E. coli BL21(DE3) were included in the 
comparative study. Competent P. putida and E. coli cells were transformed with the previously 
mentioned pJOE-CYP153A M. aq.-CPRBM3 fusion constructs (containing wild type or mutant CYP) 
by electroporation and heat shock, respectively. Cells were also transformed with empty 
religated vector as negative controls to evaluate substrate consumption by the host strains in the 
absence of monooxygenase. 
 
Freshly-plated transformants were grown overnight in LBKan and 2 ml of the pre-cultures were 
used to inoculate 400 ml TBKan. Cells were incubated at 30°C (P. putida) or alternatively at 37°C 
(E. coli) on shakers at 180 rpm.  At an OD600 of 1.2 - 1.5, cells were induced for recombinant 
protein expression with 0.2 % L-rhamnose. After 16 - 18 h (OD600 = 9-10), cells were harvested 
and washed twice with 100 mM postassium phosphate buffer pH 7.4 containing 10 g l-1 glycerol. 
Cells were suspended in 100 mM potassium phosphate buffer pH 7.4 with 10 g l-1 glycerol, 100 
µM FeSO4 and 30 µg ml-1 kanamycin to a final concentration of 100 gcww l-1. A fraction of the cell 
suspensions (15 ml) was centrifuged, the pellet weighed and stored at -20°C for cell disruption 
and determination of CYP concentration in cell lysates prior to the start of biotransformations. 
Cell suspensions (20-25 ml) were also used for cell dry-to-wet weight determinations in 
triplicates as described elsewhere.185 
 
Biotransformations of n-octane and fatty acids were conducted with solvent-untreated resting 
cells in the absence or presence of an additional carbon source (glucose/glycerol mix: 0.4 g l-1 
glucose and 10 g l-1 glycerol). In vivo bioconversions with induced resting cells were carried out 
in 100 ml shake flasks containing 20 ml fresh cell suspension (100 or 50 gcww l-1). The 
biotransformation medium consisted of 100 mM potassium phosphate buffer pH 7.4 containing 
glucose/glycerol mix, 100 µM FeSO4 and 30 µg ml-1 kanamycin. Biotransformations started by 
the addition of substrate. For the n-octane reaction setups, the substrate and co-solvent DMSO 
were added to final concentrations of 10 % (v/v) and 2 % (v/v), respectively. Octanoic and 
dodecanoic acids were added to a final concentration of 5 mM from stock solutions containing 
250 mM of the fatty acid in DMSO. In case of oleic acid, the substrate was added directly to the 
bioconversion mixture in a final concentration of 5 mM, followed by addition of 2 % (v/v) DMSO. 
Reactions were run on orbital shakers at 30°C and 180 rpm for 20 h.  
Five hundred microliter samples were collected at different time points (0, 1, 2, 4, 8, 12 and 20 h 
after substrate addition) and reactions were immediately stopped by adding 30 µl 37 % HCl. 
Samples corresponding to n-octane bioconversions were treated and analyzed by GC/FID as 
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described in section 2.3.4.1.3. For samples corresponding to fatty acid bioconversions, internal 
standard (decanoic acid for the C12:0 substrate or tridecanoic acid for the C8:0 and C18:1 substrates) 
was added in a final concentration of 1 mM. The reaction mixtures were extracted twice with 2 
volumes of diethyl ether. The organic phases were collected, dried with MgSO4 (anhydrous) and 
evaporated. Samples were resuspended in 60 µl methyl tert-butyl ether, followed by the addition 
of 60 μl of 1% trimethylchlorosilane in N,O-bis(trimethylsilyl)trifluoroacetamide and incubation 
at 75°C for 30 min for derivatization. Samples were measured by GC/FID as decribed 
elsewhere,174 with the fatty acid substrate and/or products being quantified from calibration 
curves of standard solutions treated in the same manner as the samples.  Occasionally, 
additional culture samples were taken for OD600 measurements and determination of CYP 
concentrations in whole cells in order to evaluate cell toxicity and enzyme activity over time.142  
 
2.2.3.2.3 Determination of hydrogen peroxide formation in cell crude extracts 
 
Quantitation of total (intracellular and extracellular) H2O2 was peformed by the horseradish 
peroxidase/phenol/4-aminoantipyrine spectrophotometrical assay, which is based on the 
absorbance of the quinoneimine product at 510 nm.186 Reaction mixtures were prepared in 50 
mM Tri-HCl buffer pH 7.5 to a final volume of 800 µl and contained 100 µl cell culture, 10 µl 
BugBusterTM 10X Protein Extraction Reagent (Novagen, Wisconsin, USA), 12.5 mM phenol, 1.25 
mM 4-aminoantipyrine and 0.1 mg ml-1 horseradish peroxidase. The absorbance of each sample 
was set at zero before adding the peroxidase. Hydrogen peroxide concentrations were calculated 
from a calibration curve with known concentrations of H2O2 (2 - 80 µM) that yielded 
absorbances in the linear range. In order to exclude any potential interference of the 
BugBusterTM reagent with the enzymatic assay, it was added to all standard solutions.  
 
2.2.3.2.4 Determination of acetate formation in cell cultures 
 
Cell cultures (0.5 ml) were extracted twice with 0.5 ml diethyl ether. The aqueous phase was 
collected and filtered (0.45 µm) for the determination of acetate concentration using an Agilent 
1200 series HPLC system (Agilent Technologies, Waldbronn, Germany) equipped with an 
Aminex HPX-87H Ion Exclusion Column (300 mm x 78 mm, BIO-RAD, USA). The column was set 
at 60°C. The mobile phase consisted of 5 mM sulfuric acid in water. The injection volume was 10 
μl and compounds were separated at a flow rate of 0.5 ml min-1. Acetate was detected on a RID 
set at 35°C and a DAD at 210 nm. The concentration of acetate in the samples was calculated 
using a standard curve of analyte concentrations ranging from 0.25 to 40 mM, treated in the 
same manner as the samples.  
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3 Results and Discussion 
 
3.1 Substrate screening of CYP153A biocatalysts 
 
3.1.1 Medium-chain linear alkanes and primary alcohols  
 
CYP153A16 from Mycobacterium marinum and CYP153A from Polaromonas sp. (CYP153A P. sp.) 
were expressed in soluble form in E. coli BL21(DE3), yielding 1.25 and 32 mg active protein l-1 
culture, respectively, after purification by immobilized metal affinity chromatography. The 
reduced protein yield of CYP153A16 might be caused by the use of GTG as start codon 
(originally present in the cyp153A16 gene sequence). CO-differential spectral assays indicated 
that the concentration of purified CYP153A P. sp. remained constant at room temperature for at 
least 4 h, while the characteristic 450 nm-peak of CYP153A16 decreased after 5 min due to 
lability to sodium dithionite. Nevertheless, the conventional CO-differential spectral assay with 
sodium dithionite was used as a standard method to determine the concentration of both 
purified CYP153 enzymes.  
 
The hydroxylation activities of CYP153A16 and CYP153A P. sp. were investigated using the well-
characterized putidaredoxin reductase (CamA) and putidaredoxin (CamB) from Pseudomonas 
putida as electron transfer partners.187-189 The redox proteins were selected on the basis of their 
amino acid sequence similarity (ranging from 63 to 68 %) with the natural FAD-containing 
oxidoreductases and [2Fe-2S] ferredoxins of CYP153A enzymes from Mycobacterium marinum 
M. and Polaromonas sp. strain JS666 (supplementary material table 6.4). In the absence of CamA 
and CamB, E. coli cell lysate containing CYP153A16 showed negligible CYP oxidation activity 
towards n-octane, thereby implying that the constitutive redox partners from E. coli could not 
interact with the CYP153 enzyme or they were not present in a stoichiometrical ratio to support 
P450 activity. In contrast, when purified CamA and CamB were added to the reaction, the CYP 
was able to catalyze the hydroxylation of n-octane to 1-octanol. Afterwards, the CYP 
concentration was increased by twofold and different P450-CamA-CamB ratios were tested. The 
maximum product concentration (140 µM 1-octanol) was obtained with a P450-CamA-CamB 
ratio of 1:5:10, while the activity was reduced by 23 – 49 % at ratios of 1:1:5, 1:2:10 and 1:2:20.  
 
CYP153A16 and CYP153A P. sp. were screened towards C5-C12 alkanes and C6-C12 primary 
alcohols using CamA and CamB as redox partners within a cofactor regenerating enzyme system. 
Product distributions are shown in figure 3.1. Amongst the formed products: primary alcohols 
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(Cn-1ol), secondary alcohols (Cn-2ol), α,ω-diols and products resulting from the further oxidation 
of primary alcohols (aldehydes and fatty acids) could be identified, while two other byproducts 
could not be identified (supplementary material table 6.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Product distributions using n-alkanes (above) and primary alcohols (below) as 
substrates. Cn-1ol, primary alcohol; Cn-2ol, secondary alcohol. 
 
Similarly to previously reported CYP153 enzymes,83, 84, 87 the alkane substrate range of 
CYP153A16 and CYP153A P. sp. oscillated between C5 and C12, with octane being the preferred 
alkane substrate. C5 and C6 alkanes were converted to primary alcohols with low activity but 
absolute ω-regioselectivity. In case of the primary alcohols, CYP153A16 and CYP153A P. sp. 
could not oxidize 1-hexanol and 1-heptanol, but were able to oxidize those ranging from C8 to 
C12. Consistent with the literature, there is a relationship between the substrate chain length and 
enzyme activity as well as regiospecificity.87, 190, 191 In general, ω-regioselectivities tend to 
decrease for substrates longer than C10. The concentrations of the desired terminally 
hydroxylated products obtained from alkanes and primary alcohols after 4 h incubation with 
each P450 system are shown in tables 3.1 and 3.2, respectively.  
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Table 3.1. Concentrations of primary alcohols (Cn-1ol) and α,ω-diols obtained from alkane oxidation 
catalyzed by CYP153A enzymes 
Substrate  
(1 mM) 
CYP153A16 CYP153A P. sp. 
Cn-1ol [µM] α,ω-diol [µM] Cn-1ol [µM] α,ω-diol [µM] 
n-Pentane 34 ± 3a — 30 ± 1 — 
n-Hexane 24 ± 1a — 62 ± 5 — 
n-Heptane 81 ± 8 —  103 ± 3 — 
n-Octane  120 ± 9 30 ± 3  165 ± 13 16 ± 1 
n-Nonane 35 ± 2  113 ± 6  114 ± 3 16 ± 1 
n-Decane 16 ± 1 65 ± 3 99 ± 4 — 
n-Undecane < 10   N.D. (59 %)b < 10 — 
n-Dodecane < 10 < 10 < 10 — 
Reactions were set up for a final volume of 0.5 ml and run at 30°C for 4 h. aCYP153A16 produced more 1-
pentanol than 1-hexanol in a reproducible manner. bPercentage relative to total product estimated from 
the GC peak areas. ― not detected; N.D. not determined 
 
Table 3.2. Concentrations of α,ω-diols obtained from primary alcohol oxidation catalyzed by 
CYP153A enzymes 
Substrate 
(0.2 mM) 
CYP153A16 CYP153A P. sp. 
α,ω-diol [µM] α,ω-diol [µM] 
1-Hexanol  —  — 
1-Heptanol  —  — 
1-Octanol 39 ± 3 18 ± 0.2 
1-Nonanol 93 ± 4 16 ± 1 
1-Decanol 80 ± 6  — 
1-Undecanol N.D. (74 %)a  — 
1-Dodecanol 43 ± 2  — 
Reactions were set up for a final volume of 0.5 ml and run at 30°C for 4 h. aPercentage relative to total 
product. ― not detected; N.D. not determined 
 
The most relevant results of this screening study are related to the different hydroxylation 
patterns of CYP153A16 and CYP153A P. sp., which can be summarized as follows:  
 
(1) CYP153A16 can produce α,ω-diols from medium-chain n-alkanes and primary 
alcohols, while CYP153A P. sp exhibits low to inexistent diterminal hydroxylase 
activity. CYP153A16 produced α,ω-diols from C8-C12 alkanes and primary alcohols, while 
CYP153A P. sp. produced diols only from the C8 and C9 compounds. Yet the diol yields were 
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lower than those obtained with CYP153A16 by 2- to 7-fold. As mentioned before, the ability 
of CYP153A enzymes to hydroxylate the ω-site of primary alcohols has been observed with 
other enzymes of the same subfamily.90, 91 Diols are the result of the ω-hydroxylation of the 
terminal non-activated methyl group of primary alcohols. This indicates that the -OH group 
of a C8-C12 primary alcohol does not hinder the access of the terminal C-H bond to the heme 
iron and that it does not alter the ferryl reactivity of CYP153A16. However, the hydroxyl 
group should impair either one or both processes in CYP153A P. sp., as evidenced by its 
poor catalytic activity towards the ω-site of primary alcohols. The fact that CYP153A P. sp. 
oxidizes a C10-C12 primary alcohol exclusively to the corresponding aldehyde confirms that 
its hydroxyl group rather than its terminal methyl group is positioned close to the activated 
iron.  
 
(2) CYP153A16 is more ω-regioselective than CYP153A P. sp. When considering both ω-
alcohols and α,ω-diols as the total ω-hydroxylated products, CYP153A16 showed 90 – 96 % 
ω-regioselectivity for C7-C9 compounds, while CYP153A P. sp., 83 – 95 %. Although terminal 
oxidation was the predominant reaction, CYP153A P. sp. produced more secondary alcohols 
(up to 37 % of the total product in the case of longer chain alkanes) than CYP153A16 (< 5 % 
of secondary alcohols from alkanes of all chain lengths). This implies the presence of more 
steric constraints in CYP153A16 than in CYP153A P. sp. A higher ligand mobility or higher 
dynamic protein malleability in CYP153A P. sp. should allow substrates to bind relatively 
loosely or in multiple orientations, which generally favours hydroxylation at the more 
reactive (ω-1)-site.192 
 
(3) CYP153A16 has a higher tendency to further oxidize the products derived from 
alkane hydroxylation, while CYP153A P. sp. overoxidizes primary alcohols. After the 
terminal methyl groups of alkanes were hydroxylated, they were more prone to undergo 
oxidation to aldehydes and fatty acids by CYP153A16. The concentration of aldehydes and 
fatty acids found in reactions catalyzed by CYP153A16 (representing a maximum of 32 % of 
the total product) increased with the length of the carbon chain, while two other unknown 
byproducts different from aldehydes and fatty acids were obtained from C9-C12 substrates. 
CYP153A P. sp. yielded smaller proportions of further oxidized products when using 
alkanes as starting material. Aldehydes or fatty acids were the only further oxidized 
products yielded by this enzyme. When C8 and C9 primary alcohols were used as substrates, 
a maximum of 40 – 58 % of the total product corresponded to the α,ω-diols, while the 
remaining products consisted of aldehydes and fatty acids. 
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3.1.2 Medium- and long-chain linear saturated and monounsaturated fatty acids  
 
Since CYP153A16 could produce diols from primary alcohols, we assumed this enzyme as well 
as others with highly similar amino acid sequence could ω-hydroxylate fatty acids as well. 
Following the same reasoning, as CYP153A from Polaromonas sp. (CYP153A P. sp.) had low to 
non-existent activity towards primary alcohols; it was expected to perform poorly towards fatty 
acids.  
 
In this section we screened the fatty acid hydroxylase activities of CYP153A P. sp. and 
CYP153A16. In addition to these enzymes, we selected CYP153A from Marinobacter aquaeolei 
(CYP153A M. aq.) due to its high protein sequence similarity with CYP153A16 (79 %) and other 
reported primary alcohol ω-hydroxylases,90 including CYP153 from Acinetobacter sp. OC4 
(P450aci) (83 %) and CYP153A13a from Alcanivorax borkumensis SK2 (91 %) (table 3.3). 
CYP153A P. sp. shares 85 % similarity with CYP153A6 from Mycobacterium sp. strain HXN-1500. 
CYP153A6 is basically known for catalyzing the ω-hydroxylation or epoxidation of linear 
alkanes, alkenes, cycloalkenes and alicyclic compounds.190, 193 No alcohol oxidation activity has 
been reported for CYP153A6, though it has been shown to support growth of recombinant 
Pseudomonas putida cells on C1-C8 primary alcohols.77  
 
Table 3.3. Amino acid sequence identities and similarities between the investigated 
monooxygenases and homologous proteins  
CYP Gene name aa Identity 
CYP153s used in this study 
CYP153 from A. 
sp. OC4  
(497 aa) 
CYP153A13a from 
A. borkumensis 
SK2 (470 aa)  
CYP153A6 from 
M. sp. HXN-1500 
(420 aa) 
CYP153A P. sp. Bpro_5301 418 55 % 53 % 77 % 
CYP153A16 MMAR_3154 463 68 % 66 % 55 % 
CYP153A M. aq. Maqu_0600 470 69 % 82 % 55 % 
CYP Gene name aa Similarity 
CYP153s used in this study 
CYP153 from A. sp. 
OC4  
(497 aa) 
CYP153A13a from 
A. borkumensis 
SK2 (470 aa)  
CYP153A6 from 
M. sp. HXN-1500 
(420 aa) 
CYP153A P. sp. Bpro_5301 418 70 % 72 % 85 % 
CYP153A16 MMAR_3154 463 80 % 80 % 69 % 
CYP153A M. aq. Maqu_0600 470 83 % 91 % 71 % 
Performed via blastp: http://blast.ncbi.nlm.nih.gov 
The three monooxygenases were reconstituted in vitro using putidaredoxin reductase (CamA) 
and putidaredoxin (CamB) from P. putida and screened towards C8:0-C20:0 and 9(Z)/(E)-C14:1-C18:1 
fatty acids. Preliminary activity assays with purified CYP153A16 indicated that reaction times 
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longer than 4 h did not contribute to increased conversions. CO differential spectra 
measurements confirmed that CYP153A16 retained its P450 activity at room temperature for 4 
h, while CYP153A M. aq. and CYP153A P. sp. were stable for 24 h (data not shown). In order to 
make our enzyme systems comparable, all bioconversions were stopped after 4 h. Substrate 
conversions and product distributions are detailed in table 3.4 and illustrated in figure 3.2. 
 
Table 3.4. Conversions and product distributions [%] in fatty acid oxidation reactions catalyzed by 
CYP153A enzymes  
Saturated fatty acids were oxidized by CYP153A P. sp. in very low yields (<5 % conversion). 
CYP153A16 and CYP153A M. aq. were considerable more active, with preference towards C13:0 
and C14:0, respectively. The substrate range of CYP153A16 oscillated between C10:0 and C16:0, 
while CYP153A M. aq. had a broader scope, oxidizing those between C9:0 and C20:0. Interestingly, 
CYP153A P. sp. could ω-hydroxylate compounds of shorter size (C8:0-C13:0). Monounsaturated 
fatty acids were only oxidized by CYP153A16 and CYP153A M. aq. and not by CYP153A P. sp. 
CYP153A M. aq. showed its highest activity towards 9(E)-C16:1 (93 % conversion), whereas 
substrate conversions with CYP153A16 were not higher than 35 %. From the substrate range 
tendencies observed, both enzymes might oxidize 9(E)-C14:1 and other monounsaturated fatty 
acids of chain lengths < C14:1 and ≥ C20:1. This remains unconfirmed since other monoenoic 
C
Y
P
1
5
3
 
 
Saturated 9-Monounsaturated  
8:0 9:0 10:0 12:0 13:0 14:0 16:0 18:0 20:0 
(Z)-
14:1 
(Z)-
16:1 
(E)-
16:1 
(Z)-
18:1 
(E)-
18:1 
P
. s
p
. 
Conv. 1.5 4.5 1.9 <1.0 <1.0 - - - - - - - - - 
α-OH - - - - - - - - - - - - - - 
β-OH - - - - - - - - - - - - - - 
(ω-1)-OH - - - - - - - - - - - - - - 
ω-OH 100 100 100 100 100 - - - - - - - - - 
α,ω -DCA - - - - - - - - - - - - - - 
A
1
6
 
Conv. - - 39.3 71.1 91.8 56.1 6.3 - - 34.1 32.4 34.6 3.5 1.9 
α-OH - - - 1.3 1.9 1.9 - - - 2.1 - - - - 
β-OH - - - 0.3 0.7 0.7 - - - 0.7 - - - - 
(ω-1)-OH - - - 5.1 18.8 11.4 - - - 24.2 40.5 47.0 - - 
ω-OH - - 100 88.3 68.8 75.1 100 - - 65.6 59.5 53.0 100 100 
α,ω -DCA - - - 5.0 9.8 10.9 - - - 7.4 - - - - 
M
. a
q
. 
Conv. - 2.0 52.2 63.7 78.1 83.2 39.8 25.2 4.2 34.2 75.4 93.2 66.3 73.1 
α-OH - - - - - - - - - - - - - - 
β-OH - - - - - - - - - - - - - - 
(ω-1)-OH - - - 0.9 2.9 2.7 1.0 3.0 - 8.3 4.1 - 0.8 - 
ω-OH - 100 100 97.4 95.2 96.1 99.0 97.0 100 90.1 95.9 100 99.2 100 
α,ω -DCA - - - 1.7 1.9 1.2 - - - 1.6 - - - - 
Reactions were run at 30°C for 4 h with 0.2 mM substrate. - not detected 
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compounds were not evaluated as substrates. In addition, we noticed differences in the activities 
towards saturated and monounsaturated fatty acids of the same chain length. For example, 
CYP153A16 was more active towards 9(Z)-C16:1 and 9(E)-C16:1 (~ 34 % conversion) than towards 
C16:0 (6 % conversion). The reason is unknown to us in the absence of a substrate-bound enzyme 
crystal structure and substrate affinity studies, but the double bond might confer a site for 
substrate stabilization. 
Figure 3.2. Substrate conversions (blue) and ω-regioselectivities (green) in fatty acid oxidation 
reactions catalyzed by CYP153A monooxygenases.  
 
Concerning regioselectivity, CYP153A P. sp. catalyzed hydroxylations exclusively on the ω-
position, as expected from its poor activity. Although CYP153A16 and CYP153A M. aq. 
hydroxylated both saturated and monounsaturated fatty acids preferentially on the terminal 
position, regiospecificities varied depending on the P450 and the chain length of the substrate. 
CYP153A M. aq. was considerably more ω-regioselective than CYP153A16. The latter enzyme 
produced up to 19 % and 47 % (ω-1)-OHFAs from its preferred C13:0 and 9(E)-C16:1 substrates, 
respectively. Interestingly, CYP153A16 also catalyzed α- and β-hydroxylations.  Considering that 
these atoms are situated near the carboxyl group, i.e. the opposite extreme of the non-activated 
terminal carbon, we inferred that iron-catalyzed hydroxylation on such positions could occur if 
the substrate entered the active site with its carboxyl group coordinated towards the heme 
group. This type of substrate positioning seems to be less favoured, evidenced by the low yields 
of α- and β-regioisomers (< 3 % of the total product).  
 
CYP153A16 and CYP153A M. aq. could convert C12-C14 ω-OHFAs into α,ω-DCAs. Diacid formation 
was higher with CYP153A16 (5 – 11 %) than with CYP153A M. aq (< 2 %). Other intermediate 
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oxidation products such as aldo- or ketoacids were not detected in our experiments. Epoxy 
products, which might have resulted from the 9(Z)-monounsaturated fatty acids, were not found 
either. In order to verify if using an ω-OHFA as starting material led to higher α,ω-DCA yields, we 
tested 12-hydroxydodecanoic acid as substrate for CYP153A16. Although the diacid product was 
not quantified using a calibration curve, diacid yields originating from either 0.2 mM dodecanoic 
acid or 0.2 mM 12-hydroxydodecanoic acid were estimated from the relative peak areas and 
they were found to be similar. When the fatty acid was used as substrate, 71 % of it was 
converted to oxygenated products, 5 % of which corresponded to the diacid (table 3.4). When 
the ω-OHFA was used as starting material, relative peak areas were 96.4 % for the remaining 
substrate and 3.6 % for the diacid.  
 
For comparison purposes, we tested CYP153A M. aq. against alkanes and primary alcohols. 
Despite a few variations in product distribution, CYP153A M. aq. showed similar oxidation 
activities as those of CYP153A16 (table 3.5). We could therefore confirm that CYP153A P. sp. has 
low or no catalytic activity towards aliphatic compounds with a polar group at the opposite site 
of the terminal carbon atom, while CYP153A16 and CYP153A M. aq. prefer these substrates over 
alkanes. CYP153A P. sp. can thus be classified as a predominantly alkane ω-hydroxylase, while 
CYP153A16 and CYP153A M. aq. can be referred as predominantly fatty acid ω-hydroxylases. 
 
Table 3.5. Alkane, primary alcohol and fatty acid substrates yielding maximum ratios of ω- and/or 
α,ω-oxidized products in reactions catalyzed by CYP153A enzymes 
CYP153A Substrate (0.2 mM) Conv. [%] Product distribution [%] 
ω-OH α,ωa othersb 
P. sp. n-octane + 91 3 6 
1-octanol + n.a. 60 40 
nonanoic acid + 100 – – 
monounsaturated fatty acid – – – – 
A16 n-octane + 85 12 3 
n-nonane + 18 73 9 
1-nonanol ++  n.a. 90 10 
dodecanoic acid +++ 88 5 7 
9(Z)-tetradecenoic acid  ++ 66 7 27 
M. aq. n-octane + 85 14 1 
n-nonane + 74 25 1 
1-nonanol ++ n.a. 92 8 
dodecanoic acid +++ 97 2 1 
9(E)-hexadecenoic acid ++++ 100 – – 
– (no conversion/not detected), + (1 – 30 %), ++ (31 – 60 %), +++ (61 – 90 %), ++++ (> 90 %)  
aα,ω-products: α,ω-diols from n-alkanes and 1-alcohols; α,ω-DCAs from fatty acids. bOther products: 2-
alcohols, aldehydes and fatty acids from alkanes; aldehydes and fatty acids from 1-alcohols; 
hydroxylated regioisomers from fatty acids. n.a., not applicable. 
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3.2 Creation of a focused mutant library of CYP153A from Marinobacter 
aquaeloei  
 
Our in vitro substrate screening studies showed that CYP153A M. aq. could ω-hydroxylate a 
broad range of aliphatic compounds, including alkanes, primary alcohols and fatty acids (table 
3.5). We therefore took CYP153A M. aq. as a model enzyme to create a small focused mutant 
library aiming altered substrate specificity. More specifically, we targeted the terminal 
hydroxylation of C4-C6 primary alcohols and fatty acids via a shift in substrate range or a higher 
enzyme activity (figure 3.3).  
 
 
 
 
 
 
Figure 3.3. Overview of the in vitro substrate specificity and range of wild type CYP153A M. aq. 
Enzyme engineering targeted conversion of shorter 1-alcohols and fatty acids by increasing enzyme 
activity and/or altering substrate range. 
 
The positions were selected based on: 1) multiple protein sequence alignments within the 
CYP153A subfamily and among other CYP enzymes (e.g. P450 BM3, CYP52A subfamily) 
(supplementary material figure 6.2), 2) a homology model of CYP153A16 (A. Seifert, 
unpublished data) and, 3) the existing documentation on the P450 superfamily and the CYP153A 
subfamily. Nine positions were proposed for substitution with specific residues to generate a 
library of 19 single mutants. The positions are located on four secondary structures: (1) the BC-
loop, (2) the I-helix, (3) the variable substrate recognition site 5 (SRS-5), and (4) the C-terminal 
β-sheet loop. It is noteworthy indicating that these positions also appear in the homology model 
of a previously published CYP153A enzyme, CYP153A6 from Mycobacterium sp. HXN-1500 
(figure 3.4). The rationale for each mutation is presented in table 3.6. From the 19 mutant 
enzymes, 13 were expressed in similar to slightly lower yields compared to the wild type 
enzyme, 4 were poorly expressed and 2 were non-expressible (table 3.6). 
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L303 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Homology model of CYP153A6 from Mycobacterium sp. HXN-1500. The model displays 
key secondary structural regions and 11 residues coordinating undecane (red) towards the heme 
group (green). The table on the right corner indicates the equivalent positions in CYP153A M. aq. 
Graphic adapted from Funhoff et al.193  
 
 
Table 3.6. Focused library of CYP153A M. aq.: rationale for mutation and protein expression levels  
No. Secondary 
Structure 
Sequence Position in wild 
type 
Mutation Rationale for mutation Expres-
sion 
levela  
1 n.a. Wild type n.a. n.a. n.a. ++ 
2 
BC-loop 143MFIAMD148 
M143 R 
To resemble Arg242 in 
P450Bsβ, which anchors the 
carboxyl group of fatty 
acids194 
+++ 
3 
I145 
Equivalent to F87 in 
P450 BM3195 
M 
To modify hydrophobic 
interactions with the  
substrate 
++ 
4 F To resemble P450 BM3 - 
5 S 
To anchor the carboxyl/ 
alcohol group of the 
substrate 
+/- 
6 T 
Similar to I145S, but 
bulkier 
+/- 
A6 M. aq. 
M103 M143 
I105 M145 
L252 L303 
V255 V306 
G256 G307 
T260 T311 
L303 L354 
M306 M357 
F407 F455 
V408 V456 
 
 
C-terminal 
β-sheet 
loop 
SRS-5 T260 
V408
I-helix 
BC-loop 
L252 
M103 
M306 
F407 
G256 
G257 
I105 
V255 
L303 
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Table 3.6. (continued) 
No. Secondary 
Structure 
Sequence Position in wild 
type 
Mutation Rationale for mutation Expres-
sion 
levela  
7 
I-Helix 
302TLLIVGGNDT311 
Stabilization of 
shorter compounds 
T302 
M 
To resemble other 
CYP153A enzymes with 
Met in this position 
++ 
8 V 
To resemble most 
CYP153A enzymes, which 
display Ala, Val, Leu, Ile in 
this position 
++ 
9 L303 T To anchor the carboxyl or 
alcohol group of the 
substrate 
+++ 
10 V306 T ++ 
11 
G307 
A 
To resemble the AGxxT 
motif present in the CYP 
superfamily 196 
++ 
12 V 
Similar to G307A, but 
bulkier 
++ 
13 
Substrate 
recognition 
site 5 (SRS5) 
351QTPLAYMR358 
 
L354 
Position 5 after the 
ExxR motif.196   
I Similar to native Leu +++ 
14 F 
To resemble mutation 
A328F in P450 BM3, which 
influences selectivities 
towards alkanes195 
+++ 
15 
M357 
Located in close 
vicinity to F455 
F 
To alter interaction with 
the substrate or with F465 
- 
16 Y Similar to M357F, but polar +/- 
17 N 
To resemble the yeast 
CYP52A subfamily, which 
displays a conserved Asn 
+/- 
18 
C-terminal 
β-sheet 
loop 
453SNFV456 
 
F455 
Influences 
orientation of 
terminal C-H bond 
towards the heme 
iron center193 
L 
To evaluate the influence of 
smaller hydrophobic 
residues on substrate 
positioning 
++ 
19 I ++ 
20 Y Similar to F455, but polar ++ 
aExpression level [mg P450 (gcww)-1]: - (no expression), +/- (< 0.5), + (0.5 – 1), ++ (1 – 5), +++ (5 – 10). n.a. 
not applicable. 
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The variants including the wild type enzyme were screened towards 1-heptanol and nonanoic 
acid, as they are two of the shortest compounds within the substrate range of CYP153A M. aq. 
Some variants were additionally screened towards n-octane in order to verify if their activity 
towards this compound (the preferred alkane substrate for the wild type enzyme) changed as 
well (table 3.7). As cell-free extracts were utilized, it was thus not possible to exclude the 
influence of alcohol dehydrogenases or oxidases responsible for the overoxidation of the formed 
products. This occurred most notably when large volumes of cell lysates were used in the 
reactions. Considerable amounts of heptanoic acid were detected when using 1-heptanol as 
substrate. This caused substrate conversion levels to be higher than previous in vitro results 
with purified proteins. In addition, higher conversion levels were observed for nonanoic acid 
when using cell lysates, e.g. wild type enzyme: 14 % conversion with lysate vs. 2 % conversion 
with purified CYP (table 3.4, table 3.7). This might be attributed to a more efficient electron 
transfer from the cofactor to the heme iron enzyme caused by the presence of constitutive redox 
proteins in E. coli, which might also act as redox partners of CYP153A M. aq.  
 
 
Table 3.7. Substrate conversions and production distributions in n-octane, 1-heptanol and nonanoic 
acid oxidation reactions with cell-free extracts containing CYP153A M. aq. variants 
No. Variant Conversiona, Product distribution [%] 
 n-Octane 1-Heptanol Nonanoic acid 
1 wt Conv. 
acid 
(ω-1)-OHFA 
ω-OHFA 
ω-OH 
α,(ω-1)-diol 
α,ω-diol 
15  
- 
- 
- 
71 
- 
29 
7 
28 
- 
- 
- 
3 
69 
14 
- 
1 
99 
- 
- 
- 
2 M143R Conv. - - - 
3 I145M Conv. 
ω-OHFA 
α,ω-diol 
n.d. < 1 
- 
100 
< 1  
100 
- 
4 I145F Conv. n.e. n.e. n.e. 
5 I145S Conv. 
ω-OHFA 
α,ω-diol 
n.d. < 1 
- 
100 
< 1  
100 
- 
6 I145Tb Conv. 
ω-OHFA 
α,ω-diol 
n.d. < 1 
- 
100 
< 1  
100 
- 
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Table 3.7. (continued) 
No. Variant Conversiona, Product distribution [%] 
 n-Octane 1-Heptanol Nonanoic acid 
7 T302M Conv. 
ω-OHFA 
α,ω-diol 
n.d. 4 
 - 
100 
7 
- 
100  
8 T302V Conv. 
acid 
(ω-1)-OHFA 
ω-OHFA 
ω-OH 
α,(ω-1)-diol 
α,ω-diol 
n.d. n.d. 14 
- 
1 
99 
- 
- 
- 
9 L303T Conv. - - - 
10 V306T Conv. 
ω-OHFA 
α,ω-diol 
n.d. < 1 
- 
100 
< 1  
100 
- 
11 G307A Conv. 
acid 
(ω-1)-OHFA 
ω-OHFA 
ω-OH 
α,(ω-1)-diol 
α,ω-diol 
α,ω-diacid 
48  
- 
- 
- 
3 
- 
97 
- 
67  
23 
- 
14 
- 
1 
62 
- 
39 
- 
2 
97 
- 
- 
- 
 1 
12 G307V Conv. - - - 
13 
 
L354I Conv. 
acid 
(ω-1)-OHFA 
ω-OHFA 
α,(ω-2)-diol 
α,(ω-1)-diol 
α,ω-diol 
n.d. 2 
24 
- 
- 
29 
33 
14 
17 
- 
76 
24 
- 
- 
- 
14 L354F Conv. 
acid 
(ω-1)-OHFA 
ω-OHFA 
α,(ω-2)-diol 
α,(ω-1)-diol 
α,ω-diol 
n.d. 8 
37 
- 
- 
3 
4 
56 
9 
- 
17 
83 
- 
- 
- 
15 M357F Conv. n.e. n.e. n.e. 
16 M357Yb Conv. n.d. - - 
17 M357Nb Conv. 
ω-OHFA 
α,ω-diol 
n.d. < 1 
- 
100 
< 1  
100 
- 
18 F455L Conv. - - - 
19 F455I Conv. - - - 
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Table 3.7. (continued) 
No. Variant Conversiona, Product distribution [%] 
 n-Octane 1-Heptanol Nonanoic acid 
20 F455Y Conv. - - - 
aReactions were run with 2 µM CYP (cell lysate) and additional CamA and CamB to support the reaction. 
bDue to poor protein expression, reactions with these variants were run with 0.2 µM CYP. The results 
were contrasted with those obtained with 0.2 µM wild type enzyme. - no conversion/not detected, n.d. 
not determined, n.e. not expressible. 
 
The screening test with lysates allowed us to compare each variant with the wild type enzyme 
and identify positions crucial for enzyme activity and selectivity. Mutations M143R, L303T, 
G307V, M357Y and F455L/I/Y were the most deleterious ones, resulting in no conversion of the 
target substrates. Residue F455 can be clearly inferred as determinant for catalysis, as 
demonstrated by its substitution with tyrosine and two other hydrophobic amino acids. The 
equivalent position in CYP153A6 has been suggested to cause the alkane chain substrate to 
adopt a bent conformation, resulting in the approximation of the terminal carbon atom to the 
heme iron.83 Conversions with the variants mutated on positions I145 and T302 were lower 
compared to the wild type CYP; however, these enzymes were still able to catalyze ω-
hydroxylation reactions. Variants relevant to our scope were G307A (I-helix) and L354I/F 
(SRS5), which resulted in increased substrate conversion and shifted enzyme regioselectivity, 
respectively. As indicated in table 3.6, such positions were identified from protein sequence. 
G307A was proposed considering that a glycine is found in the CYP153A subfamily (first glycine 
in the GGNDT motif), while in most members of the CYP superfamily a conserved alanine is 
observed in this position (AGxxT motif).196 L354, which resides in position 5 after the highly 
conserved ExxR motif, is equivalent to position A328 in P450 BM3. Isoleucine is alternatively 
found in the same spot in other CYP153A enzymes, while its substitution with phenylalanine has 
been shown to modify the selectivity of P450 BM3 towards alkanes.197 Variants G307A, L354I 
and L354F were purified and screened towards nonanoic acid (table 3.8).  
 
Table 3.8. Oxidation profiles of CYP153A M. aq. wild type and mutants towards 1 mM nonanoic acid 
Variant Conv. 
 [%] 
Product distribution  [%] 
 (ω-1)-OH ω-OH 
wild type 1.7 2.5 97.5 
G307A 26.0 1.1 98.9 
L354I 2.0 75.6 24.4 
L354F 1.2 17.0 83.0 
Reactions were run at 30°C for 4 h with 2 µM purified CYP, 10 µM CamA, 20 µM CamB and cofactor 
regeneration.  
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G307A was equally regioselective but significantly more active than the wild-type enzyme. 
Conversions with L354I/F resulted in higher proportions of the (ω-1)-OH product. This 
indicates that the residue in position 354 determines the orientation of the substrate close to the 
heme iron and hence controls where the activated oxygen attacks. In vitro bioconversions with 
C8:0, C9:0 and C14:0 served us to confirm that G307A was more active than the wild type (table 3.9). 
We conducted kinetic experiments to investigate if the reason for increased activity was a higher 
affinity of G307A towards fatty acids (supplementary material figure 6.4). We observed that 
G307A was more catalytically efficient than the wild type enzyme owing to an increase in kcat 
rather than changes in the substrate affinity constants (table 3.10).  
 
Table 3.9. Fatty acid oxidation by CYP153A M. aq. wild type and variant G307A  
Fatty 
acid 
(1 mM) 
Wild type G307A 
Conv. 
[%] 
Product Distribution [%] Conv.        
[%] 
Product Distribution  [%] 
(ω-1)-OHFA ω-OHFA α,ω-DCA (ω-1)-OHFA ω-OHFA α,ω-DCA 
C8:0 – – – – 20.3 1.6 98.4 – 
C9:0 1.7 2.5 97.5 – 26.0 1.1 98.9 – 
C14:0  48.4 2.8 96.8 0.4 68.6 3.1 96.6 0.3 
Reactions were run at 30°C for 4 h with 2 µM purified CYP, 10 µM CamA, 20 µM CamB and cofactor 
regeneration. – no conversion/not detected 
 
Table 3.10. Steady-state kinetic parameters of CYP153A M. aq. wild type and variant G307A  
Enzyme variant/ 
Parametera 
Fatty acid substrate 
C8:0b C9:0 C14:0 
Wild type    
KM [mM] 5.15 ± 0.04 0.217 ± 0.009 0.036 ± 0.004 
kcat [min-1] 0.13 ± 0.01 0.24 ± 0.02 4.3 ± 0.2 
kcat/KM [min mM-1] 0.025 1.1 119 
G307A   
KM [mM] 4.84 ± 0.36 0.245 ± 0.008 0.035 ± 0.004 
kcat [min-1] 2.55 ± 0.26 4.0 ± 0.3 7.5 ± 0.5 
kcat/KM [min mM-1] 0.527 16.3 214 
aKinetic constants were determined by GC analysis of substrate conversion. Reaction mixtures 
contained 0.75 - 1 µM CYP, CamA and CamB in a 1:5:10 ratio, 2 % (v/v) DMSO, 1 mM NADH and 
cofactor regeneration. Substrate concentrations used were within the substrate solubility range. 
bConversion of C8:0 to the corresponding ω-OHFA by the wild-type enzyme was detected with >1 mM 
substrate. Kinetic constants for C8:0 were thus measured after adjusting the GC method.   
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Our mutagenesis study performed by a systematic comparison of protein sequences allowed us 
to identify key residues influencing activity and regioselectivity in the hydroxylation of primary 
alcohols and fatty acids. Despite the low turnover rates of CYP153A M. aq. wild type or G307A, 
this enzyme displays similar or higher performance towards linear fatty acids than other 
bacterial CYPs. For instance, CYP124A from Mycobacterium tuberculosis, another reported 
bacterial fatty acid ω-hydroxylase, was screened towards C12:0, C16:0 and C20:0. This enzyme 
showed a specific activity of 0.07 min-1 towards C16:0  at [S] = 5*KM, while any activity towards 
C12:0 and C20:0 was detected.93 Apparent kinetic parameters for AlkB towards nonanoic acid 
methyl ester have lately been determined.15 The values, KS = 0.142 mM and Vmax = 0.204 mmol 
min-1(gcdw)-1, are difficult to compare with our results since they were determined in whole cell 
bioconversions. A P450 BM3 variant engineered for terminal alkane hydroxylation displayed a 
turnover rate of 160 min-1 towards octane.97 Even though this mutant was not highly ω-
regioselective (52 %), it would be interesting to evaluate its performance towards fatty acids.  
 
Here it is also important to discuss two reports related to our work. In the first report, it was 
demonstratred that adding mutation G248A to an 8-point mutation variant 
(F87W/Y96F/T101L/T185M/L244M/V247L/L294M/L358P) of CYP101 (P450cam) from 
Pseudomonas putida caused an increased activity towards small substrates as well as a higher 
coupling efficiency compared to the wild type. Such mutation was introduced in the light of 
structural data with the purpose of forcing substrates to bind closer to the heme iron.94 We 
realized that such position is equivalent to G307 in CYP153A M. aq. However, the kinetic 
parameters of P450cam (G248A) were then not investigated; hence it was not clear if the higher 
activity was caused by an increased substrate affinity. In the second report – published after the 
creation of our focused mutant library – the X-ray crystal structure of CYP153A7 (P450pyr) 
from Sphingopyxis macrogoltabida (PDB ID 3RWL) was solved.144 In the same study, position 
G255 (equivalent to G307 in CYP153A M. aq.) was considered within a mutant library in which 
20 active site positions were exchanged by iterative saturation mutagenesis in order to find a 
highly (S)-enantioselective variant for N-benzyl pyrrolidine hydroxylation. Nonetheless, the 
most enantioselective candidate was a triple mutant containing mutations in positions different 
than G255.144  
 
Additional insights into structure-function relationships within the CYP153A subfamily were 
provided by aligning the enzymes herein investigated with CYP153A6 and CYP153A7 
(supplementary material figure 6.3) and by analyzing the recently published crystal structure of 
CYP153A7 (figure 3.5).  
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Figure 3.5. Substrate-free crystal structure of CYP153A7 from Sphingopyxis macrogoltabida (PDB ID 
3RWL).144 The images were generated by PyMOL. Left:  Cartoon representation displaying the heme 
group (green), a section of the F-helix and adjacent F/G loop (orange) and residues (blue) bordering 
the reported missing loop (residues 88 – 96) in the published crystal structure. Right:  Active site 
residues, including G255 (I-helix) and L302 (SRS-5) (equivalent to G307 and L354 in CYP153A M. 
aq.). The region 184VTTA187 at the C-terminus of the F-helix and F/G loop is located at the entrance of 
the active site cavity, opposite to the missing loop region.  
 
 
The region located between the F-helix and the adjacent C-terminal loop (F/G loop) in the 
CYP153A enzymes is highly variable. The sequences of that region in CYP153A6, CYP153A7 and 
CYP153A P. sp. are similar among each other (VTTAL, VATAL and VTTAA) but shorter by 2 
amino acids and completely different than those found in CYP153A16 (LATSMEQ) and CYP153A 
M. aq. (RMAGAAS). One or more polar or positively charged residue(s) of this region might be 
involved in the coordination of the alcohol/carboxyl group of medium-chain primary alcohols or 
fatty acids in CYP153A16 and CYP153A M. aq., enabling their hydroxylation at the terminal 
position. This assumption is based on the crystal structure of CYP153A7, since the F/G loop is 
located at the entrance of the active site (figure 3.5). In other CYPs, a dramatic unfolding of the C-
terminus of the F-helix and large movements of the F/G loop have been observed in the presence 
of substrate, which suggests that the F/G loop and associated elements of structure can move 
into the active site and shape themselves around active site ligands.198 The reason why the chain 
length of the preferred alkane (C8), primary alcohol (C9) and fatty acid (C12-C14) substrates is not 
the same in the investigated fatty acid ω-hydroxylases (table 3.5, figure 3.3) might also be 
A187 
N100 
F403 
M305 
Heme 
G255 
L302 
I102 
V254 L252 
T186 T185 
V184 
F-helix 
I-helix 
SRS-5 
F/G loop Substrate acccess channel 
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explained by this hypothesis. The right positioning of n-octane towards the active site might be 
facilitated by its hydrophobicity. However, octanoic acid and shorter fatty acids could be 
coordinated by a residue of the dynamic F-helix or F/G loop, which would not allow the terminal 
C-atom reach the heme group of the enzyme. The elucidation of a fatty acid-bound CYP153A 
structure (e.g., from CYP153A M. aq.) and additional mutagenesis studies should contribute to 
understand this phenomenon. 
 
3.3 Bacterial whole cells for the synthesis of ω-oxyfunctionalized 
aliphatic compounds 
 
3.3.1 Biotransformations of n-octane by growing P. putida cells containing 
CYP153A gene clusters 
 
Three alkane hydroxylase operons, comprised by the CYP153A enzymes here investigated and 
their putative physiological redox partners were cloned into two different vectors for further 
studies in Pseudomonas putida (table 2.2). A derivative of the L-rhamnose-inducible pJOE4782.1 
vector and the n-alkane-inducible pCom10 vector were selected since these expression systems 
have been shown to be effective in the production of heterologous proteins in pseudomonads.177, 
179 In addition, the CYP153A6 alkane hydroxylase system from Mycobacterium sp. HXN-1500 has 
previously been functionally expressed in Pseudomonas as a gene cluster (CYP153A6-FdR-Fdx) 
within vectors of the pCom series.77, 88  
 
The functional expression of the individual components of CYP153A gene clusters in 
pseudomonads was first verified using the MmFdx→CYP153A16→MmFdR operon. P. putida S12, 
known to display high tolerance towards organic solvents including 1-butanol, was used as host 
strain.156 Cells were also transformed with empty vector (negative control) and subjected to the 
same growth and expression conditions as the gene cluster-containing strain. P. putida 
S12_pJOE-MmAlk cell extracts yielded a concentration of 23 µg active P450 (mg total protein)-1 
(equivalent to 3 µM P450 in 7 mg ml-1 total protein) after 16 h expression, which is comparable 
to a previous report involving CYP153A6 in n-octane grown P. putida Gpo12 (2.2 µM P450 in 7 
mg ml-1 total protein).199 Negative controls resulted in negligible P450 concentration (≤ 0.1 µM). 
In addition, cell extracts of P. putida S12 harboring the gene cluster showed a reductase activity 
of 130 µmol cytochrome c min-1 (mg protein)-1, approximately 4-fold higher than the 
corresponding negative control. Unfortunately, the ferredoxin component (MmFdx) could not be 
detected by SDS-PAGE nor quantified in the cell extract, since spectroscopic methods for the 
determination of ferredoxin concentration are generally performed using purified protein to 
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avoid the background effect of other redox proteins (e.g., ferredoxin reductases). Cell extracts 
from P. putida S12 containing the MmAlk gene cluster were also proven to be active in vitro. 
After 4 h, 1 mM n-octane was oxidized to 1-octanol (13 % conversion, 99 % ω-regioselectivity) 
using NADH as electron donor in a cofactor regenerating system. Negative controls did not 
display activity towards n-octane.  
 
The in vivo hydroxylation activities of recombinant P. putida containing the three alkane 
hydroxylase gene clusters as pJOE or pCom10 vector constructs were investigated. In this 
section, P. putida KT2440 was used as standard platform for whole cell biotransformations given 
its amenability for genetic manipulation, contrary to strain S12, whose genome has not been 
published yet. Pseudomonas putida KT2440 cells containing the pJOE constructs were grown in 
rich medium (TBKan), while those harboring pCom10 vectors were grown in modified M12 
mineral medium supplemented with citrate as carbon source (MM-BVTKan/citrate). To prevent 
carbon and energy source depletion, cells were fed with glucose or citrate. All recombinant P. 
putida strains grew until a maximum OD600 of 2.2 - 2.4 after 12 h of cell growth (6 - 8 h after 
substrate addition) in both TBKan and MM-BVTKan/citrate. n-Octane was mainly converted to 1-
octanol, while 2-octanol accounted only for 2 - 3.5 % of the total product. 1,8-Octanediol was not 
detected under the experimental conditions used, presumably due to low accumulation of its 
precursor, 1-octanol. Recombinant P. putida KT2440 with pJOE-MmAlk grown in TBKan yielded 
up to 10.4 mg l-1 1-octanol 18 h after induction/substrate addition, while those containing pJOE-
MaqAlk and pJOE-PspAlk reached a maximum of 2.9 and 6.7 mg l-1 1-octanol 14 h after 
induction/substrate addition, respectively (table 3.11).  
 
Table 3.11. Concentration of 1-octanol produced by pseudomonads growing in TBKan  
Recombinant P. putida strains 
1-Octanol [mg l-1], time after induction 
6h 14h 18h 
KT2440_pJOE-MmAlk - 4.1 10.4 
KT2440_pJOE-MaqAlk - 2.9 0.6 
KT2440_pJOE-PspAlk - 6.7 1.5 
 
 
Recombinant P. putida KT2440 with pCom10-MmAlk grown in MM-BVTKan/citrate produced a 
maximum of 2.4 mg l-1 1-octanol 12 h after induction/substrate addition, respectively (table 
3.12), while 1-octanol concentration in pCom10-PspAlk cultures reached 18.7 mg l-1 in 12 h. In 
addition, in most cases it was observed that product formation decreased dramatically 18 h after 
substrate addition, indicating that 1-octanol was further metabolized by the pseudomonads.  
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FdR CYP153A
Fdx
e- CYP153A
CPR
CYP153A
CPR
G307A
Table 3.12. Concentration of 1-octanol produced by pseudomonads growing in MM-BVTKan/citrate  
Recombinant P. putida strains 
1-Octanol [mg l-1], time after induction 
4h 12h 18h 
KT2440_pCom10-MmAlk 0.7 2.4 1.1 
KT2440_pCom10-PspAlk 3.5 18.7 3.6 
 
In an additional experiment performed only with strain KT2440_pJOE-MmAlk grown in MMKan 
supplied with 5 g l-1 glucose every 6 h to prevent C-source starvation, the product yield was 2.3 
mg l-1 1-octanol 16 h after induction/substrate addition. This value is similar to that obtained 
with the same strain in TB medium (2.9 mg l-1 1-octanol). In order to increase substrate 
solubility, dimethyl sulfoxide (DMSO) was added in a final concentration of 2 % (v/v). This 
resulted in a 2-fold increase of the product yield (4.3 mg l-1 1-octanol). DMSO was thus used as a 
co-solvent in further experiments.  
 
3.3.2 Biotransformations of n-octane and fatty acids by resting P. putida and E. coli 
cells containing CYP153A fusion constructs  
 
Aiming to increase the efficiency of electron transfer, CYP153A from Marinobacter aquaeolei was 
fused to the reductase domain of P450 BM3 from Bacillus megaterium (CPRBM3). Such construct 
has been demonstrated to be functional in alkane and fatty acid hydroxylation reactions in vitro 
and in vivo, with 3-fold higher coupling efficiency than that of our artificial system of three 
separate protein components (D. Scheps, unpublished data). As a combined strategy to increase 
product yields, mutation G307A which is responsible for the higher in vitro hydroxylation 
activity in CYP153A M. aq., has been incorporated in the fusion construct (figure 3.6).  
 
 
 
 
 
Figure 3.6. Combining two strategies for optimized CYP153A-mediated ω-hydroxylations. CYP153A 
M. aq. harbors mutation G307A fused to CPRBM3. Abbreviations: CPR: Cytochrome P450 Reductase 
(FAD/FMN-containing reductase domain) 
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Non-metabolically engineered P. putida KT2440, P. putida S12, E. coli JM109 and E. coli 
BL21(DE3) were transformed with the CYP153A M. aq. (G307A)-CPRBM3 fusion construct and 
evaluated as hosts in n-alkane and fatty acid ω-oxygenation reactions. Strains JM109 and 
BL21(DE3) were selected because they perform as suitable hosts for pJOE vector constructs.178 
 
3.3.2.1 Biotransformations of n-octane  
 
To initially assess the biocatalytic performance of the four recombinant strains described above, 
each one was assayed towards n-octane in one single experiment with glucose and glycerol 
added only at the start of the reaction. Figure 3.7 follows the formation of 1-octanol, 2-octanol, 
octanal, octanoic acid and 1,8-octanediol during the entire biotransformation. Each strain 
behaved differently towards the substrate and formed products, thus the highest concentrations 
of target product (1-octanol) were reached at different time points. Table 3.13 features relevant 
reaction parameters (biomass and biocatalyst concentrations) as well as product distributions at 
the time maxima 1-octanol concentrations were observed. E. coli resulted in a more effective 
host for n-octane ω-hydroxylation than P. putida under the experimental conditions used. In 
average, E. coli yielded 10 times more 1-octanol and 1,8-octanediol than P. putida. Strains JM109 
and BL21(DE3) produced 130 - 260 mg l-1 1-octanol and around 55 mg l-1 1,8-octanediol after 8 
h, while KT2440 and S12 yielded a maximum of 3 - 15 mg  l-1 1-octanol and 1.6 - 5 mg l-1  1,8-
octanediol after 1 - 2 h. Cell aggregation was observed in both pseudomonads, which is likely to 
occur as an energy-dependent stress response due to exposure to n-octane and 1-octanol, 
resulting in a lower capacity for redox biocatalysis. P. putida KT2440 cells aggregated after 8 h 
and product concentrations remained constant or decreased after this time, while P. putida S12 
cells aggregated after 2 h and yielded very low product concentrations. In addition to this, target 
hydroxylation products can be degraded by non-engineered pseudomonads, as they are able to 
utilize primary alcohols as carbon and energy source.77, 87 Larger amounts of the aldehyde and 
fatty acid (40-60 % of the total product) were detected in the pseudomonads, while in E. coli 
these byproducts accounted for less than 12 %. Given that CYP153A M. aq. has a low intrinsic 
ability to oxidize 1-octanol to octanoic acid (table 3.5), overoxidation can be attributed to a 
higher alcohol dehydrogenase/oxidase activity in the pseudomonads compared to E. coli. 
Possible causes for observing a product plateau in E. coli after 8 hours are: equal rates of product 
formation and degradation, substrate or product toxicity, product inhibition and mass transfer 
rate limitations caused by the presence of bio-emulsifier released due to cell lysis.200 Alcohols 
tend to accumulate in the membrane bilayer and cause ion leakage.201, 202 Octane and 1-octanol 
cause changes in cell morphology and membrane physiology, resulting in hole formation in the 
membrane and reduced viability of both P. putida and E. coli.203, 204 
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Figure 3.7. Whole cell biotransformations of 10 % (v/v) n-octane with resting P. putida and E. coli 
cells. (A) P. putida KT2440, (B) P. putida S12, (C) E. coli JM109 and (D) E. coli BL21(DE3) harbored 
the pJOE-CYP153A M. aq.(G307A)-CPRBM3 vector construct. Cell concentrations were 100 gcww l-1 (20-
24 gcdw l-1). The glucose/glycerol mix was added only at the beginning of the biotransformation.  
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Table 3.13. Maximum 1-octanol concentrations and product distributions obtained with resting P. 
putida and E. coli cells harboring CYP153A M. aq. (G307A) fused to CPRBM3 in conversions without 
additional C-source 
Parameter Units 
P. putida 
KT2440 
P. putida 
S12 
E. coli 
JM109 
E. coli 
BL21(DE3) 
Biotransformation time h 2 1 8 8 
Biomass concentration1 gcdw l-1 20 20 22 24 
Active P450 concentration1 mg (gcdw)-1 40.5 56.7 38.9 56.7 
Initial substrate concentration % (v/v) 10 10 10 10 
Substrate conversion2 % 0.05 0.01 0.26 0.43 
1-octanol concentration mg l-1 15.3 3.3 130 258 
1,8-octanediol concentration  mg l-1 5.1 1.6 59 51 
Product distribution 
     1-octanal + 2-octanol3 % 7.8 29.2 5.7 4.6
1-octanol % 39.6 29.0 62.7 75.0 
octanoic acid % 40.8 29.1 6.3 7.2 
1,8-octanediol % 11.8 12.7 25.2 13.2 
1At start of biotransformation. 2Substrate converted to oxygenated products (not equivalent to substrate 
consumption). The values were calculated from initial substrate and product concentrations and 
represent the molar percentage yields. 3Similar retention times of 1-octanal and 2-octanol in GC/FID. 
 
 
3.3.2.2     Biotransformations of fatty acids  
 
3.3.2.2.1 Dodecanoic acid oxidation without additional C-source by resting P. 
putida and E. coli cells containing mutant CYP153A in a fusion construct 
 
In vivo bioconversions of dodecanoic acid by each one of the four recombinant strains described 
in the previous section were run once. Glucose and glycerol were added only at the start of the 
reaction. Biotransformations yielded mainly 12-hydroxydodecanoic acid (12-OHFA) and 1,12-
dodecanedioic acid (1,12-DCA) as well as small amounts of the subterminally oxygenated 
product (11-OHFA). Figure 3.8 displays substrate consumption and product formation within a 
biotransformation time of 20 h as well as product yield coefficients (YP/S) after 8 h. 
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Figure 3.8. Whole cell biotransformations of 1 g l-1 dodecanoic acid with resting P. putida and E. coli 
cells. (A) P. putida KT2440, (B) P. putida S12, (C) E. coli JM109 and (D) E. coli BL21(DE3) harbored 
the pJOE-CYP153A M. aq.(G307A)-CPRBM3 vector construct. Cell concentrations were 100 gcww l-1 (20-
24 gcdw l-1). The glucose/glycerol mix was added only at the start of the biotransformation. Product 
yield coefficients (YP/S) correspond to g of total products per g substrate after 8 h. Abbreviations: 
C12FA, dodecanoic acid; 11-OHFA, 11-hydroxydodecanoic acid; 12-OHFA, 12-hydroxydodecanoic 
acid; 1,12-DCA, 1,12-dodecanedioic acid. 
Biotransformation time [h] 
YP/S = 0.053  
YP/S = 0.509  
YP/S = 0.303  
YP/S = 0.500 
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In agreement with the results obtained with n-octane, E. coli strains yielded significantly more 
ω-hydroxylated product from dodecanoic acid than P. putida. The pseudomonads also depleted 
the substrate completely after 15 - 20 h in the absence of constant carbon source feeding. On one 
hand, the observation that the 12-OHFA decreased over time is an evidence that it was readily 
oxidized to 1,12-DCA to enter the β-oxidation pathway for energy generation. The appearance of 
low 12-OHFA and 1,12-DCA yields in pseudomonads might thus be attributed to a higher rate of 
product degradation than of product formation, which is likely to occur because CYP153A 
enzymes are less active than fatty alcohol oxidases. On the other hand, as observed in n-octane 
bioconversions, P. putida KT2440 and S12 cells aggregated as well, but this phenomenon began 
later, 10 hours after the start of biotransformation. This means that the fatty acid and its derived 
oxidation products do not exert such a burden to the cells as n-octane and 1-octanol do. The 
pseudomonads were thus metabolically active towards dodecanoic acid and derived 12-OHFA 
by a longer period of time than towards the alkane and primary alcohol. This might be also 
influenced by the higher solubility of the ω-OHFA product compared to the fatty acid substrate. 
 
E. coli strains consumed 70 % of the substrate within 20 h. From this percentage, 57 - 60 % 
ended up as oxygenated products, while the remaining 10 - 13 % must have been utilized as 
carbon and energy source. In contrast with the results observed in n-octane oxidation, both E. 
coli JM109 and BL21(DE3) yielded similar 12-OHFA concentrations. Given that the rates of 
formation of the target product (12-OHFA) dropped after 8 h in all four strains, product 
concentrations and distributions obtained with each in vivo system are compared at this time 
point (table 3.14). After 8 h, both E. coli strains produced in average 450 mg l-1 12-OHFA. 
However, the total accumulated 12-OHFA concentrations after 20 h were 528 and 480 mg l-1 for 
JM109 and BL21(DE3), respectively.  
 
Strain JM109 was less prone to oxidize 12-OHFA to 1,12-DCA than strain BL21(DE3). P. putida 
KT2440 produced up to 103 mg l-1 12-OHFA, while strain S12 barely yielded 16 mg l-1 12-OHFA. 
Both pseudomonads also produced larger amounts of 1,12-DCA (62 - 66 % of the total product)  
in comparison with E. coli (5 - 12 % of the total product). Considering that CYP153A M. aq. has 
low in vitro oxidation activity towards ω-OHFAs, constitutive fatty alcohol oxidases (FAOs) seem 
to be involved in the terminal oxidation of ω-OHFAs in P. putida strains. 
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Table 3.14. Product concentrations and distributions obtained with resting P. putida and E. coli cells 
harboring CYP153A M. aq. (G307A) fused to CPRBM3 in conversions without additional C-source 
Parameter Units 
P. putida 
KT2440 
P. putida 
S12 
E. coli 
JM109 
E. coli 
BL21(DE3) 
Biotransformation time h 8 8 8 8 
Biomass concentration1 gcdw l-1 20 20 22 24 
Active P450 concentration1 mg (gcdw)-1 40.5 56.7 38.9 56.7 
Initial substrate concentration mg l-1 954 954 954 954 
Substrate conversion2 % 27 4.7 46.2 46.8 
12-OHFA concentration mg l-1 103 16 460 436 
1,12-DCA concentration mg l-1 182 34 14 46 
Product distribution 
     11-OHFA % 1.2 1.8 0.7 0.8
12-OHFA % 37.2 32.3 96.6 90.3 
1,12-DCA % 61.6 65.9 2.7 8.9 
1at start of biotransformation, 2Substrate converted to oxygenated products (not equivalent to substrate 
consumption). The values were calculated from initial substrate and product concentrations and 
represent the molar percentage yields.  
 
 
In order to identify factors responsible for the decreased product formation rates after 8 h, 
hydrogen peroxide and acetate formation were determined in dodecanoic acid 
biotransformation mixtures corresponding to P. putida KT2440 and E. coli JM109 
(supplementary material figure 6.5). The concentrations of total (intracellular and extracellular) 
H2O2 after 8 h were 166 µM and 262 µM in E. coli JM109 and P. putida KT2440 cultures, 
respectively. After 20 h, up to 274 µM H2O2 was quantified in the investigated E. coli strain, while 
585 µM H2O2 was detected in the pseudomonad. Hydrogen peroxide and other reactive oxygen 
species (ROS) originate from oxidative stress205 and electron uncoupling during P450-mediated 
biocatalysis (figure 1.3). ROS accumulation results in the damage of DNA, RNA, proteins and 
lipids. E. coli is known to possess an efficient repair machinery when exposed to ROS,206 while P. 
putida KT2440 has high tolerance towards ROS because the high cofactor demand caused by 
oxidative stress is covered by the NADPH-producing glucose-6-phosphate oxidation step leading 
to the Entner-Doudoroff pathway.207 Nevertheless, concentrations of 400 µM are known to 
irreversibly inactivate CYPs in vitro by the loss of the heme group.208 The fatty acid α-
hydroxylase from Clostridium acetobutylicum, with both monooxygenase and peroxygenase 
activities, has been reported to catalyze reactions in the presence of 200 µM H2O2, but becomes 
inactivated after a few minutes.209 Concerning acetic acid formation, P. putida produced 3 to 4 
times less acetate than E. coli, which is in agreement with the existing literature.210 Although 
glucose was added only at the start of biotransformation, E. coli JM109 produced as much as 3.5 
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g l-1 after 8 h and 4.4 g l-1 after 20 h. P. putida KT2440 produced less than 1 g l-1 within 20 h. 
Acetate concentrations above 2.4 g l-1 are known to reduce biomass production, the proton-
motive force and the stability of intracellular proteins.211 Acetate also reduces the pH of the 
medium, which might decrease product formation rates. A pH outside the 6.8 – 7.3 range has 
been reported to cause a 50-fold decrease in fatty acid oxidation rates in reactions catalyzed by 
CYP119 from Sulfolobus solfataricus.212  
 
 
3.3.2.2.2 Dodecanoic acid oxidation with additional C-source by resting P. putida 
and E. coli cells containing wild type and mutant CYP153A in a fusion 
construct 
 
Further in vivo shake flask assays with dodecanoic acid were conducted in P. putida KT2440, E. 
coli JM109 and E. coli BL21(DE3). P. putida S12 was not included given its low performance in 
hydroxylation reactions under the previous experimental conditions used. On this occasion, each 
strain contained the fusion construct with CYP153A M. aq. either in its wild type form (wt) or as 
a G307A variant (G307A). In addition, cell concentrations were halved from 100 gcww l-1 to 50 
gcww l-1 in order to reduce the amount of costly biocatalyst as well as to minimize mass and 
oxygen transfer limitations arising from high cell density fermentations. Resting cells were fed 
with glucose/glycerol at time points 0, 4, 8 and 12 h in order to diminish unproductive substrate 
consumption, i.e. for biomass and energy production. Although glucose is not the preferred 
carbon source for Pseudomonas strains, this sugar was used in the mix for the sake of preserving 
similar fermentation conditions as those of E. coli cultures. P. putida KT2440 and E. coli JM109 
harboring empty religated pJOE vector (without gene insert) were used as negative controls to 
measure substrate depletion in the absence of the biocatalyst.  
 
Figure 3.9 exhibits substrate consumption and production formation by P. putida KT2440. Cells 
without the monooxygenase fusion construct depleted the substrate completely in 12 hours 
despite the presence of additional C-source. In the reactions with the monooxygenase-
containing pseudomonads, 65 - 80 % of the fatty acid was consumed within 20 h. From these 
values, around 20 % resulted in the effective formation of oxygenated products, while the 
remaining 45 - 60 % was used as carbon and energy source. As explained in section 3.3.2.1, even 
though dodecanoic acid was still available, we did not observe any significant increase in 
product yields compared to the previous setup without constant C-source feeding. Under these 
conditions, biotransformations with the pseudomonads harboring the G307A variant resulted in 
only 24 % higher product yields compared to the wild type enzyme.  
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Figure 3.9. Whole cell biotransformations of 1 g l-1 dodecanoic acid with resting P. putida cells in the 
presence of additional C-source. P. putida KT2440 cells contained either (A0) empty pJOE, (A1) pJOE-
CYP153A M. aq.-CPRBM3 or (A2) pJOE-CYP153A M. aq.(G307A)-CPRBM3. Cell concentrations were 50 
gcww l-1 (9.4 – 9.9 gcdw l-1). Cells were fed with additional C-source at 0, 4, 8 and 12 h. Product yield 
coefficients (YP/S) correspond to g of total products per g substrate. Abbreviations: C12FA, 
dodecanoic acid; 11-OHFA, 11-hydroxydodecanoic acid; 12-OHFA, 12-hydroxydodecanoic acid; 1,12-
DCA, 1,12-dodecanedioic acid. 
 
Once again, aggregation of P. putida cells was evident after 10 h of biotransformation. The 
phenomenon was more dramatic for the cells without CYP (negative control) (supplementary 
material figure 6.6). As mentioned before, aggregate formation is an energy-dependent survival 
strategy in front of toxic compounds. Severe aggregation in cells lacking CYP might be attributed 
to the high energy supply used for the synthesis of extracellular polymeric substances,213 while 
in the CYP-containing cells, part of the energy ought to be chanelled to redox biocatalysis.  
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Figure 3.10. Whole cell biotransformations of 1 g l-1 dodecanoic acid with resting E. coli cells in the 
presence of additional C-source. (B) E. coli JM109 and (C) E. coli BL21(DE3) cells contained either (0) 
empty pJOE, (1) pJOE-CYP153A M. aq.-CPRBM3 or (2) pJOE-CYP153A M. aq.(G307A)-CPRBM3. Cell 
suspensions were 50 gcww l-1 (11 - 12.7 gcdw l-1). Cells were fed with additional C-source at 0, 4, 8 and 
12 h. Product yield coefficients (YP/S) correspond to g of total products per g substrate. 
Abbreviations: C12FA, dodecanoic acid; 11-OHFA, 11-hydroxydodecanoic acid; 12-OHFA, 12-
hydroxydodecanoic acid; 1,12-DCA, 1,12-dodecanedioic acid. 
 
E. coli containing the empty pJOE vector practically did not consume the substrate when the cells 
were fed with glycerol and glucose. Total product yields obtained with the G307A variants were 
37- 40 % higher than those observed with the wild type (figure 3.10). As observed in table 3.15, 
CYP concentrations in JM109 and BL21(DE3) reached in average 30 and 40 mg (gcdw)-1, 
respectively. In both strains the G307A variant was expressed in similar levels than the wild type 
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enzyme. CYP expression levels correlated with the product yields observed, with JM109 and 
BL21(DE3) producing similar amounts of 12-OHFA (300 – 400 mg l-1). Once again, BL21(DE3) 
produced more α,ω-DCA than JM109, presumably due to a higher alcohol and/or aldehyde 
dehydrogenase activity. 
 
Table 3.15. Product concentrations and distributions obtained with resting P. putida and E. coli cells 
harboring CYP153A M. aq. (wt) or (G307A) fused to CPRBM3 in conversions with additional C-source 
Parameter Units 
P. putida  
KT2440 
E. coli  
JM109 
E. coli 
BL21(DE3) 
wt G307A wt G307A wt G307A 
Biotransformation time h 20 20 20 20 20 20 
Biomass concentration1 gcdw l-1 9.5 9.9 11.3 10.9 12.7 12.1 
Active P450 concentration1 mg (gcdw)-1 46.6 40.3 27.6 33.5 39.5 40.0 
Initial substrate concentration mg l-1 938 803 944 859 1095 938 
Substrate conversion2 % 15.4 19.3 34.5 48.7 27.1 37.3 
12-OHFA concentration mg l-1 53 72 342 439 305 360 
1,12-DCA concentration mg l-1 108 100 7 9 13 15 
Product distribution 
 
   
   
11-OHFA % 1.2 1.1 1.1 0.8 1.3 1.1 
12-OHFA % 33.7 43.2 97.0 97.2 95.0 95.2 
1,12-DCA % 65.1 55.7 1.9 2.0 3.7 3.8 
1at start of biotransformation. 2Substrate converted to oxygenated products (not equivalent to substrate 
consumption). The values were calculated from initial substrate and product concentrations and 
represent the molar percentage yields. 
 
 
3.3.2.2.3 Dodecanoic, octanoic and oleic acid oxidation with additional C-source by 
resting E. coli cells containing wild type and mutant CYP153A in a fusion 
construct 
 
A short fatty acid (octanoic acid) and a long monounsaturated fatty acid (oleic acid) were 
selected as substrates for biotransformations with E. coli JM109 containing the fusion construct 
in their CYP153A M. aq. (wt) and (G307A) versions. Dodecanoic acid was tested again for 
comparison purposes, as other measurements were included on this ocassion. In order to 
investigate the stability of the in vivo systems, cell densities, cell viability and whole cell P450 
concentrations were determined over time as well. Although the yields of ω-OHFA products 
from octanoic and oleic acids were significantly lower compared to those obtained with 
dodecanoic acid, ω-OHFA concentrations reached by mutant G307 were respectively 34 to 61 % 
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higher compared to the wild type enzyme (figures 3.11 - 3.13). E. coli harboring empty vector 
consumed octanoic and oleic acid over time, even though cells were fed with glucose and 
glycerol every 4 hours. Cell densities did not change significantly over time, indicating that the 
host strain remained stable during biotransformation. In addition, cell viability tests showed no 
logarithmic decrease in the number of colony forming units after 4, 8 and 20 h (data not shown).  
Growing E. coli cells have been reported to be susceptible towards C2:0-C8:0 and C12:0-C18:0,214 but 
resting cells appear to be more robust. CO differential spectral analysis of whole cells indicated a 
50 % decrease in active CYP concentration in the case of cultures exposed to dodecanoic and 
oleic acids, thereby indicating that intrinsic biocatalyst stability depends on the fatty acid.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Whole cell biotransformations of 1 g l-1 dodecanoic acid with resting E. coli JM109 cells. 
Cells contained (A1) pJOE-CYP153A M. aq.-CPRBM3 or (A2) pJOE-CYP153A M. aq.(G307A)-CPRBM3. Cell 
concentrations were 11 gcdw l-1. Cells were fed with additional C-source at 0, 4, 8 and 12 h. Product 
yield coefficients (YP/S) correspond to g of total products per g substrate. Abbreviations: FA, fatty acid 
substrate; (ω-1)-OHFA, subterminally hydroxylated fatty acid; ω-OHFA, terminally hydroxylated 
fatty acid; α,ω-DCA, dicarboxylic acid. 
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Figure 3.12. Whole cell biotransformations of 0.75 g l-1 octanoic acid with resting E. coli JM109 cells. 
Cells contained (A0) empty pJOE, (A1) pJOE-CYP153A M. aq. -CPRBM3 or (A2) pJOE-CYP153A M. aq. 
(G307A)-CPRBM3. Cell concentrations were 11 gcdw l-1. Cells were fed with additional C-source at 0, 4, 8 
and 12 h. Product yield coefficients (YP/S) correspond to g of total products per g substrate. 
Abbreviations: FA, fatty acid substrate; (ω-1)-OHFA, subterminally hydroxylated fatty acid; ω-OHFA, 
terminally hydroxylated fatty acid; α,ω-DCA, dicarboxylic acid. 
 
Co
n
ce
n
tr
at
io
n
 
[m
g 
l-1
] 
Biotransformation time [h] 
A0 
Y P/S = 
0  
A1 
Y P/S = 
0.043  
A2 
Y P/S = 
0.058  
Results and Discussion 75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. Whole cell biotransformations of 1.4 g l-1 oleic acid with resting E. coli JM109 cells. Cells 
contained (A0) empty pJOE, (A1) pJOE-CYP153A M. aq.-CPRBM3 or (A2) pJOE-CYP153A M. aq. 
(G307A)-CPRBM3. Cell concentrations were 11 gcdw l-1. Cells were fed with additional C-source at 0, 4, 8 
and 12 h. Product yield coefficients (YP/S) correspond to g of total products per g substrate. 
Abbreviations: FA, fatty acid substrate; (ω-1)-OHFA, subterminally hydroxylated fatty acid; ω-OHFA, 
terminally hydroxylated fatty acid; α,ω-DCA, dicarboxylic acid. 
A1 
Y P/S = 
0.031  
A2 
Biotransformation time [h] 
Co
n
ce
n
tr
at
io
n
 
[m
g 
l-1
] 
A0 
Y P/S = 
0  
Y P/S = 
0.050  
76 Results and Discussion 
 
 
As indicated in table 3.16, CYP concentrations were in average 20 mg (gcdw)-1 at the start of 
biotransformation. Maximum ω-OHFA yields for the G307A variant towards octanoic and oleic 
acids were 43 and 70 mg l-1 after 20 h, respectively. Considering that E. coli consumes octanoic 
and oleic acids, the use of β-oxidation knockout for biotransformations with theses substrates 
seems imperative.  
 
Table 3.16. Product concentrations and distributions obtained with resting E. coli JM109 cells 
harboring CYP153A M. aq. (wt) or (G307A) fused to CPRBM3 in conversions with additional C-source 
Parameter Units 
Octanoic  
acid 
Dodecanoic 
acid 
Oleic  
acid 
wt G307A wt G307A wt G307A 
Biotransformation time h 20 20 20 20 20 20 
Biomass concentration1 gcdw l-1 11.0 11.0 11.0 11.0 11.0 11.0 
Active P450 concentration1 mg (gcdw)-1 19.9 17.5 18.8 21.7 21.2 24.2 
Initial substrate concentration mg l-1 750 741 908 998 1412 1412 
Substrate conversion2 % 3.8 4.5 32.2 41.3 2.9 4.7 
ω-OHFA concentration mg l-1 32 43 309 438 44 70 
α,ω-DCA concentration mg l-1 ― ― 4 5 ― ― 
Product distribution 
 
      
(ω-1)-OHFA % ― ― 1.0 0.7 ― ― 
ω-OHFA % 100 100 97.7 98.3 100 100 
α,ω-DCA % ― ― 1.3 1.0 ― ― 
1at start of biotransformation. 2Substrate converted to oxygenated products (not equivalent to substrate 
consumption). The values were calculated from initial substrate and product concentrations and 
represent the molar percentage yields. 
 
 
In summary, the best results of the in vivo shake flask bioconversions herein presented were 
achieved with resting E. coli JM109 cells harboring the engineered CYP153A M. aq.(G307A)-
CPRBM3 fusion construct towards dodecanoic acid after 8 h (YP/S =  0.45 – 0.5; ≥ 96 % ω-
regioselectivity). Biotransformations were run at 30°C, 180 rpm. Experimental conditions 
resulting in higher product yields included the use of 11 gcdw l-1 cells, 1 g l-1 substrate and 2 % 
(v/v) DMSO. Higher cell or substrate concentrations did not contribute to increase product 
yields significantly. Cells were fed with glucose/glycerol (0.4 g l-1/ 1 g l-1) every 4 h to minimize 
substrate depletion.  
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4 Conclusion and outlook 
 
We have investigated biocatalysts for the synthesis of industrially relevant ω-oxyfunctionalized 
medium- and long-chain length aliphatic compounds. Prokaryotic CYP153A enzymes were 
selected on the basis of their high ω-regiospecificity, expression in soluble form (suitable for in 
vitro studies) and straightforward application within a bacterial system. 
  
CYP153A enzymes from Polaromonas sp. JS666, Mycobacterium marinum M. and Marinobacter 
aquaeolei VT8 were investigated. The CYP153A enzyme from M. marinum is herein referred as 
CYP153A16, based on the CYP nomenclature system.128 There are no former reports on 
CYP153A16; however, one CYP153 enzyme from M. marinum (referred as CYP153A14) was 
formerly expressed in Pseudomonas putida and demonstrated to ω-oxidize C6-C10 alkanes, among 
other compounds.190 The monooxygenases from Polaromonas sp. and M. aquaeolei have not been 
assigned a CYP systematic name yet, thus the terms CYP153A P. sp. and CYP153A M. aq. were 
adopted in agreement with the Cytochrome P450 Engineering Database (CYPED).215 CYP153A P. 
sp. and CYP153A M. aq. have not been characterized prior to this work, but Polaromonas sp. and 
M. aquaeolei are known to grow on and metabolize alkanes216 and alkanes/fatty acids,217-219 
respectively. 
 
The monooxygenases were first screened towards C5-C12 alkanes and C6-C12 primary alcohols. 
CYP153A16 and CYP153A M. aq. were found to oxidize alkanes to primary alcohols and these 
further to α,ω-diols. CYP153A P. sp. was active towards the investigated alkanes, but lacked the 
ability to terminally hydroxylate primary alcohols. Diol formation has been documented for 
CYP153 from Acinetobacter sp. OC4 (P450aci) and CYP153A13a (P450balk).90, 91 In a more 
recent study, CYP153A13a was shown to ω-hydroxylate C8-C12 alkanes, though α,ω-diols were 
not observed as products.89 Our findings are consistent with the fact that P450aci shares higher 
protein sequence similarity with CYP153A16 and CYP153A M. aq. (≥80 %) than with CYP153A P. 
sp. (70 %). Likewise, there is a high amino acid sequence similarity between CYP153A P. sp. and 
CYP153A6 from Mycobacterium sp HXN-1500, which has never been reported to yield diols. Our 
substrate screening studies towards C8-C20 saturated and 9(Z)/(E)-C14:1-C18:1 monounsaturated 
fatty acids provided further insights into the capabilities of CYP153A enzymes. We 
demonstrated that primary alcohol ω-hydroxylases CYP153A16 and CYP153A M. aq. are also 
able to convert fatty acids to ω-OHFAs. CYP153A M. aq. exhibited higher flexibility towards fatty 
acids of different size and saturation level. A combined rational design approach enabled us to 
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identify key residues for the activity and selectivity of CYP153A M. aq. An important aim was 
achieved by the creation of variant G307A, which was able to ω-oxygenate shorter primary 
alcohols and fatty acids owing to a higher catalytic efficiency compared to the wild type enzyme.  
 
The biotechnological potential of CYP153A M. aq. can be estimated by comparing its activity with 
those of yeast CYP52 alkane/fatty acid ω-hydroxylases. We are though unable to perform such 
comparison as previous publications have focused on studying CYP52 activity under different 
conditions, using either insect/yeast microsomal fractions14, 81 or improved whole yeast cells.4, 
136 However, the low intrinsic oxidation activity of  CYP153A M. aq. towards ω-OHFAs contrasts 
the behaviour of CYP52 enzymes, known to be per se responsible for the overoxidation of ω-
OHFAs to diacids without the intervention of other oxidoreductases.17, 220 This means CYP153A 
M. aq. allows more control of the reaction, which is an ideal feature for ω-OHFA synthesis. 
Compared to the most active bacterial CYPs known from the literature, i.e. CYP102A enzymes, 
the performance of CYP153 enzymes is still low. Nevertheless, attempts to mutate the former 
enzymes for alkane terminal oxidation have resulted in low ω-regiospecificities,96, 97 indicating 
that engineered CYPs from other bacterial families are yet not able to compete against CYP153A 
enzymes in terms of selectivity. The fact that CYP153A6 was formerly evolved for increased 
activity towards short-chain alkanes without affecting its selectivity77 is a proof that these 
enzymes are overall promising biocatalysts which can be tailored for higher activity and altered 
substrate specificity. 
 
As CYP activity also relies on coupling efficiency, it is important to consider that product yields 
shown in our in vitro reactions belong to the non-natural CamA-CamB-CYP153A electron 
transfer chain. Even though CamA/CamB are known to interact reasonably well with CYP153A 
enzymes,91 higher oxidation activities should be expected by using physiological redox partners 
or an artificial reductase in a single polypeptide chain arrangement. Here this limitation was 
tackled by the application of a fusion construct comprised by the CYP153A monooxygenase and 
the reductase domain of CYP102A1 (P450 BM3).  
 
Oxygenation reactions with the fusion proteins were carried out in P. putida and E. coli. The 
pseudomonads were included mainly due to their higher solvent tolerance and redox capacity. A 
comparative study with non-improved strains showed that higher concentrations of primary 
alcohols and ω-OHFAs were accumulated by E. coli than by P. putida. The fusion protein 
containing mutation G307A did not display the same efficiency in vivo as in vitro, but it 
performed better than the wild type enzyme.  Figure 4.1 illustrates potential limitations in a 
whole cell fatty acid ω-hydroxylation reaction with our established fusion construct and 
proposed strategies to overcome them. Given the high tendency of P. putida to consume the 
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substrate and the target products, production yields should be increased by the use of solvent-
treated knock-out strains. These cells should have a higher tolerance towards the 
substrate/product and a more efficient metabolism for redox biocatalysis.  
 
Figure 4.1. Limitations in whole cell fatty acid ω-hydroxylations 
catalyzed by CYP153A-CPR systems. Possible solutions for each 
bottleneck are: (1a-b) addition of surfactants; (2) overexpression of 
the constitutive fatty acid transporter/co-expression of a heterologous 
one; (3) stirred-tank reactor design; (4a) enzyme engineering to 
increase activity and stability; (4c) heme-reductase linker engineering 
to maximize electron transfer efficiency, co-expression of ROS-
scavenging enzymes; (4b, 8) reaction configuration in a two-phase 
system to prevent product inhibition/toxicity; (5) deletion of selected 
enzymes to prevent substrate and product depletion; (6) selection of 
an adequate vector or gene integration into the chromosome; (7) 
overexpression of a constitutive cofactor-regenerating enzyme/co-
expression of a heterologous one or increase the flux of NADPH-
producing reactions; (8) use of solvent-tolerant and solvent-adapted 
host strains. Based on van Beilen et al.,139 Grant et al.221 and D. Scheps 
et al., Microb Technol, 2013, manuscript accepted. 
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Additional efforts in both P. putida and E. coli should be oriented to maximize mass transfer and 
transport of the substrate across the membrane. In fact, substrate solubilization and uptake is 
not completely relieved by the addition of surfactants and cosolvents.222, 223 Recently, the co-
expression of the outer membrane protein transporter AlkL of P. putida Gpo1 has been shown to 
increase AlkB monooxygenase-based reaction rates towards methyl dodecanoate by 62-fold.222 
Another issue is cellular cofactor availability, which can be increased by protein and metabolic 
engineering as well. An elegant strategy described for E. coli consists of modifying an NADPH-
depending monooxygenase for dual NADH/NADPH specificity. At the same time, increasing the 
flux of the NADPH-producing pentose phosphate pathway and eliminating NADH-utilizing 
processes resulted in a more efficient utilization of the energy source in redox biocatalysis.224  
 
Hydrogen peroxide and other ROS accumulated in P. putida as a response to stress or as a side-
product of the CYP-mediated reaction can be immediately removed in situ by co-expressing 
catalase and other ROS-scavenging enzymes (e.g., superoxide dismutase). ROS generated by 
electron uncoupling could be minimized by increasing the coupling efficiency of the fusion 
construct. Varying the length of the polypeptide linker between the heme and the reductase 
domains has been reported to influence the coupling efficiency of chimeric fusion proteins.225, 226 
However, one in vitro study on a human CYP fused to the CPR from P450 BM3 suggests that 
uncoupling is an intrinsic property of the heme domain and that the covalent linkage of the 
reductase in a single polypeptide chain has little influence on activity coupled to product 
formation, with factors like cofactor concentration, pH and ionic strength having a significant 
role in uncoupling.227 Acetate formation in E. coli can be minimized by using a low acetate-
producing strain. At high glucose concentrations, growing JM109 cells have been reported to 
accumulate up to 11 g l-1 acetate, while growing BL21(DE3) cells produce around 3 g l-1  (≥ 2.4 g 
l-1 is detrimental).211 Other strategies to reduce acetate production in high-cell density E. coli 
fermentations can be applied at the bioprocess level (use of alternative C-sources and feeding 
approaches) and at the genetic level (regulation of futile cycles, anapleurotic pathways, 
coenzyme levels, acetate-producing and ATP-consuming pathways), with the latter giving the 
best results.228  
 
To conclude, we have reported the selective ω-hydroxylation of a broad set of alkanes, primary 
alcohols and fatty acids by bacterial CYP153A enzymes. The hydroxylation activity of a CYP153A 
candidate was increased by a rational design approach and the construction of a catalytic self-
sufficient monooxygenase. Although E. coli appeared to be a more effective host than P. putida, 
higher product titers could be obtained with adapted and improved pseudomonads. Finally, 
further protein, strain and process engineering strategies will eventually lead to the generation 
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of an alternative bacterial-based platform for the production of commercially attractive primary 
alcohols, α,ω-diols and ω-OHFAs.  
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6 Supplementary material 
 
6.1 Genes, vectors and strains 
 
6.1.1 Genes  
 
MmAlk gene cluster (MmFdx→CYP153A16→MmFdR) 
Gene IDs: MMAR_3155→MMAR_3154→MMAR_3153  
ATGGCAGTTGTCACATTTGTCTCCCACGGCGGCGAGAAGTATGAGGCGCCTCTCGAGGAAGGTCAGTCACTGATGCGGG
TCGCGACCAACAATGCGGTGCCCGGCATCGACGGCGACTGCGGAGGCGAAGCCGCGTGCGGCACCTGCCATGTGATCGT
CGATCCGCAATGGTCCGATCGGGTCGGCCTCTCCGGGGCCAATGAAGAGGAGATGCTCGCGATGAACCCCGAGCGTCAG
CCGACCTCCCGGCTGTCCTGCCAGATGCAGGTCTCTGAGGCGTGGGACGGTTTGATCGTCCATCTGCCCGAGTTCCAAC
TGTGATGACGAAAGAGAGGTGAGACGTGAGCAATATTCGCGAGGCAGTCACTGCCAAGGCTCAGGCAACAATTCCGATG
GACCGAATAATCCAGGGCGCCCACCTCTACGACAGAACGCGGCGCTGGGTCACCGGCACCAACGGTGAAAAAATCTTCA
TCGAGCGACCGATCCCGCCGGCTGACGAGGTTGAACTGACCGACATCGACCTTAGCAATCCTTTCCTCTATCGTCAGGG
TCGCTGGAAGTCCTATTACGAGCGCCTACGCAACGAGGCTCCCGTGCACTATCAGGCCCACAGCGCGTTCGGCCCGTTC
TGGTCGGTGACGCGGCATGCCGACATCGTGGCCGTCGACAAGAACCACGAGGTCTTCTCCTCCGAGCCGTTCATCGTCA
TCGGGAGCCCGCCGCGCTTCCTCGACATTGCGATGTTCATCGCGATGGACCCCCCAAAACACGACCGGCAACGGCAGGC
TGTCCAGGGTGTGGTCGCACCGAAGAACCTGCGTGAGATGGAGGGCCTCATCCGCGAGCGGGTGGTAGACGTGCTCGAC
GCTCTGCCGCTTGGCGAACCGTTCAACTGGGTGCAGCACGTCTCGATCGAGCTAACCGCGCGCATGCTGGCCACGCTGC
TGGACTTCCCGTTCGAGCAGCGGCGCAAGCTCGTCCAATGGTCCGATCTCGCCACCTCCATGGAGCAAGCCAACGGTGG
GCCCTCGGACAACGACGAGATATTTCGCGGCATGGTCGATATGGCTAGAGGTCTCAGCGCTCACTGGCGGGACAAGGCA
GCCCGGACAGCTGCCGGAGAGCTGCCCGGCTTCGATCTGATCACCATGTTGCAGAGCGACGAGAGCACCAAGGACCTGA
TCGATCGCCCGATGGAGTTCTTGGGCAACTTGGTATTGCTGATCGTGGGTGGCAACGATACGACCCGCAATTCCATGAG
CGGTGGTGTTCTGGCGCTGAACGAGTTCCCTGACCAGTTTGAGAAGCTGAAGGCGAACCCCGAGCTGATCCCCAACATG
GTCTCGGAGATCATCCGGTGGCAAACCCCGCTCGCGCATATGCGCCGGATCGCCAAGGCCGACACTGTGCTCAACGGGC
AGTTCATCCGCAAGGGCGACAAGGTCCTGATGTGGTACGCCTCGGGCAACCGCGACGAGCGCGTGTTCGATCGGCCCG 
ATGACCTGATTATCGATCGGGCCAACGCCCGTAACCACATCTCCTTCGGTTTCGGCGTGCACCGCTGTATGGGTAACCG
GCTGGCCGAGATGCAGTTGCGGATCCTGTGGGAGGAGCTGCTTCCGCGGTTCGAGAACATCGAGGTCGTCGGTGAGCCC
GAGTACGTGCAGTCCAACTTCGTGAGGGGGATCAGTAAGCTGATGGTCCGCCTCACCCCGAAAGGTGGCGCATGACCGT
GCAGCGAGCGGTCATCGCGGGGGCCAGCCACGCGGGCACCCAGCTCGCCGCCAGTCTTCGCCGAGAAGGGTGGGACGGC
GAAATCGTCCTCGTCGGCGATGAGTCGGCGTTGCCCTACCAGCGGCCCCCGCTGTCCAAGTCGTACCTGGCCGACAAAT
GCGAACTGGCCGAACTCGCGATCCGCAACTCGGATTTCTACGCCAAGCAGCGGATCCGACTCCTGGATGCGACGGTGGC
GGCGGTCGACCGCTCGGCTGGTCATGTCGTGCTGAGTACCGGCGACGCACTGCCCTACGACAAGCTCGCGCTGTGCACT
GGCGCCCGGCCTCGTCGGCTCCCCACCCCGGGAGCGGACCTGGCCGGAGTCTTCTACCTACGCACCGCCGCGGACGGCG
AGATGATCCGAGAGGCCGCCGGCCCCGGGCGTCGGGCGGTGATCGTCGGCGGCGGCTACATCGGACTGGAGACAGCCGC
CTCGTTGCGTGCACTGGGTCTGGAGGTCACCCTGCTCGAGGCGACCGGGCGCGTCCTTGAACGGGTCACCGCCCCGGAG
GTATCGGAGTTCTTCGACCGGATCCACCGGGAGGAGGGCGTCAACATCCGGACGGGCACGCTGGTCGAGGCTCTGTCCG
GCGACGGCAGGGTCCGCGAAGTAATCCTGGCCGGTGGCGAATCAATTCCCGCCGACCTCGTCATTGTCGGCATCGGCGT
GGAGCCGAACACCGAGCTCGCCGCCACCGCGGGCCTGGTCGTCGACAACGGCGTCGTGATCGACGATCAGGCCCGGACT
AGCGACCCCGACATCGTGGCCGCCGGGGACTGCGCCAGCCACGACATGGCCCGTTACGGCCGTCGCATCCGCCTGGAGT
CCGTGCCGAGCGCGGCCGAGCAGGCCAAGGTCGCCGCCGCGACCGTCTGTGGGAAGTCCAAGAAGATAGCGGCCCTTCC
ATGGTTCTGGTCAGATCAATACGACCTCAAGCTCCAGATCGCCGGTCTCAACACCGGGTACGACGAGGTCGTCCTCAGC
GGCGACCCGACCCGGGAGCGCGACTTCACCTGCTTCTACCTCCGTGCCGGCGAGCTTCTTGCCGCCGACTGCATCAACC
GTCCCCGCGACTTCATGTTCAGCAAGCGGGTCATCACGCAGCAAGTCGCCGTCGAACGGGCCGAACTGGTGCTCGCCGG
CTCGGACTGA 
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MaqAlk gene cluster (MaqFdx→CYP153A M. aq.→MaqFdR) 
Gene IDs: Maqu_0599→Maqu_0600→Maqu_0601  
ATGGGCGGTCACGATGGGCCGGAATATGCACATGTCGCAGAATTCAAAGCTGGTTCCTCGGTAATGCAAATCGCTGTTG
ATAGCGCCATTCCCGGTATCGACGGGGATTGTGGGGGGGAGTGCGCCTGCGGTACCTGCCACGTTATCGTCACGAACGA
ATGGTTCAGCAAGACAGGCACGCCTGGCAATGAGGAAGAACAAATGCTGTCAATGACACCGGAGCGGGCGAGCACTTCG
CGCCTGGGCTGCCAGGTGGTACTGACTGATGAAATGGACGGCATGACCGTGCATTTACCCGAGTTCCAGATGTGAACAC
AGGAGGACGCATGCCAACACTGCCCAGAACATTTGACGACATTCAGTCCCGACTGATTAACGCCACCTCCAGGGTGGTG
CCGATGCAGAGGCAAATTCAGGGACTGAAATTCTTAATGAGCGCCAAGAGGAAGACCTTCGGCCCACGCCGACCGATGC
CCGAATTCGTTGAAACACCCATCCCGGACGTTAACACGCTGGCCCTTGAGGACATCGATGTCAGCAATCCGTTTTTATA
CCGGCAGGGTCAGTGGCGCGCCTATTTCAAACGGTTGCGTGATGAGGCGCCGGTCCATTACCAGAAGAACAGCCCTTTC
GGCCCCTTCTGGTCGGTAACTCGGTTTGAAGACATCCTGTTCGTGGATAAGAGTCACGACCTGTTTTCCGCCGAGCCGC
AAATCATTCTCGGTGACCCTCCGGAGGGGCTGTCGGTGGAAATGTTCATAGCGATGGATCCGCCGAAACACGATGTGCA
GCGCAGCTCGGTGCAGGGAGTAGTGGCACCGAAAAACCTGAAGGAGATGGAGGGGCTGATCCGATCACGCACCGGCGAT
GTGCTTGACAGCCTGCCTACAGACAAACCCTTTAACTGGGTACCTGCTGTTTCCAAGGAACTCACAGGCCGCATGCTGG
CGACGCTTCTGGATTTTCCTTACGAGGAACGCCACAAGCTGGTTGAGTGGTCGGACAGAATGGCAGGTGCAGCATCGGC
CACCGGCGGGGAGTTTGCCGATGAAAATGCCATGTTTGACGACGCGGCAGACATGGCCCGGTCTTTCTCCAGGCTTTGG
CGGGACAAGGAGGCGCGCCGCGCAGCAGGCGAGGAGCCCGGTTTCGATTTGATCAGCCTGTTGCAGAGCAACAAAGAAA
CGAAAGACCTGATCAATCGGCCGATGGAGTTTATCGGTAATTTGACGCTGCTCATAGTCGGCGGCAACGATACGACGCG
CAACTCGATGAGTGGTGGCCTGGTGGCCATGAACGAATTCCCCAGGGAATTTGAAAAATTGAAGGCAAAACCGGAGTTG
ATTCCGAACATGGTGTCGGAAATCATCCGCTGGCAAACGCCGCTGGCCTATATGCGCCGAATCGCCAAGCAGGATGTCG
AACTGGGCGGCCAGACCATCAAGAAGGGTGATCGAGTTGTCATGTGGTACGCGTCGGGTAACCGGGACGAGCGCAAATT
TGACAACCCCGATCAGTTCATCATTGATCGCAAGGACGCACGAAACCACATGTCGTTCGGCTATGGGGTTCACCGTTGC
ATGGGCAACCGTCTGGCTGAACTGCAACTGCGCATCCTCTGGGAAGAAATACTCAAGCGTTTTGACAACATCGAAGTCG
TCGAAGAGCCCGAGCGGGTGCAGTCCAACTTCGTGCGGGGCTATTCCAGGTTGATGGTCAAACTGACACCGAACAGTTA
ATTAACCGATTGACCAGGATGGCATCCGAACGTGTGGAGAGTCCAATCCCAGGGCACAGCGAAAGAGATAGCCTATGGT
AAGCAAACGTAAAGAGAGGACGGTCATTGTTGGCGGTGGGCACGCAGCAGGTGCCCTCCTGACAGCCTTACTCCAAAAA
AAATATCAACATGAGGTCGTTCTGGTGGGGAATGAACCTCATCCGCCCTACCATCGACCGCCGCTGTCCAAGAATTACC
TGACAGGAGACGTTGATCAGGAGTCGCTGTACCTGAAACCGCGCTCGGTATACGAGAACGCAGGCCATCAGTTGCGGCT
CGGTGTGCGCGTCGAACAAATTGATCGGGACAGTAGCACCATCAGCTTGTCGGATCAGAGCAGGCTGCAATACGATCGA
CTGGTCCTGGCCACCGGGTCACACCTTCGACACCTGAACGCGCCCGGGGCTGACTTAAATGGCATTCATTACCTGCACG
ACATAGCTGATTCAGAGGTACTGCGTGAACAGTTAGTTGCTGGAAAGCGCCTGGTCGTCGTGGGTGGTGGTTACATCGG
CCTTGAGGTGGCGGCCAGTGCCAACAAAAAAGGTGTTAATGTCACGGTGCTAGAAGCCGCCGAACGTCTTATGCAGCGC
GTTACGGGCCCGGAAATATCAGCGTTCCTTTACGACAAACACCGTGGCGCCGGCGTGGACGTACGTCTGAACACAGCGG
TAACCGGCTTCGAAGCGGGCGATCAGGGGCATGTGGCTGGCGTGACGTTGGCGGACGGAAGCACCGTACCGGCCGACAT
CGTCCTTGTGTCGATCGGCATTATCCCGGAAACCGCTCTGGCTAAGGACGCCGGCCTGCCCTGTGATAACGGTATTATT
GTTGACGAATTTACCCGTACCGAGGACCCCGCCATCTTGGCGATCGGTGACTGCACCCGGCACCGGAATCTTTTCTTCG
AGAAGATGCAACGACTCGAGTCTGTCGCCAATGCTGTCGATCAGGCTCGTACAGCCGCGGCAACCCTGATGGGTGAGGA
GAAACCCTATGATAGCGTTCCATGGTTCTGGTCAAACCAGTACGATGTTCGTCTGCAGATGGTAGGATTGTCGCAAAAT
CATGATCAGCGAGTGGTTCGAGGCACCCCCGAGGATAAAGGATTTGCCGTGTTCTATCTCCGCGAAGGCTGTGTTATTG
CTGTTGACGCGGTCAACCTGCCCCTTGCTTTTTTGGTAGGCAAGACACTCGTTCAACAACGCAGAACGATCAACCCGGA
ACTAATAGAGGATCCGGATACTGAACTGAAATCTTTGGTGAACGGAAGGCTCCAGAGTTGA 
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PspAlk gene cluster (CYP153A P. sp.→PspFdR→PspFdx) 
Gene IDs: Bpro_5301→Bpro_5300→Bpro_5299  
ATGAGTGAAGCGATTGTGGTAAACAACCAAAACGACCAAAGCAGGGCATACGCGATCCCGCTTGAGGACATTGATGTAA
GCAATCCGGAGCTGTTTCGCGACAATACGATGTGGGGTTATTTTGAGCGTCTGCGCCGCGAAGACCCCGTGCATTACTG
TAAGGACAGCTTGTTTGGTCCGTACTGGTCGGTGACCAAGTTCAAGGACATCATGCAGGTGGAGACCCATCCGGAGATA
TTTTCATCCGAGGGCAATATCACCATCATGGAGTCCAATGCGGCGGTAACCCTGCCGATGTTCATTGCGATGGATCCGC
CCAAGCACGACGTGCAGCGCATGGCGGTCAGTCCGATCGTGGCGCCGGAGAACCTCGCCAAGCTCGAAGGTCTGATCCG
CGAGCGTACCGGTCGTGCGCTGGATGGCCTGCCGATCAACGAGACCTTTGACTGGGTCAAGCTCGTTTCGATCAACCTG
ACGACGCAGATGCTGGCGACGCTGTTTGATTTCCCTTGGGAAGACCGTGCCAAGCTGACGCGCTGGTCGGATGTCGCGA
CGGCGCTGGTCGGCACGGGCATTATTGATTCGGAAGAGCAGCGCATGGAGGAGCTCAAGGGGTGCGTGCAATACATGAC
CCGGCTGTGGAACGAGCGCGTCAATGTGCCACCGGGCAATGATCTGATATCGATGATGGCGCACACCGAGTCCATGCGC
AACATGACGCCGGAAGAGTTTCTGGGCAACCTCATTTTGCTGATCGTCGGCGGCAATGACACGACCCGCAACTCGATGA
CCGGCGGCGTGCTGGCGCTCAACGAAAATCCGGACGAATACCGCAAGCTGTGCGCCAACCCGGCGCTGATCGCCTCCAT
GGTGCCGGAGATCGTTCGTTGGCAGACACCGCTGGCGCACATGCGGCGTACCGCGCTGCAGGACACCGAGCTCGGCGGC
AAGTCCATTCGCAAGGGTGACAAGGTCATCATGTGGTATGTCTCCGGCAACCGTGATCCCGAAGCGATTGAAAATCCGG
ACGCGTTCATCATTGATCGCGCCAAGCCGCGCCATCACCTCTCGTTCGGTTTCGGCATTCACCGCTGCGTGGGCAACCG
TCTCGCCGAGTTGCAGCTGCGCATCGTTTGGGAGGAGTTGCTCAAGCGCTGGCCCAATCCAGGTCAGATCGAGGTCGTT
GGCGCGCCCGAGCGCGTGCTGTCGCCCTTTGTGAAGGGCTATGAGTCGCTGCCCGTCCGCATCAACGCTTGAAGCCGCG
CTGATCGTGAGCGAAACTGTGATTATTGCCGGCGCCGGTCAGGCGGCCGGCCAGGCGGTTGCGAGCCTGCGGCAAGAGG
GATTCGACGGGCGCATCGTGCTGGTCGGCGCCGAGCCGGTGTTGCCGTATCAGCGCCCGCCGCTGTCGAAGGCATTTTT
GGCGGGCACCTTGCCGCTGGAGCGATTGTTCCTGAAGCCGCCGGCATTCTACGAGCAGGCGCGTGTGGACACGCTGCT 
CGGGGTGGCCGTCACCGAACTTGATGCCGCCCGGCGGCAGGTGAGGCTGGACGATGGCCGCGAACTGGCGTTTGATCAT
CTGCTGCTGGCGACTGGCGGGCGTGCCCGTCGGCTTGACTGCCCGGGTGCCGACCATCCGCGCCTGCACTATCTGCGCA
CCGTGGCTGATGTTGACGGCATTCGTGCCGCTCTGCGTCCCGGGGCCCGGCTGGTGCTGATCGGCGGCGGCTACGTCGG
ACTCGAGATCGCCGCCGTGGCCGCCAAACTGGGGCTCGCGGTGACCGTGCTGGAAGCGGCGCCGACGGTGCTGGCGCGT
GTCACTTGTCCGGCCGTGGCGCGCTTCTTCGAAAGCGTGCACCGGCAGGCGGGCGTGACGATCCGCTGCGCGACGACGG
TCTCCGGCATCGAGGGCGATGCTTCGCTGGCGCGGGTCGTGACCGGCGATGGCGAACGCATTGACGCCGACCTGGTCAT
TGCCGGCATCGGTCTGCTGCCGAACGTCGAGTTGGCGCAGGCCGCGGGTCTGGTCTGCGACAACGGCATCGTCGTCGAC
GAGGAATGCCGGACCTCTGTGCCCGGCATTTTCGCGGCTGGCGACTGCACGCAGCATCCGAACGCGATCTACGACAGTC
GGCTGCGTCTCGAATCGGTGCACAACGCCATTGAGCAGGGCAAGACGGCGGCGGCGGCCATGTGTGGCAAGGCCAGGCC
GTATCGGCAGGTGCCGTGGTTCTGGTCCGATCAGTACGACCTCAAGTTACAAACCGCGGGACTCAACCGCGGCTATGAC
CAGGTCGTGATGCGGGGCAGTACCGACAACCGTTCGTTTGCGGCGTTCTACCTGCGCGACGGGCGATTGCTTGCCGTCG
ATGCGGTCAACCGCCCGGTCGAGTTCATGGTGGCCAAAGCGCTGATTGCGAACCGCACCGTCATCGCGCCCGAGCGGCT
CGCCGACGAGCGTATCGCAGCGAAGGACCTGGCCGGCTGATGTCGCTGTGCCGGGCCATGGATTTAATTTTATCGAACT
ATCAATTCACAAGGGCGCTGCCAAGGCGCGCCCCATTTTGGAAAATCAACATGACAAAAGTTACTTTTATTGAACACAA
TGGTACGGTCCGCAACGTGGACGTCGACGACGGCCTGTCGGTGATGGAGGCCGCCGTCAACAACCTGGTGCCGGGCATC
GATGGCGACTGCGGTGGCGCCTGCGCCTGCGCCACCTGCCATGTGCACATCGACGCCGCCTGGCTGGACAAGTTGCCGC
CGATGGAGGCGATGGAAAAGTCGATGCTTGAGTTTGCCGAGGGCCGCAACGAAAGCTCGCGCCTGGGTTGTCAGATCAA
GCTCAGCCCCGCGCTTGACGGCATTGTGGTGCGCACGCCGCTCGGCCAGCACTGA 
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6.1.2 Vectors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Maps of non-commercial vectors used in this study: pJOE and pCom10.  The pJOE vector 
series, developed at the University of Stuttgart, contain the L-rhamnose promoter (rhaPBAD) from the 
catabolic operon rhaBAD as well as transcriptional activators rhaR and rhaS. pJOE vectors have 
reported protein expression yields of 20 % in E. coli and Pseudomonas strains.177, 178  The pCom 
vector series were developed in the Swiss Federal Institute of Technology Zurich (ETH Zürich). They 
contain the PalkB promoter which originally controls the expression of the alkBFGHIJKL operon 
located in the OCT plasmid from P. putida Gpo1. The AlkS protein activates transcription from PalkB 
upon exposure to C7-C12 n-alkanes, alkenes, ethyl acetate or dicyclopropyl ketone. pCom10 is a 
medium to high copy number plasmid able to yield recombinant protein levels as high as 25 % in E. 
coli and Pseudomonas.179  
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Table 6.1. Vector constructs used in this work 
Name Gene Insert 
Available 
at ITB? 
ITB No. 
pET28a(+)-CamA 
Putidaredoxin reductase (CamA) from P. 
putida ATCC 17453 
Yes pITB692 
pET28a(+)-CamB 
Putidaredoxin (CamB) from P. putida ATCC 
17453 
Yes pITB691 
pKK223-3-CYP153A16 
CYP153A16 (MMAR_3154) from 
Mycobacterium marinum M. ATCC BAA-535 
Yes pITB442 
pET28a(+)-CYP153A P. sp. 
CYP153A P. sp. (Bpro_5301) from 
Polaromonas sp. JS666 ATCC BAA-500 
Yes pITB376 
pET28a(+)-CYP153A M. aq. 
T302M 
Focused mutant library of CYP153A M. aq. 
(Maqu_0600) from Marinobacter aquaeolei 
VT8 DSM 11845 
Yes pITB719 
pET28a(+)-CYP153A M. aq. 
T302V 
Focused mutant library of CYP153A M. aq. 
(Maqu_0600) from Marinobacter aquaeolei 
VT8 DSM 11845 
Yes pITB751 
pET28a(+)-CYP153A M. aq. 
V306T 
Focused mutant library of CYP153A M. aq. 
(Maqu_0600) from Marinobacter aquaeolei 
VT8 DSM 11845 
Yes pITB726 
pET28a(+)-CYP153A M. aq. 
M357Y 
Focused mutant library of CYP153A M. aq. 
(Maqu_0600) from Marinobacter aquaeolei 
VT8 DSM 11845 
Yes pITB720 
pET28a(+)-CYP153A M. aq. 
F455I 
Focused mutant library of CYP153A M. aq. 
(Maqu_0600) from Marinobacter aquaeolei 
VT8 DSM 11845 
Yes pITB721 
pET28a(+)-CYP153A M. aq. 
F455L 
Focused mutant library of CYP153A M. aq. 
(Maqu_0600) from Marinobacter aquaeolei 
VT8 DSM 11845 
No† - 
pJOE  
[pJOE4782.1 (malE-, eGFP-)] 
None. Empty religated vector lacking malE 
(maltose binding protein) and eGFP 
(enhanced green fluorescent protein)  
Yes pITB437 
pJOE-BM3 
CYP102A1 or P450 BM3 (CPXB_BACME) 
from Bacillus megaterium DSM 319 
Yes pITB438 
pJOE-MmAlk 
MmAlk operon: Ferredoxin (MMAR_3155), 
CYP153A16 (MMAR_3154), ferredoxin 
reductase (MMAR_3153) from 
Mycobacterium marinum M.  ATCC BAA-
535 
Yes pITB439 
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Table 6.1. Vector constructs used in this work (continued) 
Name Gene Insert 
Available 
at ITB? 
ITB No. 
pJOE-MaqAlk 
MaqAlk operon: Ferredoxin (Maqu_0599), 
CYP153A M. aq. (Maqu_0600), ferredoxin 
reductase (Maqu_0601) from Marinobacter 
aquaeolei VT8 DSM 11845 
Yes pITB457 
pJOE-PspAlk 
PspAlk operon: CYP153A P. sp. 
(Bpro_5301), ferredoxin reductase 
(Bpro_5300), ferredoxin (Bpro_5299) from 
Polaromonas sp. JS666 ATCC BAA-500 
Yes pITB458 
pCom10-alkB-BMO2 
AlkB (alkane-1-monooxygenase, BMO2 
mutant), AlkF (rubredoxin 1), AlkG 
(rubredoxin 2) from P. putida Gpo1 
Yes - 
pCom10-MmAlk MmAlk operon Yes pITB459 
pCom10-MaqAlk MaqAlk operon Yes pITB460 
pCom10-PspAlk PspAlk operon Yes pITB461 
pJOE-CYP153A M. aq.-CPR 
CYP153A M. aq. fused to the reductase 
domain (CPR) of P450 BM3 from Bacillus 
megaterium DSM 319 
Yes pITB468 
pJOE 
-CYP153A M. aq.(G307A)-CPR 
CYP153A M. aq. (G307A variant) fused to 
the reductase domain (CPR) of P450 BM3 
from Bacillus megaterium DSM 319 
Yes pITB469 
pKK223-3-MmAlk MmAlk operon Yes pITB750 
†Available only as cell-free extract. 
 
Supplementary material 105 
 
 
6.1.3 Strains  
 
Table 6.2. Strains used in this work 
Name Description / Use 
Available 
at ITB? 
ITB No. 
JM105_pKK223-3-153A16 Expression of CYP153A16 in E. coli JM105 Yes ITB442 
BL21 (DE3)_pET28a(+)-M. aq.-Enz-
N-Term 
Expression of CYP153A M. aq. in E. coli 
BL21(DE3) 
Yes ITB372 
BL21 (DE3)_pET28a(+)-P. sp.-Enz-
C-Term 
Expression of CYP153A P. sp. in E. coli 
BL21(DE3) 
 
No† 
 
- 
BL21 (DE3)_ pET28a(+)-CYP153A 
M. aq. M143R 
Focused mutant library of CYP153A M. aq.  Yes ITB383 
BL21 (DE3)_ pET28a(+)-CYP153A 
M. aq.  I145M 
Focused mutant library of CYP153A M. aq.  yes ITB392 
BL21 (DE3)_ pET28a(+)-CYP153A 
M. aq. I145F 
Focused mutant library of CYP153A M. aq.  Yes ITB393 
BL21 (DE3)_ pET28a(+)-CYP153A 
M. aq.  I145T 
Focused mutant library of CYP153A M. aq.  Yes ITB394 
BL21 (DE3)_ pET28a(+)-CYP153A 
M. aq. I145S 
Focused mutant library of CYP153A M. aq.  Yes ITB399 
BL21 (DE3)_ pET28a(+)-CYP153A 
M. aq. L303T 
Focused mutant library of CYP153A M. aq.  Yes ITB388 
BL21 (DE3)_ pET28a(+)-CYP153A 
M. aq. L354F 
Focused mutant library of CYP153A M. aq.  Yes ITB389 
BL21(DE3)_ pET28a(+)-CYP153A 
M. aq. L354I 
Focused mutant library of CYP153A M. aq.  Yes ITB390 
BL21 (DE3)_ pET28a(+)-CYP153A 
M. aq. F455Y 
Focused mutant library of CYP153A M. aq.  Yes ITB391 
BL21 (DE3)_ pET28a(+)-CYP153A 
M. aq. G307A 
Focused mutant library of CYP153A M. aq.  Yes ITB396 
BL21 (DE3)_ pET28a(+)-CYP153A 
M. aq. G307V 
Focused mutant library of CYP153A M. aq.  Yes ITB397 
BL21 (DE3)_ pET28a(+)-CYP153A 
M. aq. M357N 
Focused mutant library of CYP153A M. aq.  Yes ITB398 
DH5α_pET28a(+)-CYP153A M.aq. 
M357F 
Focused mutant library of CYP153A M. aq.  Yes ITB470 
JM109_pJOE 
E. coli JM109 with religated pJOE vector 
(negative control) 
Yes ITB437 
JM109_pJOE-MmAlk Expression of the MmAlk operon in E. coli  Yes ITB439 
S12_pJOE 
P. putida S12 with religated pJOE vector 
(negative control) 
Yes ITB440 
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Table 6.2. Strains used in this work (continued) 
Name Description / Use 
Available 
at ITB? 
ITB No. 
S12_pJOE-MmAlk 
Expression of the MmAlk operon in P. 
putida S12 
Yes ITB441 
DH5α_pJOE-MaqAlk Propagation of pJOE_MaqAlk in E. coli Yes ITB457 
DH5α_pJOE-PspAlk Propagation of pJOE_PspAlk in E. coli Yes ITB458 
DH5α_pCom10-MmAlk Propagation of pCom10_MmAlk in E. coli Yes ITB459 
DH5α_pCom10-MaqAlk Propagation of pCom10_MaqAlk in E. coli Yes ITB460 
DH5α_pCom10-PspAlk Propagation of pCom10_PspAlk in E. coli Yes ITB461 
KT2440_pJOE 
P. putida KT2440 with religated pJOE 
vector (negative control) 
Yes ITB450 
KT2440_pJOE-MmAlk 
Expression of the MmAlk operon in P. 
putida KT2440 
Yes ITB451 
KT2440_pJOE-MaqAlk 
Expression of the MaqAlk operon in P. 
putida KT2440 
Yes ITB452 
KT2440_pJOE-PspAlk 
Expression of the PspAlk operon in P. 
putida KT2440 
Yes 
ITB423, 
ITB453 
KT2440_pCom10-MmAlk 
Expression of the MmAlk operon in P. 
putida KT2440 
Yes ITB454 
KT2440_pCom10-MaqAlk 
Expression of the MaqAlk operon in P. 
putida KT2440 
Yes ITB455 
KT2440_pCom10-PspAlk 
Expression of the PspAlk operon in P. 
putida KT2440 
Yes 
ITB422, 
ITB456 
DH5α_pJOE-CYP153A M. aq. 
(G307A)-CPR 
Propagation of the pJOE_CYP153A M. aq. 
(G307A)-CPR fusion construct in E. coli 
Yes ITB462 
KT2440_pJOE-CYP153A M. aq.-CPR 
Expression of the CYP153A M. aq.-CPR 
fusion construct in P. putida KT2440 
Yes ITB463 
KT2440_pJOE-CYP153A M. aq. 
(G307A)-CPR 
Expression of the CYP153A M. aq.(G307A)-
CPR fusion construct in P. putida KT2440 
Yes ITB464 
S12_pJOE-CYP153A M. aq. 
(G307A)-CPR 
Expression of the CYP153A M. aq.(G307A)-
CPR fusion construct in P. putida S12 
Yes ITB465 
JM109_pJOE-CYP153A M. aq.-CPR 
Expression of the CYP153A M. aq.-CPR 
fusion construct in E. coli JM109 
Yes ITB466 
JM109_pJOE-CYP153A M. aq. 
(G307A)-CPR 
Expression of the CYP153A M. aq.(G307A)-
CPR fusion construct in E. coli JM109 
Yes ITB467 
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Table 6.2. Strains used in this work (continued) 
Name Description / Use 
Available 
at ITB? ITB No. 
BL21(DE3)_pJOE-CYP153A M. aq.-
CPR 
Expression of the CYP153A M. aq.-CPR 
fusion construct in E. coli BL21(DE3) 
Yes ITB468 
BL21(DE3)_pJOE-CYP153A M. aq. 
(G307A)-CPR 
Expression of the CYP153A M. aq.(G307A)-
CPR fusion construct in E. coli BL21(DE3) 
Yes ITB469 
†Available only as vector construct (pITB376). 
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6.2 Multiple protein sequence alignments 
 
CYP153A1           FDAAVDAAKHFAELWHRKAAQKSAGAEMGYDLISLMQSNEATKDLIYR-PMEFMGNLVLL 331 
CYP153AspOC4       FDAAVDAAKHFAELWHRKAAQKSAGAEMGYDLISLMQSNEATKDLIYR-PMEFMGNLVLL 331 
CYP153A13a         FDDAADMAWAFSKLWRDKEARQKAGEEPGFDLISMLQSNEDTKDLINR-PLEFIGNLALL 304 
CYP153Maq          FDDAADMARSFSRLWRDKEARRAAGEEPGFDLISLLQSNKETKDLINR-PMEFIGNLTLL 304 
CYP153A16          FRGMVDMARGLSAHWRDKAARTAAGELPGFDLITMLQSDESTKDLIDR-PMEFLGNLVLL 295 
CYP153M.gamma      RTIMGEMLQSFTQLWHDHKANDRES----FDLIRMLQRDPKTQNMVDE-PFSYLGNLMLL 259 
CYP153A6           MAELMECATYFTELWNQRVNAEPKN-----DLISMMAHSESTRHMA---PEEYLGNIVLL 253 
CYP153Psp          MEELKGCVQYMTRLWNERVNVPPGN-----DLISMMAHTESMRNMT---PEEFLGNLILL 251 
CYP153A8           RAELIECAMYFKGLWEQRINAEPKN-----DLISMMAHSPATRDMP---FLEFLGNLLLL 255 
CYP153A11          RQELIECAMYFKGLWDQRIDRSEGS-----DLITMMANSPATREMP---FLEFLGNLLLL 260 
CYP153A7           KTELLECAAYFQVLWNERVNKDPGN-----DLISMLAHSPATRNMT---PEEYLGNVLLL 252 
CYP52A10           FKRCNKIVHKFSDYYIKKALTATPEELEKHS--SYIFLYELAKQTRD--PIVLRDQSLNI 312 
CYP52A11           FKRCNKIVHKFSDYYIKKALTATPEELEKHS--SYIFLYELAKQTRD--PIVLRDQSLNI 312 
CYP52A17           FRDCTKSVHKFTNYYVQKALDASPEELEKQS--GYVFLYELVKQTRD--PNVLRDQSLNI 310 
CYP52A4            FNKSIKTVHKFADFYVQKALSLTDDDLEKQE--GYVFLYELAKQTRD--PKVLRDQLLNI 331 
CYP52A3            FRDCNAKVHKLAQYFVNTALNATEKEVEEKSKGGYVFLYELVKQTRD--PKVLQDQLLNI 317 
CYP124             MQVSADIGAYATALAEDRRVNHHDD------LTSSLVEAEVDGERLS--SREIASFFILL 264 
P450BM3            KRQFQEDIKVMNDLVDKIIADRKASGEQSDDLLTHMLNGKDPETGEPLDDENIRYQIITF 262 
P450Bsbeta         PRAEEWIEVMIEDARAGLLKTTSGT-----ALHEMAFHTQEDGSQLDS---RMAAIELIN 239 
                                                                                
CYP153A1           IVGGNDTTRNSMTGGVYALNLFPNEFVKLKNNP-----------------------SLIP 368 
CYP153AspOC4       IVGGNDTTRNSMTGGVYALNLFPNEFVKLKNNP-----------------------SLIP 368 
CYP153A13a         IVGGNDTTRNSMSGGVLALNQFPEQFEKLKANP-----------------------KLIP 341 
CYP153Maq          IVGGNDTTRNSMSGGLVAMNEFPREFEKLKAKP-----------------------ELIP 341 
CYP153A16          IVGGNDTTRNSMSGGVLALNEFPDQFEKLKANP-----------------------ELIP 332 
CYP153M.gamma      IVGGNDTTRNSMTGGVLHLHQNPSEMAKLKANH-----------------------GLIP 296 
CYP153A6           IVGGNDTTRNSMTGGVLALNEFPDEYRKLSANP-----------------------ALIS 290 
CYP153Psp          IVGGNDTTRNSMTGGVLALNENPDEYRKLCANP-----------------------ALIA 288 
CYP153A8           IVGGNDTTRNSISGGVLALNQNPDAYLKLNNDP-----------------------GLIT 292 
CYP153A11          IVGGNDTTRNSISGGVIALNQNPDQYEKLRQHP-----------------------SLIG 297 
CYP153A7           IVGGNDTTRNSMTGGVLALHKNPDQFAKLKANP-----------------------ALVE 289 
CYP52A10           LLAGRDTTAGLLSFAVFELGRNPEVWSKLRQEIGHKFGLDSYSRVEDISFELLKLCEYLK 372 
CYP52A11           LLAGRDTTAGLLSFAVFELGRNPEVWSKLREEIGDKFGLDPDSRIEDISFELLKLCEYLK 372 
CYP52A17           LLAGRDTTAGLLSFAVFELARHPEIWAKLREEIEQQFGLGEDSRVEEITFESLKRCEYLK 370 
CYP52A4            LVAGRDTTAGLLSFLFFELSRNPTVFEKLKEEIHNRFGAKEDARVEEITFESLKLCEYLK 391 
CYP52A3            MVAGRDTTAGLLSFAMFELARNPKIWNKLREEVEVNFGLGDEARVDEISFETLKKCEYLK 377 
CYP124             VVAGNETTRNAITHGVLALSRYPEQRDRWWSDFD----------------------GLAP 302 
P450BM3            LIAGHETTSGLLSFALYFLVKNPHVLQKAAEEAARVLVDPVP------SYKQVKQLKYVG 316 
P450Bsbeta         VLRPIVAISYFLVFSALALHEHPKYKEWLRSGNS----------------------RERE 277 
                   ::    :    :      :   *                                      
 
CYP153A1           NMVSEIIRWQTPLAYMRRIAKQDVELNGQ---------TIKKGDKVVMWYVSGNRDERVI 419 
CYP153AspOC4       NMVSEIIRWQTPLAYMRRIAKQDVELNGQ---------TIKKGDKVVMWYVSGNRDERVI 419 
CYP153A13a         NMVSEIRRWQTPLAYMRRVAKQDVELNGQ---------TIKKGDRVLMWYASGNQDERKF 391 
CYP153Maq          NMVSEIIRWQTPLAYMRRIAKQDVELGGQ---------TIKKGDRVVMWYASGNRDERKF 392 
CYP153A16          NMVSEIIRWQTPLAHMRRIAKADTVLNGQ---------FIRKGDKVLMWYASGNRDERVF 383 
CYP153M.gamma      SMVSEIIRYQTPLPHMRRTATRDVELNGT---------VIPKGGRVVLWYVSGNRDSNAI 347 
CYP153A6           SMVSEIIRWQTPLSHMRRTALEDIEFGGK---------HIRQGDKVVMWYVSGNRDPEAI 341 
CYP153Psp          SMVPEIVRWQTPLAHMRRTALQDTELGGK---------SIRKGDKVIMWYVSGNRDPEAI 339 
CYP153A8           SMVPEIIRWQTPLTHMRRTALQDWEIGGK---------KIRKGDKVVMWYLSGNRDETVI 343 
CYP153A11          SMVPEIIRWQTPLTHMRRTALADSEIGGK---------RIAKGDKVVMWYLSGNRDETVI 348 
CYP153A7           TMVPEIIRWQTPLAHMRRTAIADSELGGK---------TIRKGDKVVMWYYSGNRDDEVI 340 
CYP52A10           AVLNETLRLYPSVPRNARFAAKNTTLPHGGGPDGMSPILVRKGQTVMYSVYALQRDEKYY 432 
CYP52A11           AVINETLRLYPSVPRNGRFAAANTTLPHGGGPDGMSPILVRKGQTVMYSVYALQRDEKYY 432 
CYP52A17           AFLNETLRIYPSVPRNFRIATKNTTLPRGGGSDGTSPILIQKGEAVSYGINSTHLDPVYY 430 
CYP52A4            ACVNEALRVYPSVPHNFRVATRNTTLPRGGGKDGMSPIAIKKGQNVMYTISATHRDPSIY 451 
CYP52A3            AVLNETLRMYPSVPINFRTATRDTTLPRGGGKDGNSPIFVPKGSSVVYSVYKTHRLKQFY 437 
CYP124             TAVEEIVRWASPVVYMRRTLTQDIELRGT---------KMAAGDKVSLWYCSANRDESKF 353 
P450BM3            MVLNEALRLWPTAPAFSLYAKEDTVLGGEY--------PLEKGDELMVLIPQLHRDKTIW 368 
P450Bsbeta         MFVQEVRRYYPFGPFLGALVKKDFVWNNC---------EFKKGTSVLLDLYGTNHDPRLW 328 
                       :     .           :                .  *  :       :       
Figure 6.2. Section of a multiple alignment of CYP153A, CYP52 and other CYP sequences (ClustalW2, 
Gonnet matrix, gap open: 10, gap extension: 0.20, gap distances: 5). The alignment explains 
mutations T302V/M, G307A, L354I/F and M357N in CYP153A M. aq. Residue L354 is aligned with 
A328 in P450 BM3 (Substitutions of A328 with I/L/V/F influence its selectivity on alkanes).  
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CYP153A6        --------------------------------------------MTEMTVAAS-DATNAA 15 
CYP153APsp      --------------------------------------------MSEAIVVNNQNDQSRA 16 
CYP153A7        ---------------------------------------------------MEHTGQSAA 9 
CYP153A16       -------MSNIREAVTAKAQATIPMDRIIQGAHLYDRTRRWVTGTNGEK-IFIERPIPPA 52 
CYP153AMaq      MPTLPRTFDDIQSRLINATSRVVPMQRQIQGLKFLMSAKRKTFGPRRPMPEFVETPIPDV 60 
                                                                           . 
CYP153A6        YGMALEDIDVSNPVLFRDNTWHPYFKRLREEDPVHYCKSSMFGPYWSVTKYRDIMAVETN 75 
CYP153APsp      YAIPLEDIDVSNPELFRDNTMWGYFERLRREDPVHYCKDSLFGPYWSVTKFKDIMQVETH 76 
CYP153A7        ATMPLDSIDVSIPELFYNDSVGEYFKRLRKDDPVHYCADSAFGPYWSITKYNDIMHVDTN 69 
CYP153A16       DEVELTDIDLSNPFLYRQGRWKSYYERLRNEAPVHYQAHSAFGPFWSVTRHADIVAVDKN 112 
CYP153AMaq      NTLALEDIDVSNPFLYRQGQWRAYFKRLRDEAPVHYQKNSPFGPFWSVTRFEDILFVDKS 120 
                  : * .**:* * *: :.    *::*** : ****   * ***:**:*:. **: *:.  
         BC-loop 
CYP153A6        PKVFSSEAKSGGITIMD-----DNAAASLPMFIAMDPPKHDVQRKTVSPIVAPENLATME 130 
CYP153APsp      PEIFSSE---GNITIME-----SNAAVTLPMFIAMDPPKHDVQRMAVSPIVAPENLAKLE 128 
CYP153A7        HDIFSSDAGYGGIIIDDGIQKGGDGGLDLPNFIAMDRPRHDEQRKAVSPIVAPANLAALE 129 
CYP153A16       HEVFSSE---PFIVIGS-----PPRFLDIAMFIAMDPPKHDRQRQAVQGVVAPKNLREME 164 
CYP153AMaq      HDLFSAE---PQIILGD-----PPEGLSVEMFIAMDPPKHDVQRSSVQGVVAPKNLKEME 172 
                 .:**::     * : .           :  ***** *:** ** :*. :*** **  :* 
              F-helix→F/G loop     
CYP153A6        SVIRQRTADLLDGLPINEEFDWVHRVSIELTTKMLATLFDFPWDDRAKLTRWSDVTT--A 188 
CYP153APsp      GLIRERTGRALDGLPINETFDWVKLVSINLTTQMLATLFDFPWEDRAKLTRWSDVAT--A 186 
CYP153A7        GTIRERVSKTLDGLPVGEEFDWVDRVSIEITTQMLATLFDFPFEERRKLTRWSDVTT--A 187 
CYP153A16       GLIRERVVDVLDALPLGEPFNWVQHVSIELTARMLATLLDFPFEQRRKLVQWSDLATSME 224 
CYP153AMaq      GLIRSRTGDVLDSLPTDKPFNWVPAVSKELTGRMLATLLDFPYEERHKLVEWSDRMAGAA 232 
                . **.*.   **.** .: *:**  ** ::* :*****:***:::* **..***  :    
  F/G 
CYP153A6        LPGGGIIDSEEQRMAELMECATYFTELWNQR-----VNAEPKNDLISMMAHSESTRHMA- 242 
CYP153APsp      LVGTGIIDSEEQRMEELKGCVQYMTRLWNER-----VNVPPGNDLISMMAHTESMRNMT- 240 
CYP153A7        APGGGVVESWDQRKTELLECAAYFQVLWNER-----VNKDPGNDLISMLAHSPATRNMT- 241 
CYP153A16       QANGGP-SDNDEIFRGMVDMARGLSAHWRDKAARTAAGELPGFDLITMLQSDESTKDLID 283 
CYP153AMaq      SATGGEFADENAMFDDAADMARSFSRLWRDKEARRAAGEEPGFDLISLLQSNKETKDLIN 292 
                    *   . :         .  :   *.::     ..  *  ***:::      :.:   
          __I-helix__            _SRS-5_ 
CYP153A6        -PEEYLGNIVLLIVGGNDTTRNSMTGGVLALNEFPDEYRKLSANPALISSMVSEIIRWQT 301 
CYP153APsp      -PEEFLGNLILLIVGGNDTTRNSMTGGVLALNENPDEYRKLCANPALIASMVPEIVRWQT 299 
CYP153A7        -PEEYLGNVLLLIVGGNDTTRNSMTGGVLALHKNPDQFAKLKANPALVETMVPEIIRWQT 300 
CYP153A16       RPMEFLGNLVLLIVGGNDTTRNSMSGGVLALNEFPDQFEKLKANPELIPNMVSEIIRWQT 343 
CYP153AMaq      RPMEFIGNLTLLIVGGNDTTRNSMSGGLVAMNEFPREFEKLKAKPELIPNMVSEIIRWQT 352 
                 * *::**: **************:**::*::: * :: ** *:* *: .**.**:**** 
          SRS-5 
CYP153A6        PLSHMRRTALEDIEFGGKHIRQGDKVVMWYVSGNRDPEAIDNPDTFIIDRAKPRQHLSFG 361 
CYP153APsp      PLAHMRRTALQDTELGGKSIRKGDKVIMWYVSGNRDPEAIENPDAFIIDRAKPRHHLSFG 359 
CYP153A7        PLAHMRRTAIADSELGGKTIRKGDKVVMWYYSGNRDDEVIDRPEEFIIDRPRPRQHLSFG 360 
CYP153A16       PLAHMRRIAKADTVLNGQFIRKGDKVLMWYASGNRDERVFDRPDDLIIDRANARNHISFG 403 
CYP153AMaq      PLAYMRRIAKQDVELGGQTIKKGDRVVMWYASGNRDERKFDNPDQFIIDRKDARNHMSFG 412 
                **::*** *  *  :.*: *::**:*:*** ***** . ::.*: :****  .*:*:*** 
            C-terminal β-sheet loop 
CYP153A6        FGIHRCVGNRLAELQLNILWEEILKRWPDPLQIQVLQEPTRVLSPFVKGYESLPVRINA- 420 
CYP153APsp      FGIHRCVGNRLAELQLRIVWEELLKRWPNPGQIEVVGAPERVLSPFVKGYESLPVRINA- 418 
CYP153A7        FGIHRCVGNRLAEMQLRILWEEILTRFS---RIEVMAEPERVRSNFVRGYAKMMVRVHA- 416 
CYP153A16       FGVHRCMGNRLAEMQLRILWEELLPRFEN---IEVVGEPEYVQSNFVRGISKLMVRLTPK 460 
CYP153AMaq      YGVHRCMGNRLAELQLRILWEEILKRFDN---IEVVEEPERVQSNFVRGYSRLMVKLTPN 469 
                :*:***:******:**.*:***:* *:     *:*:  *  * * **:*   : *:: .  
 
Figure 6.3. Multiple protein sequence alignment of CYP153A enzymes (ClustalW2, Gonnet matrix). 
CYP153A7 shares 79 % protein similarity with CYP153A6 or CYP153A P. sp., 71 % with CYP153A16 
and 69 % with CYP153A M. aq. The gray-shadowed letters represent conserved and variable regions 
within identified secondary structures involved in substrate specificity. Underlined letters display 
key active site residues proposed in the homology model of CYP153A6.83 The blue-shadowed region 
is the loop missing in the X-ray crystal structure of CYP153A7.144 The letters in red stand for highly 
variable residues at the C-terminus of the F-helix and on the F/G loop ― located at the top of the 
active site cavity in CYP153A7 ― which might play a role in the docking of primary alcohols and fatty 
acids in CYP153A16 and CYP153A M. aq.  
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6.3 Supplementary tables 
 
Table 6.3. Macrocyclic musk products derived from C16-C18 saturated and unsaturated fatty acids 
Fatty 
acid 
Inter-
mediate 
Macrocyclic product   
Name 
 
Ring 
size 
Structure Price/ 
Kg (€)* 
Producer 
C16:0 
(palmitic) 
ω-OHFA Silvanone 
 
17 
 
240 Givaudan, 
International 
Flavors and 
Fragrances Inc., 
Vigon International 
α,ω-DCA Exaltolide 16 
 
450 China Aroma 
Chemical Co., Ltd., 
Firmenich, Soda 
Aromatic, Symrise, 
Vigon International 
Exaltone 15 
 
136 Givaudan, 
Firmenich, Chemos 
GmbH 
(R,S)-Muscone 15 
 
1100 Firmenich, Vigon 
International 
(R)-Muscone 15 
 
n.r. None 
C17:0 
(margaric) 
α,ω-DCA Isomuscone 16 
 
156 Symrise, Vigon 
International 
C18:0 
(stearic) 
ω-OHFA 18-Octadecanolide 19 
 
n.r. None 
α,ω-DCA 17-Heptadecanolide 18 
 
n.r. None 
Dihydrozibetone 17 
 
n.r. None 
9(Z)-C18:1 
(oleic) 
ω-OHFA Zibetone 17 
 
n.r. None  
* Referential prices as of July, 2012 (www.vigoninternational.com). n.r., not reported 
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Table 6.4. Amino acid sequence similarities between the putative natural redox partners of 
CYP153A16 or CYP153A P. sp. and CamA or CamB  
Putative natural redox partner 1: 
Ferredoxin reductase 
CamA (422 aa):  
Ferredoxin reductase from P. putida  
Strain Gene name aa Identity Similarity Score 
Mycobacterium 
marinum M. 
MMAR_3153 400 50 % 64 % 354 
Polaromonas sp. 
JS666 
Bpro_5300 405 47 % 63 % 357 
Putative natural redox partner 2: 
Ferredoxin 
CamB (107 aa):  
Ferredoxin from P. putida 
Strain Gene name aa Identity Similarity Score 
Mycobacterium 
marinum M. 
MMAR_3155 106 41 % 63 % 87 
Polaromonas sp. 
JS666 
Bpro_5299 106 50 % 68 % 103 
performed via blastp, http://blast.ncbi.nlm.nih.gov 
 
 
 
Table 6.5. Retention times of products analyzed by GC  
Chain length 
Product 
Retention time [min] 
C5 C6 C7 C8 C9 C10 C11 C12 
2-alcohol — — 9.2 11.2 14.8 14.8 10.9 12.5 
Aldehyde — — — 11.3 13.1 14.9 11.0 12.6 
1-alcohol 5.5 8.5 10.6 12.5 14.2 15.8 12.1 13.5 
fatty acid — — — 14.3 15.7 17.2 13.4 14.5 
unidentified product 1* — — — — 17.3 18.6 14.8 16.0 
unidentified product 2* — — — — 17.4 18.7 14.9 16.2 
α,ω-diol  — — — 17.0 18.4 19.4 15.7 17.1 
FS-Supreme-5 column (30 m x 0.25 mm x 0.25 µm); — not detected 
*unidentified products 1 and 2 were obtained only with CYP153A16. Experiments with CYP153A16 and 1-
decene or α,ω-decanediol as starting substrate material showed these compounds were neither 
epoxidation products nor further oxidized α,ω-diols (e.g., dialdehydes or ω-hydroxyaldehydes). 
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6.4 Supplementary figures 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4. Michaelis-Menten plots of octanoic, nonanoic and tetradecanoic acids in reactions 
catalyzed by CYP153A M. aq. Wild type (blue) and variant G307A (red). Measurements were done 
with concentrations below the substrate solubility limit.   
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Figure 6.5. Formation of hydrogen peroxide (A) and acetate (B) by P. putida KT2440 and E. coli 
JM109 cells harboring pJOE-CYP153A M. aq. (G307A)-CPRBM3 in bioconversions of dodecanoic acid 
with glucose/glycerol-feeding only at the start of biotransformation. 
 
A 
B 
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Pseudomonas putida 
 
 
 
 
 
 
 
 
 
Escherichia coli 
 
 
 
 
 
 
 
 
 
Figure 6.6. Aggregation in P. putida KT2440 cells after 10 h bioconversions of 1 g l-1 dodecanoic acid. 
Cell aggregation occurred in all P. putida variants, but it was more drastic in cells not harboring the 
CYP construct. E. coli cells without CYP (not shown) and with CYP did not aggregate. 
Biotransformations were run with glucose/glycerol feeding every 4 hours. 
KT2440 without CYP  
(negative control) 
KT2440 with CYP153A 
M.aq.-CPRBM3  
KT2440 with CYP153A 
M.aq. (G307A)-CPRBM3  
 
JM109 and BL21(DE3) with  
CYP153A M.aq (G307A)-CPRBM3  
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Abstract 
A two-phase biotransformation process for selective hydroxylation of n-octane to 1-octanol 
via Pseudomonas putida KT2440 harboring heterologously expressed P450 monooxygenase 
from Mycobacterium marinum is presented.  Maximum cell-specific conversion rates of 12.7 
mgoctanol gCDWh-1 were observed not only in shaking flasks but also in 3.7L bioreactor studies. 
Notably the latter have been performed obeying strict safety precautions thus lowering 
volumetric power input, aeration rates and substrate concentrations. Based on a stoichiometric 
network of Pseudomonas putida KT2440 topological studies were carried out. As a 
conclusion, potential limitations of NAD(P)H and/or ATP supply at production conditions can 
be excluded. In contrast, the great potential of the host for further improving performance data 
is outlined.  
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Introduction 
Pseudomonas strains such as Pseudomonas putida KT2440 are gaining increasing interest for 
industrial applications due to their native ability to withstand potential stress conditions 
properly (1)-(4). For instance, Rühl et al. (5) identified solvent tolerant Pseudomonas strains 
showing n-butanol resistance up to 6% and Blank et al. (2) observed non-deteriorated 
substrate uptake rates in the presence of organic solvents which is a significantly different 
behavior compared to uptake reductions that usually occur with e.g. solvent stressed E. coli. 
Because genome sequencing was already finished in 2002 (5) metabolic engineering tools can 
be well applied for constructing novel recombinant Pseudomonas putida KT2440 producers. 
Motivated by these basic properties Pseudomonas putida KT2440 has been chosen as a 
promising host for recombinant 1-octanol formation. The basic idea was to selectively oxidize 
n-octane via recombinant Pseudomonas activity to produce 1-octanol. It was anticipated that 
high product titers should be possible due to the strain’s capacity to withstand organic solvent 
stress. Furthermore, heterologous octane oxidation should be achieved via recombinant 
expression of P450 monooxygenase CYP153A16 originating from Mycobacterium marinum. 
In addition, Pseudomonas putida strains have been reported to be suitable hosts for the 
expression of CYP153A monooxygenases and their natural redox partners. In this sense, 
pseudomonads have been utilized for the growth-based selection of CYP153A mutants (6) 
and for the whole cell-mediated biotransformation of alkanes, alkenes and alicyclic 
compounds ((8)(8)). CYP153A16 from Mycobacterium marinum has been reported to be 
poorly expressed in E. coli. 
1-Octanol has been chosen as an attractive product because it is used in the chemical industry 
as starting material for the synthesis of ethoxylates, alkyl sulfates and ether sulfates, in 
petroleum chemistry as anti-foaming agent, as a solvent in paints, varnishes and surface 
coatings and in agricultural chemistry, e.g., to inhibit excessive growth of tobacco plants (11). 
Besides, it serves as additive in the perfume industry (12), totally summing up to ~3.2 million 
tpa production worldwide (13). The naphta-derived substrate n-octane is available at large 
quantities with reasonable prices compared to the product value of 1-octanol. However, any 
process approach dealing with n-octane needs to take into account its relatively high vapor 
pressure, its low water solubility and its low flash point which consequently set severe 
constraints on technically safe 1-octanol production from n-octane. Interesting enough, not 
only these basic properties need to be taken into account but also their interplay with 
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fermentation conditions. For instance bioreactor power input via stirring and aeration should 
be carefully installed to prevent critical droplet formation in head space (14)-(14). Besides 
technical issues, the successful expression of P450 monooxygenase CYP153A16 from 
Mycobacterium marinum in Pseudomonas putida KT2440 needed to be shown for the first 
time as well. 
It is therefore the goal of this contribution to present a Pseudomonas putida-based 1-octanol 
production approach using n-octane as substrate and applying technically safe production 
conditions that may serve as a blueprint for scale-up. The latter seems to be worth mentioning 
with respect to alternative E. coli based approaches which are often designed as feasibility 
studies. 
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Materials and Methods 
 
Bacterial Strain 
In these experiments we used Pseudomonas putida KT2440 (DSMZ Braunschweig, 
Germany) and P. putida KT2440 MmarAlk (10).  
The genomic DNA from Mycobacterium marinum M. ATCC BAA-535 was obtained from 
the American Type Culture Collection (ATCC). The gene cluster containing the CYP153A16 
enzyme and its natural redox partners from Mycobacterium marinum M. were cloned into the 
L-rhamnose-inducible p4782.1 (pJOE,(16)) vector for expression in Pseudomonas putida 
KT2440. Expression vector pJOE was obtained from Josef Altenbuchner, Institute of 
Industrial Genetics, University of Stuttgart (Stuttgart, Germany).  
For protein expression, Pseudomonas putida KT2440 cells were transformed with the plasmid 
by electroporation. Transformants were then cultivated in 200 ml liquid media with 30 µg ml-
1
 kanamycin. Strains containing the pJOE construct were grown in Terrific Broth (TB) (17). 
To prevent carbon- and energy source depletion, 5 g l-1 glucose was added to TB medium 6 h 
after starting the cultures.  
 
Media 
If not mentioned otherwise, chemicals were purchased from Fluka (Buchs, Switzerland). 
Special chemicals are listed in the analytical section. 
M12 Mineral salts media containing 2.2 g l1 (NH4)2SO4, 0.4 g l-1 MgSO4 × 7 H2O, 0.04 g l-1 
CaCl2 × 2 H2O, 0.02 g l-1 NaCl, 2 g l-1 KH2PO4 and trace elements (2 mg l-1 ZnSO4 × 7 H2O, 
1 mg l-1 MnCl2 × 4 H2O, 15 mg l-1 Na3-Citrat × 2 H2O, 1 mg l-1 CuSO4 × 5 H2O, 0.02 mg l-1 
NiCl2 × 6 H2O, 0.03 mg l-1 NaMoO4 × 2 H2O, 0.3 mg l-1 H3BO3 (Merck), 10 mg l-1 FeSO4 × 7 
H2O).  
Shake flask media: Glucose, 4 g l-1; M12 mineral salts containing trace elements; phosphate 
buffer, kanamycin. 
Batch media: 10 g l-1 glucose; M12 mineral salts containing trace elements; phosphate buffer, 
kanamycin  
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Feed media: 150 g l-1 glucose; 150 mM CaCl2 × 2 H2O, 150mM; 1 M MgSO4, 150 g l-1 NaCl; 
trace elements; phosphate buffer.  
Induction solution: L-rhamnose, (0.2% (w/v), 2g l-1; FeSO4 × 7 H2O, 0.1 mM 
Antibiotics: Kanamycin 30 µg ml-1 filter sterilized 
 
Cultivation 
Working cell bank: Strains were stored in 16% (v/v) glycerol stock at -70°C (storage 
condition: exponential growth at OD600nm = 2). 
Pre cultivation: A shake flask culture (130 ml) was inoculated with 13.6 ml cells from a 
working cell bank (OD600nm = 2) in a 500 ml baffled shake flask. The culture was incubated 
for 6 hours at 30°C under shaking. For biotransformation in shaking flasks cells were induced 
after 4.5 h and 2 hours later production was started by adding 10% (v/v) n-octane. 
Cultivation: Batch fermentation was started by inoculating the pre culture (150 ml) in 1170 ml 
batch media (10 g l-1 glucose) in a 3.7 l KLF Bioreactor (Bioengineering AG, Wald, 
Switzerland). The cells were cultivated at T =  30°C and pH = 7.0 ±0.05 (controlled by 
addition of 25% (v/v) NH4OH solution), stirring speed increased from 500 rpm up to 
1200 rpm depending of dissolved oxygen concentration (> 30%) (aeration rate VG = 2 nl min-
1
, temperature set to 30°C, pressure set to 1.5 bar). After C-limitation feed pump was started 
with 75 ml h-1.  
Biotransformation: 3 hours prior to production induction solution was added, pH was set to 
pH = 6 by addition of approximately 15 ml 10% (v/v) phosphoric acid. Also safety operation 
procedures were adjusted (pressure raised to 2.2 bar, reduction of aeration rate to 1 nl min-1 
air and additionally 2 nl min-1 nitrogen in reactor head space, limiting of stirring speed to 
1200 rpm). Frothing was suppressed by addition of 500 µl contraspum 210 (Zschimmer and 
Schwarz, Lahnstein, Germany), Biotransformation was started by adding 10% (v/v) n-octane 
and by replacing the feed media with glucose solution (50% (w/v) glucose, feed rate 25 ml h-
1). 
Reference experiments with P. putida KT2240 were performed under same parameters and 
conditions excluding induction and production phase.  
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Sampling and analytical methods 
Sampling: Samples were withdrawn with a capillary sampling probe as developed by 
Theobald (18). The sampling of the extracellular substrate was carried out by filtration with a 
0.2 m pore size ceramic membrane (FIPS sampling probe, Flownamics, Madison, USA). 
GC-FID: Quantification of carboxylates and alcohols was performed on a GC Hewlett 
Packard 5890 series II (Agilent, Waldbronn, Germany) equipped with an Agilent 6890 
autosampler and a flame ionization detector. The column (Permabond CW20-M 0.25 µm, 
30 m x 0.32 mm ID, Macherey-Nagel, Düren, Germany) was loaded with 0.5 µl aqueous 
sample or 1.0 µl organic sample. The flow rate of the helium carrier gas was set to 2.0 ml min-
1
. Injector 220 °C and detector 220 °C; oven program: 50 °C, heating to 90 °C (4 °C min-1); 
heating to 220 °C (10 °C min-1); 220 °C, 4 min; cooling to 50 °C (30 °C min-1). 
HPLC-RI: Agilent Technologies Type 1200 Series isocratic (Agilent, Waldbronn, Germany) 
was used for the quantification of organic acids. A Rezex ROA-Organic Acid H+ 
250 x 4.6 mm column equipped with a SecurityGuard Cartridge Kit with Carbo-H 4 x 3.0 mm 
ID Cartridges was used (all from Phenomenex, Aschaffenburg, Germany). A Flow rate of 
0.2 ml min-1 of 5 mM sulphuric acid (HPLC-grade Sigma-Aldrich, Taufkirchen, Germany) 
and temperature of 35 °C were used.  
Glucose quantification was done with LaboTRACE (TRACE Analytics, Braunschweig, 
Germany) 
Enzymatic assays: For gluconate quantification the D-gluconic acid Kit (Megazyme, 
Wicklow, Ireland) was used. The glucose concentration was measured using an enzymatic 
assay (R-Biopharm AG, Darmstadt, Germany). 
Cell dry weight: 10 ml of broth from the bioreactor was dried with a MB35 Moisture 
Analyzer (Ohaus Europe GmbH, Switzerland). Filtrate samples were individually quantified 
and later subtracted from the corresponding biosuspension.  
Optical density: Samples were diluted in 0.9% (w/v) NaCl solution, measured at wavelength 
600 nm with Ultraspec 1100 pro (GE Healthcare, formerly Amersham Biosciences, USA). In 
presence of organic solvents the samples were put on ice for 45 seconds and the organic phase 
was collected. The remaining phase was remixed, diluted and quantified. 
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Modeling and Simulation  
For estimation of exchange fluxes, the process has been subdivided into 4 process phases. 
Within each process phase, exponential growth with a constant mean growth rate has been 
assumed, as well as constant biomass specific rates of substrate uptake and product formation. 
Rates have been determined simultaneously for all phases and all consumed and produced 
substances, including biomass, in a nonlinear optimization process. 
Using a genome based stoichiometric model, substrate uptake and product formation rates 
have been reconciled for each process phase, such that supply and demand of all intracellular 
metabolites is balanced with a minimum of quadratic deviations between estimated and 
reconciled rates. The stoichiometric model was based on the annotated genome of 
Pseudomonas putida KT2440 (5) and consisted of 1093 reactions for 607 balanced 
compounds. It exceeded the reactome of Pseudomonas putida KT2440 by a set of 
recombinant biotransformation reactions, including the P450-mediated oxidation of n-octane 
to 1-octanol. For rate reconciliation, overdetermined submodels were identified for each 
process phase by applying convex analysis, maximizing energetic efficiency within each 
submodel. 
The substrate uptake and product formation rates have been used to determine the formation 
and utilization fluxes for reduction equivalents (NADH, NADPH) and energy metabolites 
(ATP) for each process phase. By constraining the stoichiometry in respiration, ATP 
generation efficiency in the respiratory chain (P/O-ratio) has been chosen to be 1.75 for both 
the unmodified strain and the strain carrying recombinant P450 monooxygenase. This is the 
same level as assumed by Nogales et al. (19). 
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Results and Discussion 
The goal of this study was to investigate an aerobic 1-octanol production process using n-
octane as substrate for the selective hydroxylation via P450 monooxygenase CYP153A16, 
which was heterologously expressed in the host P. putida KT2440. While the basic feasibility 
of P450 monooxygenase mediated oxidation of C5-C12 alkanes has already been shown by 
heterologous expression in E. coli in shaking flask scale (10), this contribution aims at 
studying 1-octanol production in a 3.7 L bioreactor. Noteworthy, experimental conditions 
needed to be installed such that sensitive properties of n-octane (flash point: 13°C; vapor 
pressure 1.47 kPa (20°C), water solubility 0.007 g l-1 (20°C) are carefully considered. 
Because 1-octanol is hardly miscible in water, the production process consists of two liquid 
phases: The first, aqueous phase harbored P. putida cells that converted slightly resolved n-
octane into 1-octanol and the second, organic phase consisted of n-octane, basically serving as 
a sink preventing 1-octanol accumulation in the water phase.  
 
Safety Precaution Measures 
If a safe, industry-like production process is planned, highest interest should be paid to the 
critical explosion limits caused by the use of n-octane. To be precise, not only the obvious 
sensitive headspace concentration for n-octane and oxygen had to be considered, but also the 
formation of critical water/solvent droplets need to be prevented. As outlined by Schmid et al. 
(14) their presence, can significantly increase the risk of non-wanted headspace explosion, 
presumably by creating local, critical ignition.  
As a consequence aeration and stirring (i.e. superficial velocity and volumetric power input) 
have been limited to non-critical values (see Materials and Methods). Furthermore additional 
measures were taken such as the increase of operating pressure, tight control of oxygen 
concentration and electrical grounding of the experimental set-up. For precaution the 
bioreactor pressure was raised to 2.2 bar when n-octane has been used. (Remark: Based on 
Raoul and Dalton’s law the relative gas fraction of explosive octane reduces by increasing the 
absolute pressure.) Additionally, aeration via sparger was limited to 1 nl min-1, (~0.3-0.5 
vvm). Furthermore, nitrogen ventilation (2 nl min-1) of the bioreactor headspace was installed 
to prevent the creation of an explosive atmosphere. Consequently, only sub-critical oxygen 
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concentrations in the headspace were allowed (< 8% (v/v)). Finally additional electric 
grounding of all reactor parts was installed to prevent ignition by static discharges.  
Noteworthy, these measures have been taken for the sake of safe experimental conditions. 
They are motivated by the explosive properties of n-octane and they could be alleviated in 
case of applying less challenging substrates. While these actions are well qualified for risk 
protection they cause sub-optimal mass transfer conditions inside the liquid phase. Because of 
reduced stirring and aeration, substrate import and product export to and from the microbial 
cells may be deteriorated.   
 
Process Approach 
During the first process phase biomass is produced using glucose as the main carbon source. 
Because no n-octane is added so far, cultivation conditions can be installed optimally for cell 
growth (see Material and Methods). When the planned biomass concentration is achieved, 
glucose supply is reduced significantly to a minimum. At the same time, process conditions 
were switched to ‘safe mode’ because octane supply was started. The basics of 1-octanol 
production are outlined in figure 1. Notably, the selective oxidation of n-octane to 1-octanol 
via P450 monooxygenase does not require for additional carbon supply at first sight. But it is 
well known, that these enzymes activate so far non-active C-H bonds via hydroxylation not 
only requiring oxygen but also redox equivalents such as NADH or NADPH. To ensure their 
supply via basic metabolic activity and to fulfill cellular maintenance demands in the presence 
of organic solvents, a low glucose feed was yet installed. Hence, 1-octanol production was 
performed with resting cells complying with their maintenance needs.  
Considering the safety restrictions for n-octane, experimental studies were performed as 
indicated in figure 2. P. putida grew to cell densities of ~18 gCDW l-1 within 16 h using glucose 
as main carbon source. While cell growth was exponential at process start, a constant 
substrate feed was installed after ~8 h to ensure biomass formation at limited growth 
conditions without potential oxygen limitation. About 2 h before the end of the growth phase, 
the rhamnose induced expression system coding for P450 monooxygenase was induced via 
rhamnose addition at glucose limited conditions. As a result monooxygenase activity was 
provided for the subsequent n-octane biotransformation to 1-octanol. 
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Figure 3 deciphers typical courses of substrate and product concentrations during a 3.7 L 
bioreactor run. Phase I is characterized by exponential growth with P. putida consuming the 
main carbon source glucose. As a basic property of glucose metabolism in Pseudomonas 
strains, gluconate is produced via periplasmatic glucose dehydrogenases from glucose and 
phosphorylated to gluconate-6-phosphate (19). This is why gluconate accumulates initially 
and it is converted further in phase II. Cell growth is reduced by the limited supply of glucose 
in phase III which also lacks gluconate formation. 1-octanol production takes place in phase 
IV. 
Applying safe operations procedures we achieved 1-octanol titer of 330 mg l-1 after 1.75 h 
(Figure 4). The specific 1-octanol formation rate (12.4 ±2.1 mg gCDW-1 h-1) for whole cell 
biocatalysis by CYP153A16 is in the range of performance values of alternative approaches 
using resting E. coli cells with P450 monooxygenase CYP153s (20)(21) and CYP153A6 (6). 
Application with P. putida GPo12 (formerly known as P. oleovorans) have shown higher 
conversions of octane to 1-octanol (8)(22), but in these studies 1-octanol was used as energy 
and carbon source at the same time.  
It needs to be outlined that 1-octanol production via P450 monooxygenase in P. putida was 
accompanied by low by-product formation. Common by-products such as iso-octanol could 
not be detected at all, 1,8-octanediol titers accumulated to less than 1% only. The tendency of 
low by-product formation is remarkable with respect to potential savings in further 
downstream processing of 1-octanol containing broth. These process simplifications need to 
be taken into account when the current approach is compared to relatively high 1-octanol 
formation rates with AlkB monooxygenase in E. coli (23). The latter were accompanied by 
equimolar formation of octane carboxylic acid. Besides, the current approach represents a 
‘one-pot’ example, not only considering industry-like safety concepts but also preventing any 
cell harvesting from a primary culture followed by its transfer to a 2nd reaction vessel. 
Notably, the approach has been demonstrated in lab-bioreactor scale and not only under 
milliliter and/or shaking flask conditions which rather give evidence to feasibility than to 
technical realization.   
Figure 5 indicates that the current approach is well scalable comparing preliminary shaking 
flasks studies and final 3.7 L bioreactor results. n-octanol formation rates were always found 
to be in the range of 9.5 to 12.7 mg gCDW-1 h-1. Biological triplicates in shaking flasks revealed 
product formation variance of 12.6±1.2 mg gCDW-1 h-1. Hence shaking flask results are very 
similar to reactor studies. Differences in final 1-octanol titers were mainly due to variations in 
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initial n-octane concentrations and n-octane supply which have been changed in the course of 
experimental design. 
 
Impact on Cellular Redox and Energy Management 
As outlined above, the selective oxidation of n-octane basically represents a hydroxylation at 
C-H bond thus requiring for reduction equivalents such as NADH and/or NADPH. The 
reduced nucleotides need to be supplied by basic central metabolism and may represent a 
significant drain in overall redox balances. To investigate how much cellular metabolism is 
affected by 1-octanol formation, the stoichiometric model of Pseudomonas putida (see 
Material and Methods) has been applied for topology studies. Figure 6 gives an overview of 
the flux balance analysis assuming a realistic P/O ratio of 1.75 [12] and considering fixed 
substrate uptake and product formation rates during 1-octanol formation. Presuming no 
biomass production, only 0.4% of the reductions equivalents are needed to cope with the 
experimentally determined 1-octanol formation rates. In case of maximum cell growth, this 
fraction increases up to 0.6%. Hence the vast majority of NAD(P)H supply (with or without 
growth) is still available for oxidative phosphorylation. Together with the catabolic ATP 
synthesis in central metabolism, a significant ATP supply is enabled that can either be used 
for cell growth or for other demands, not specified in Figure 6.  
To evaluate the capacities of the P. putida system further, an extreme scenario of tenfold 
increase of 1-ocantol formation rate was assumed, still fixing glucose uptake rates at the ‘old’ 
values. Under this condition, the biotransformation contributes to the total balance of NADH, 
NADPH and CoQH2 only by approximately 5%. This demonstrates that the native redox 
capacity of P. putida offers a great potential for further increasing 1-octanol formation rates 
without hitting the regeneration limits of the system. 
Complementary to the question of redox capacity, the cellular maintenance ATP demand is 
worth studying to judge whether or not maintenance needs are at a challenging level. Based 
on the stoichiometric P. putida model a flux balance approach has been performed, again 
fixing measured rates for substrate uptake and biomass formation. To estimate the impact of 
plasmid-encoded gene expression, maintenance ATP requirements were calculated not only 
for the P. putida 1-octanol producer but also for the parental P. putida KT2440 wild type. The 
later was in the focus of supplemental chemostat studies published elsewhere (25). Data of the 
parental strain are thus based on steady-state experiments, while maintenance demands of the 
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1-octanol producer were extracted from the cell growth phase I-III of fedbatch experiments 
discussed above. 
In case of the wild type KT2440, ATP maintenance requirements mATP [mmolATP gCDW-1 h-1] 
were found to be (23.6 ± 5.9) + µ * (78.0 ± 16.5). (20.0 ± 9.6) + µ * (142.2 ± 37.4) were 
calculated for the currently used 1-octanol producer (see table 1). Obviously, ATP 
requirements are the same for both strains at resting cell conditions. However, slightly 
increasing needs are identified for growing 1-octanol producers harbouring the heterologous 
monooxygenase on plasmid. The slope of the growth () dependent ATP demand is higher for 
producing cells than for non-producers. 
Considering the fact that 1-octanol formation was realized with almost resting cells, i.e. no 
significant cell growth  could be detected during phase IV (see figure 3), maintenance 
requirements of the 1-octanol producer should be similar to wild type demands except for 
potential increases reflecting raised cellular needs to cope with the production stress 
conditions. Indeed only somewhat increased ATP requirements were derived from the 
measurements during 1-octanol production phase. The maintenance ATP flux was determined 
as 33.2 – 38.0 mmolATP gCDW-1 h-1. However, these absolute values are yet far from being 
critical with respect to cellular total ATP formation capacities (2). Summarizing neither redox 
regeneration nor ATP supply unravel obvious limits for 1-octanol formation. In contrast, the 
strain offers great potential for further improvement of 1-octanol performance data. 
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Summary and Conclusion 
It has been shown that the heterologous expression of P450 monooxygenase in P. putida 
KT2440 succeeded allowing the selective oxidation of n-octane to 1-octanol. Safe, industry-
like product formation could be achieved in 3.7 L scale, revealing 1-octanol formation rates of 
~12 mg gCDW-1 h-1. At these production conditions neither the formation of reduction 
equivalents nor ATP maintenance demands significantly limit 1-octanol formation. In 
contrast, the strain’s properties offer great promise for further improvement of performance 
data.  
The question arises what is the most prominent factor limiting product formation in the 
current approach? Table 2 gives an overview of competing studies. E. coli has been chosen as 
the host system in all approaches except for the one presented in this contribution. It is fair to 
state that performance data of the P. putida producer are well keeping up with those of the 
others – apart from the approach of Grant et al. (23). Noteworthy, safe production conditions 
have been installed for the Pseudomonas approach, while most of the others were realized in 
significantly smaller scale. However, the approach of Grant et al. (23) is outperforming, 
roughly by a factor of 10. This seems to be remarkable because the native Pseudomonas 
oleovorans alkane utilizing systems alkB was expressed in E. coli (26). Recently, Gudiminchi 
et al. (27) have demonstrated that overexpression of the alkB P450 monooxygenase in E. coli 
did not yield at increased performance data. Obviously this host system has reached a (high 
level) boundary for biotransformation.  
Considering the current P. putida example one may wonder whether mass transport limits 1-
octanol formation. Isken and de Bont (2) already outlined that the uptake of organic solvents 
in bacteria is usually driven by diffusion. Taking into account the poor substrate solubility of 
about 7 mgoctane l-1 (at 20°C) and considering the volumetric 1-octanol formation rate of 12.7 
mgoctanol gCDW-1 h-1 * 20 gCDW l-1 = 254 mgoctanol l-1 h-1, less than 100 s are theoretically enough 
to totally replenish maximum dissolved n-octane levels with the observed biological activity 
of the cells. Studying the n-octane based growth of P. oleovorans, Schmid et al. (27) 
identified maximum octane transfer rates > 45 mmol l-1 h-1 which are ~20 fold higher than the 
n-octane biotransformation rates observed here. Notably, with 2500 rpm and 1.9 vvm 
significantly better mixing and aeration conditions were installed by Schmid et al. (27) than 
applied in this approach. So, it cannot be excluded that safety precautions finally limited 
diffusion-driven-n-octane transport to the cells. Additionally, biotransformation rates may be 
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hampered by 1-octanol export as well which, again, could be affected by the operating 
conditions installed. 
However, irrespective of potentially limiting mass transport conditions, the host P. putida 
offers a great potential for heterologous hydroxylation processes because of its low 
maintenance demand and its high reductive power thus offering himself as a platform 
organism for other approaches as well. 
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Figure 1: Basic principle of 1-octanol formation from n-octane using P450 monooxygenase 
(CYP153A16) from Mycobacterium marinum which was heterologously expressed in P. 
putida KT2440. n-Octane is imported via diffusion and converted to 1-octanol in the cytosol. 
Besides oxygen, reduction equivalents such as NADH are needed for hydrogenation of the 
substrate which are delivered by concomitant glucose metabolization in (almost) resting cells. 
 
Figure 2: Process Design under Safety operation procedures (parameters to avoid explosive 
atmosphere in bioreactor headspace): process parameter in vivo biotransformation of n-octane 
to 1-octanol by Pseudomonas putida MmarAlk (p4782.1 MMAR_3155 MMAR_3154 
MMAR_3153) using a 3.7 L bioreactor; solid black line: concentration of biomass cx [gCDW l-
1]; solid grey line: concentration of oxygen air supply [%], dotted line: pressure [bar]; broken 
line: air supply rate VG [nl min-1]; induction with 2 g l-1(0,2 % w/v) L-rhamnose und 0.1mM 
FeSO4 min. 2 h before addition of 10% (v/v) n-octane. 0-8 h batch phase; 8-16 h fed-batch 
phase (constant feed rate); 16-18 h biotransformation 
 
Figure 3: Time courses of glucose and gluconate during the initial exponential growth phase 
(I), the growth-limiting fed-batch phase (II), the induction period (III) and the n-octane 
conversion to 1-octanol with ‘resting’ cells at phase IV. The process was performed at 3.7 L 
scale. 
 
Figure 4: In vivo biotransformation of n-octane to 1-octanol by Pseudomonas putida 
MmarAlk  using a 3.7 L bioreactor; ×: cell dry weight cx [gCDW l-1]; ○: optical density 600 nm;  
●: concentration of 1-octanol coctanol [mg l-1]; induction with 2 g l-1(0,2 % w/v) L-rhamnose 
und 0.1mM FeSO4 2.5 h before addition of 10 % (v/v) n-octane. 
 
Figure 5: In vivo biotransformation of n-octane to 1-octanol by Pseudomonas putida 
MmarAlk (p4782.1 MMAR_3155 MMAR_3154 MMAR_3153), concentration of 1-octanol 
coctanol [mg l-1] from shake flask scale up to optimized bioreactor experiments. ▲: shake flask 
scale; ○: 3.7 L bioreactor scale. □: 3.7 L bioreactor scale with optimized conditions. Solid 
line: start biotransformation. 
 
Figure 6: Distribution of the sources and sinks for reduction equivalents (NADH, NADPH, 
and ubiquinol CoQH2) and energy metabolites (ATP) during the octanol production phase of 
the fed-batch process, replicate 1. With respect to growth rate, two extreme scenarios are 
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described: no growth (top numbers) and growth with a maximal growth rate of 0.43 h-1 
(bottom numbers), assuming no ATP is consumed without obvious use. 
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Table 1: Growth rate µ dependent rate of ATP hydrolysis without any purpose that is obvious 
from stoichiometry. 
 
Table 2: Overview of competing approaches for 1-octanol production making use of 
(heterologous) monooxygenase activity. 
** estimated  
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Figure 1: Basic principle of 1octanol formation from noctane using P450 monooxygenase (CYP153A16) 
from Mycobacterium marinum which was heterologously expressed in P. putida KT2440. nOctane is 
imported via diffusion and converted to 1octanol in the cytosol. Besides oxygen, reduction equivalents 
such as NADH are needed for hydroxylation of the substrate which are delivered by concomitant glucose 
metabolization in (almost) resting cells. 
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Figure 2: Process Design under Safety operation procedures (parameters to avoid explosive atmosphere 
in bioreactor headspace): process parameter in vivo biotransformation of noctane to 1octanol by 
Pseudomonas putida MmarAlk (p4782.1 MMAR_3155 MMAR_3154 MMAR_3153) using a 3.7 L bioreactor; 
solid black line: concentration of biomass cx [gCDW l1];solid grey line: concentration of oxygen air supply 
[%], dotted line: pressure [bar]; broken line: air supply rate VG [nl min1]; induction with 2 g l 1(0.2 % 
w/v) Lrhamnose und 0.1mM FeSO4 min. 2 h before addition of 10% (v/v) noctane. 08 h batch phase; 
816 h fedbatch phase (constant feedrate); 1618 h biotransformation 
106x54mm (300 x 300 DPI) 
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Figure 3: Time courses of glucose and gluconate during the initial exponential growth phase (I), the 
growthlimiting fedbatch phase (II), the induction period (III) and the noctane conversion to 1octanol 
with ‘resting’ cells at phase IV. The process was performed at 3.7 L scale. 
113x78mm (300 x 300 DPI) 
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Figure 4: in vivo biotransformation of noctane to 1octanol by Pseudomonas putida MmarAlk using a 3.7 L 
bioreactor; ×: cell dry weight cx [gCDW l1]; ○: optical density 600 nm; ●: concentration of 1octanol coctanol 
[mg l1]; induction with 2 g l1(0.2 % w/v) Lrhamnose und 0.1mM FeSO4 2.5 h before addition of 10% 
(v/v) noctane 
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Figure 5: in vivo biotransformation of noctane to 1octanol by Pseudomonas putida mmarAlk (p4782.1 
MMAR_3155 MMAR_3154 MMAR_3153) specific concentration of 1octanol coctanol [mg gCDW1] from shake 
flask scale up to optimized bioreactor experiments. ▲: shake flask scale; ○: 3.7 L bioreactor scale. □: 3.7 
L bioreactor scale with optimized conditions. Solid line: start biotransformation 
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Figure 6: Distribution of the sources and sinks for reduction equivalents (NADH, NADPH, and ubiquinol 
CoQH2) and energy metabolites (ATP) during the octanol production phase of the fedbatch process, 
replicate 1. With respect to growth rate, two extreme scenarios are described: no growth (top numbers) 
andgrowth with a maximal growth rate of 0.43 h1 (bottom numbers), assuming no ATP is consumed 
without obvious use 
123x73mm (300 x 300 DPI) 
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Table 1 
strain 
Rate of ATP hydrolysis without obvious purpose  
(mmol ATP gCDW-1 h-1) 
KT2440 (14.1 ± 3.5)  +  µ * (27.6 ± 9.8) 
KT2440 + Plasmid (12.1 ± 5.7)  +  µ * (67.8 ± 22.2) 
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Table 2  
publication strain monooxygenase P450 qoctanol  [mg*gcdw-1*h-1] 
max. coctanol 
[mg*LBRM-1] conditions 
Hamilton-Kemp et al. 
2005 E. coli strain ATCC 25922 - 53.8 50 mL, 8 h 
Fujii et al. 2006 E. coli CYP153A from Acinetobacter sp. OC4 11 2300 1.5 mL, 24 h 
Nodate et al. 2006 E. coli BL21(DE3) 
CYP153A13a from 
Alcanivorax borkumensis 
SK2 
- 800 1.5 mL, 24 h 
Fujita et al. 2009 E. coli BL21(DE3) 
CYP153A from 
Acinetobacter sp. OC4 12.2 700 1.5 mL, 24 h 
Koch et al. 2009 E. coli BL21(DE3) 
CYP153A6 from 
Mycobacterium sp. 
HXN-1500 
13.3 10 1 mL, 1 h 
Bordeaux et al. 2011 E. coli BL21(DE3) 
CYP153A13a from 
Alcanivorax borkumensis 
SK2 
30.5 n/a 5 mL, 24 h 
Grant et al. 2011 E. coli BL21(DE3) 
AlkB complex from 
P. putida GPo1 - 680 1000 mL, 30 h 
Gudiminchi et al. 2012 E. coli BL21(DE3) 
CYP153A6 from 
Mycobacterium sp. 
HXN-1500 
- 2500 1 mL, 15 h 
This work 
P. putida 
KT2440 
MmarAlk 
CYP153A16 from 
Mycobacterium marinum  12.7 320 
#
 
1500 mL, 1.75 
h SOP 
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